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The first description of diabetes symptoms dates back to 1500 B.C. 
and was found in an ancient Egyptian medicine book called the 
Papyrus Ebers, containing various prescriptions for the treatment of 
polyuria1. A more precise description of diabetes was found in the 
works of Indian physicians around 300 B.C., who called the disease 
‘Madhumeh’ – a disease of sweet urine – and described signs, symp-
toms, acute complications, and prognoses. These physicians also 
differentiated between types of diabetes2. 
   The term ‘diabetes’ was conceived by the Greek physician Deme-
trius of Apamea (270 BC), and literally means ‘flow through’, as these 
patients seem to lose more fluid than they can drink. Later this was 
expanded to ‘diabetes mellitus’: ‘honeysweet flow through’2. 
   In 1869, Paul Langerhans discovered islands of cells in the pan-
creas – later referred to as the Islets of Langerhans – which differ 
from the exocrine glandular cells. Laguesse later showed that these 
islets have a sugar-regulating function, suggested to be the result 
of an internal secretion formed by those islets1,2. Twenty years later 
it was proven that the pancreas can play a role in the causation of 
diabetes, when Von Mering and Minkowski removed the pancreas from 
dogs which consequently developed diabetes1. 
   In 1921, Banting and Best found the secretion substance from 
the pancreas that had sugar regulation functions as suggested by 
Laguesse, which they named ‘Isletin’ (later renamed ‘Insulin’), and 
demonstrated that injection with this substance decreased blood 
sugar levels and alleviated symptoms in patients. The next important 
milestone in diabetes research was the discovery of the structure of 
insulin by Sanger, which opened the door for the synthetic develop-
ment of insulin and improved treatment options for diabetics1,2.
Type 1 and type 2 diabetes
The prevalence of diabetes is increasing worldwide, reaching epidemic 
proportions. In the Netherlands, the number of people with diabetes 
has increased rapidly from 2,8% of the population in 2001 to 4,5% 
in 2013, affecting around 750 thousand people3. There are two main 




  Type 1 diabetes is characterized as an autoimmune disease in 
which autoantibodies lead to the progressive destruction of beta (β)-
cells – insulin-producing cells located in the pancreas4. Because insu-
lin stimulates the transport and uptake of glucose5, the progressive 
loss of β-cells eventually leads to a loss of insulin production, and 
consequently to hyperglycaemia. 
   The etiology of type 2 diabetes is multifactorial and involves com-
plex interactions between genetic and environmental factors, but is 
generally accepted as a disease resulting from an unhealthy lifestyle 
– including a sedentary lifestyle and over-nutrition6. In these patients, 
hyperglycaemia is the result of insulin resistance and β-cell dysfunc-
tion, which lead to changes in insulin secretion7. Various factors can 
initiate insulin resistance, including defects in insulin signalling8 and 
glucose uptake5, whereas β-cell dysfunction could result from oxida-





The diabetes epidemic is more an epidemic of its complications. 
Diabetes complications are characterized by (micro)vascular disease. 
Although the pathophysiology linking diabetes and vascular disease 
is complex and multifactorial, the role of hyperglycaemia and altered 
growth factor expression in the development of diabetes complica-
tions is eminent. Various mechanisms have been postulated by which 
hyperglycaemia could lead to vascular complications.  
Increased levels of glucose result in the activation of four different 
mechanisms: i) increased flux through the polyol pathway, ii) intra-
cellular production of advanced glycation end products, iii) protein 
kinase C activation, and iv) increased hexosamine pathway activity. 
These four mechanisms are driven by the overproduction of superox-
ide by the mitochondrial electron transport chain11. Via these mecha-
nisms, hyperglycaemia leads to the activation of nuclear factor-kappa 
B (Nf-kB), the generation of advanced glycation end products (AGEs), 
and oxidative stress, but also results in changes in the expression of 
various growth factors. Nf-kB is a key transcriptional factor involved 
in the regulation of pro-inflammatory12 and pro-atherosclerotic13 tar-
get genes in endothelial cells14, vascular smooth muscle cells15, and 
macrophages16. Elevated glucose levels also promote the formation of 
AGEs, resulting in oxidative stress17 and changes in endothelial func-
tion (i.e. increased vasoconstriction)18. Additionally, hyperglycaemia 
can directly result in oxidative stress19, which has been implicated 
in the pathogenesis of atherosclerosis and other vascular diseases20. 
Similarly, altered expression of growth factors (including vascular en-
dothelial growth factor-A; VEGF-A) results in vascular changes such as 
pathological angiogenesis21, endothelial activation and dysfunction22, 
and capillary rarefaction23. VEGF-A is also reported to be involved in 
the development of atherosclerosis24.
Endothelial cell activation is a key mediator of vascular da- 
mage and subsequent tissue damage. Endothelial cells can be ac-
tivated by various stimuli resulting from the four above mentioned 
mechanisms22,25,26. Endothelial cell activation is characterized by the 
augmented cell-surface expression of adhesion molecules, such as 
vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion 
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molecule-1 (ICAM-1), and E-selectin27, an enhanced permeability, and 
a pro-inflammatory, pro-thrombotic phenotype28. The increased ex-
pression of adhesion molecules on endothelial cells aids in leukocyte 
extravasation and subsequent tissue inflammation29.
Target organs of diabetes complications
Microvascular disease in diabetes patients results in diabetic retino- 
pathy, the leading cause of blindness in working-age adults; diabetic 
neuropathy, the leading cause of non-traumatic lower extremity am-
putations; and diabetic nephropathy, the leading cause of end-stage 
renal disease. As these complications are all characterized by vascu-
lar damage, it is no surprise that these complications are significantly 
associated with each other; specifically, the presence of retinopathy 
significantly predicts the presence of neuropathy and of nephropathy 
(confidence interval: 1.56–3.18 and 3.06–10.62, respectively), and ac-
counts both for patients with type 1 diabetes and for those with type 
2 diabetes30.
Diabetic nephropathy 
Diabetic nephropathy develops in around twenty to forty percent of 
patients with diabetes, and is the main cause of end-stage renal 
disease31. Early signs of diabetic nephropathy are albuminuria, hy-
perfiltration, and glomerular hypertrophy, whereas advanced stages 
of diabetic nephropathy are characterized by loss of podocytes and 
endothelial cells, and progression towards glomerulosclerosis.
Diabetic nephropathy can be diagnosed clinically or histologically. 
Clinical diabetic nephropathy is diagnosed i) when micro- or ma- 
croalbuminuria is present – which is defined as a spot urine albumin 
measurement of 30-299 mg/g creatinine and ≥300 mg/g creatinine, 
respectively – or ii) when the estimated glomerular filtration rate is 
less than or equal to 60 ml/min/1.73m232,33. The diagnosis of diabetic 
nephropathy can also be based on histology with the use of a renal 
biopsy. As proposed by our group, histologically diagnosed diabetic 
nephropathy encompasses four classes (Figure 1)34: class I: mild or 




Figure 1: Histological representations of the different classes of diabetic 
nephropathy. Class 1 is defined as mild or non-specific histological lesions (A), toge- 
ther with a thickened glomerular basement membrane (B). Class 0 represents a dia-
betic patient without nephropathy due to normal thickness of the glomerular basement 
membrane (B). Class II is defined as mild (IIa; C) or severe (IIb; D) mesangial expansion 
in more than 25% of the observed mesangium. Class III is defined by the presence 
of nodular glomerulosclerosis in at least one glomerulus (E). Class IV is defined as 
global glomerulosclerosis in more than 50% of the glomeruli (F). Scale bars, 50 µm 
(A,C-F) and 2 µm (B), respectively. A and C-F: silver staining on formalin-fixed, paraffin- 
embedded tissue; B: electron microscopy on glutaraldehyde-fixed, epon-embedded tis-
sue; section was contrasted with uranyl acetate and lead citrate. 
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glomerular basement membrane thickening; class II: mild (IIa) or se-
vere (IIb) mesangial expansion in more than 25% of the observed me-
sangium; class III: Kimmelstiel-Wilson lesion in at least one glomerulus; 
class IV: global glomerular sclerosis in more than 50% of glomeruli34. 
As mentioned, diabetes is characterized by hyperglycaemia which 
plays an important role in the development of diabetes complica-
tions. However, despite glucose control regimens, the percentage of 
diabetes patients progressing towards end-stage renal disease has 
remained similar for the last two decades35, indicating that other fac-
tors besides hyperglycaemia are involved in the pathogenesis of this 
disease. Various factors have been demonstrated to increase the risk 
of developing diabetic nephropathy, including genetic susceptibility, 
hypertension, and hyperlipidaemia.
Genetic susceptibility
The risk of developing diabetic nephropathy is partly attributable 
to genetic susceptibility. This is supported by findings that diabe- 
tic nephropathy occurs in familial clusters36,37, and by differences in 
the prevalence of diabetic nephropathy between ethnicities38. Various 
gene variants are found to be associated with diabetic nephropathy, 
including variants of genes encoding for i) inflammatory cytokines 
(interleukins, tumor necrosis factor-alpha (TNF-alpha)), ii) extracellular 
matrix components (collagen type 4 alpha 1, laminins, matrix metallo-
proteinase 9), iii) blood pressure regulators (angiotensin I converting 
enzyme, angiotensin II receptor type 2), iv) proteins involved in en-
dothelial function and oxidative stress (VEGF-A, nitric oxide synthase 
3, catalase, superoxide dismutase 2), and v) proteins involved in the 
glucose and lipid metabolism (apolipoprotein C-I (apoCI), adiponectin, 
apolipoprotein E, aldose reductase, glucose transporter 1)39,40.
Hypertension
Hypertension is defined as a systolic blood pressure over 140 mmHg, 
or a diastolic blood pressure over 90 mmHg, or both41. The preva-
lence of hypertension in patients with diabetes is up to three times 
higher than that in patients without diabetes42. A higher blood pres-




including micro- and macroalbuminuria, a decline in the estimated 
glomerular filtration rate, and the development of end-stage renal 
disease43. Blood pressure lowering therapy is effective in reducing the 
incidence of both micro- and macrovascular diabetic complications. 
Interestingly, intensive blood pressure control therapy (i.e. targeting 
systolic blood pressure below 120 mmHg), compared to standard, 
moderate regimens (i.e. targeting systolic blood pressure below 140 
mmHg), does not further reduce the risk of developing cardiovascu-
lar events and even leads to more serious adverse events attributed 
to side effects of the antihypertensive treatment44. Accordingly, the 
American Diabetes Association recommends that patients with diabe-
tes and hypertension should be treated to maintain a systolic blood 
pressure below 140 mmHg45.
Hyperlipidaemia
The increase in lipids in the blood, such as cholesterol and tri-
glycerides, is referred to as hyperlipidaemia. Diabetic nephropathy is 
associated with a lipid profile characterized by high triglyceride levels 
– predominantly smaller very-low-density lipoprotein (VLDL) classes46 – 
and lower high-density lipoprotein (HDL) cholesterol levels47,48. It has 
been demonstrated that the content of apoCI per VLDL particle is 
important for the metabolism of triglycerides during the fasting and 
postprandial state (i.e. the increased content of apoCI per VLDL leads 
to less uptake of triglycerides and thus higher serum triglyceride le- 
vels), and is associated with atherosclerosis49. Treatment with statins 
in diabetic patients reduces low-density lipoprotein (LDL) cholesterol 
and triglyceride plasma levels, and increases levels of HDL choleste- 
rol50, thereby reducing the risk of vascular and renal disease. A ge-
nome-wide association study demonstrated that statin-induced chang-
es in LDL cholesterol levels are associated with a polymorphism in 
the APOC1 gene51, potentially due to its effect on lipid metabolism52.
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Innate immune system 
Diabetes has traditionally been considered a metabolic disease. But 
from the late 1990’s, the concept of diabetes and its complications 
as an innate immunity-related disease started to emerge53,54 and has 
been elucidated since. 
The innate immune system is the first defence barrier against 
environmental threats, and consists of various components including 
monocytes and macrophages, and complement proteins. It has been 
demonstrated that serum levels of inflammatory markers, such as 
C-reactive protein, TNF-alpha, and interleukin-6, are increased in pa-
tients with diabetes compared to those in non-diabetic subjects. This 
increase in inflammatory markers in patients with diabetes correlates 
with insulin resistance and hyperglycaemia, and predicts the progres-
sion to micro- and macroalbuminuria55-58. Insulin resistance may be 
caused by the effect of TNF-alpha on endothelial cells, as TNF-alpha 
suppresses both the expression and the phosphorylation of the insulin 
receptor by these cells59,60.
The increase in serum levels of inflammatory markers in patients 
with diabetic nephropathy may be the result of insulin resistance, as it 
has been demonstrated that insulin resistance promotes inflammation. 
More specifically, insulin has anti-inflammatory properties both at cel-
lular and molecular levels. Insulin reduces the production of reactive 
oxygen species, inhibits various pro-inflammatory transcription factors 
including Nf-kB, and stimulates the expression of inhibitor of kB (IkB; 
an inhibitor of Nf-kB) in mononuclear cells61,62. Insulin also inhibits 
Nf-kB and monocyte chemoattractant protein-1 in endothelial cells63. 
Therefore, the loss of insulin (type 1 diabetes) and the loss of insulin 
signalling (type 2 diabetes) prevent the anti-inflammatory effect of 
insulin from being exerted. 
Glomerular inflammation
Monocytes and macrophages have diverse roles in protective immunity 
and homeostasis, however, they also contribute to many pathological 
processes. The number of macrophages is increased in patients with 
diabetic nephropathy compared to that in non-diabetic subjects, both 




reported in animal models of diabetic nephropathy66-69. The infiltration 
of glomerular and interstitial macrophages correlates with albuminuria 
and histopathological changes such as mesangial matrix expansion, 
fibrosis, and interstitial fibrosis and tubular atrophy (IFTA), which 
is suggested to develop as a consequence of macrophage-derived 
TNF-alpha69. By reducing or inhibiting renal macrophage infiltration, 
the development of diabetic nephropathy is attenuated68,70, further 
demonstrating the involvement of macrophages in this disease.
Vascular endothelial growth factor-A
VEGF-A contributes to the renal infiltration of macrophages in at least 
two ways. First, it has been demonstrated that VEGF-A binds to the 
fms-like tyrosine kinase-1 (FLT-1) on monocytes and macrophages, 
thereby promoting the migration of these cells71-73. Second, various 
adhesion molecules (such as VCAM–1, ICAM–1, and E-selectin) are 
involved in monocyte transmigration through the vascular endothe- 
lium into the tissue29. These adhesion molecules are upregulated by 
various stimuli, including VEGF-A22. Therefore, VEGF–A aids in the in-
filtration of macrophages by stimulating monocyte and macrophage 
migration, and by inducing endothelial cell activation. 
VEGF-A, previously known as vascular permeability factor, was 
first discovered in a tumor cell line74. There are multiple isoforms of 
VEGF-A which are derived from alternative splicing of exons 6 and 7. 
This alternative splicing gives rise to VEGF-A121, VEGF-A165, VEGF-A189, 
and VEGF-A206, with VEGF-A165 being the most frequently expressed 
isoform. Henceforth, VEGF-A indicates isoform VEGF-A165. In the kidney, 
VEGF-A is mainly expressed by podocytes and tubular epithelial cells.
Vascular endothelial growth factor-A functioning
VEGF-A is involved in vasculogenesis and angiogenesis, and regulates 
the proliferation, migration, specialization, and survival of endothelial 
cells75. Physiological levels of VEGF-A are crucial for the development 
of the vasculature in glomeruli. A tight regulation of VEGF-A is im-
portant, as both downregulation and upregulation of VEGF-A result in 
glomerulopathies. For instance, mice with a homozygous deletion of 
VEGF-A are not viable and have many endothelial cell defects; podo-
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cyte-specific heterozygosity for VEGF-A in mice results in proteinuria, 
endotheliosis, and loss of endothelial cells; and podocyte-specific 
overexpression of VEGF-A in mice results in a striking collapsing glo-
merulopathy76. Besides differences in VEGF-A expression, changes in 
serum levels of soluble FLT-1 (sFLT-1), an inhibitor of VEGF-A (as de-
scribed below), also result in renal disease. Specifically, administration 
of sFLT-1 to rats results in hypertension, proteinuria, and glomerular 
endotheliosis77. 
Vascular endothelial growth factor receptors 
The two main receptors for VEGF-A are FLT-1 and VEGF receptor 2 
(VEGFR2) – both primarily expressed on vascular endothelial cells (Ta-
ble 1). Of these receptors, FLT-1 has the highest affinity for VEGF-A. 
The affinity of FLT-1 for VEGF-A is about ten times as strong as the 
affinity of VEGFR2 for VEGF-A78,79. VEGF-A functioning is mainly medi-
ated via the VEGFR2, whereas FLT-1 is considered a decoy receptor 
to sequester VEGF-A, thereby regulating VEGFR2 activity. sFLT-1 binds 
VEGF-A with the same affinity as the membrane-bound form, and is 
able to inhibit VEGF-A-induced mitogenesis – similar to FLT-1 – sug-
gesting that it functions as a negative regulator of VEGF-A signalling 
(Table 1)80. However, it has recently been demonstrated that sFLT-1 
has functions other than sequestering VEGF-A, as binding of sFLT-1 to 
podocytes (independent of VEGF-A) – via the glycosphingolipid mono-
sialodihexosylganglioside in lipid rafts on the surface of podocytes 
– is crucial for podocyte functioning and morphology81. Interestingly, 
monocytes also express glycosphingolipid monosialodihexosylganglio-
side on their surface, and this expression is increased upon differen-
tiation towards macrophages82, and upon exposure to inflammatory 
stimuli83. Conceivably, sFLT-1 may be able to bind to monocytes and 
macrophages via glycosphingolipid monosialodihexosylganglioside in 
a similar fashion as the binding of sFLT-1 to podocytes, and conse-
quently regulate monocyte/macrophage morphology and/or function-
































Vascular endothelial growth factor-A in diabetic nephropathy 
In animal models for diabetic nephropathy, glomerular levels of 
VEGF-A are increased84,85 compared to those in non-diabetic animals. 
The increase in glomerular VEGF-A levels contributes to the severity 
of diabetic nephropathy. This is supported by the finding that type 1 
diabetic mice with a podocyte-specific overexpression of VEGF-A de-
velop nodular glomerulosclerosis86, whereas wild-type, type 1 diabetic 
mice only develop mesangial matrix expansion. In patients with dia-
betic nephropathy, glomerular VEGF-A levels are decreased compared 
to those in non-diabetic subjects. In these patients, the glomerular 
expression of VEGF-A correlates negatively with the severity of di- 
sease and positively with the number of podocytes87,88. In the kidney, 
VEGF-A is mainly expressed by podocytes, and the number of podo-
cytes decreases during disease progression in patients with diabetic 
nephropathy. This is in concert with the finding that VEGF-A levels 
decrease during the progression of diabetic nephropathy. Therefore, 
we hypothesize that during early diabetes, as mimicked in animal 
models, glomerular VEGF-A levels are increased – potentially by the 
effect of hyperglycaemia on podocytes89 – and contribute to early 
diabetic renal changes, whereas during the progression of diabetic 
nephropathy, as demonstrated in patients, glomerular levels of VEGF-A 
are decreased due to the loss of podocytes88, consequently leading 
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to more chronic lesions of diabetic nephropathy. 
Various studies report that reducing glomerular VEGF-A levels 
during early diabetes in animal models prevents the development of 
albuminuria and renal damage; however, reports are inconsistent90-94. 
This may be due to differences in the type or dose of anti-VEGF-A 
therapy used. Furthermore, it is unclear from these studies whether 
treatment to reduce glomerular VEGF-A levels improves renal histology 
and renal function if started when albuminuria and renal histological 
lesions are already present. Also, the mechanism by which anti-VEGF-A 
treatment is beneficial is currently unknown. For instance, it has not 
been studied whether anti-VEGF-A treatment in diabetic animals re-
duces the number of glomerular macrophages compared to that in 
untreated diabetic animals. This might be accomplished by inhibiting 
the migration of macrophages, or by reducing glomerular endothelial 
cell activation, or both. 
Apolipoprotein C-I
ApoCI is expressed on HDL and on triglyceride-rich lipoproteins, and 
has several functions in both lipid metabolism and lipid transport95. 
ApoCI inhibits the uptake of lipoproteins via suppression of the lipo-
protein lipase-dependent triglyceride-hydrolysis pathway52,96, resulting 
in hyperlipidaemia (predominantly hypertriglyceridemia). 
In addition to its role in lipid metabolism, apoCI is also involved in 
inflammation. ApoCI, either derived from the circulation (mainly bound 
to chylomicrons, VLDL, and HDL) or from macrophages97, strongly 
binds to the lipid A moiety of lipopolysaccharide (LPS) – a highly 
inflammatory constituent of the outer membrane of Gram-negative 
bacteria – thereby augmenting the inflammatory response to LPS by 
macrophages via the cluster of differentiation 14/myeloid differenti-
ation protein-2/toll-like receptor 4 (CD14/MD2/TLR4) pathway, inclu- 
ding the production of TNF-alpha (Figure 2)98,99. By augmenting the 
production of TNF-alpha by macrophages, apoCI accelerates LPS- 
induced atherosclerosis in mice100. Similarly, in humans, the apoCI 
content of triglyceride-rich lipoproteins – including VLDL – predicts 




Figure 2: Schematic representation of the mechanism by which apoCI augments 
LPS-induced inflammatory responses in macrophages. ApoCI binds to the lipid A 
moiety of LPS, subsequently presenting LPS to CD14, which transfers LPS to the MD2/
TLR4 complex leading to increased production of TNF-alpha via transcription of Nf-kB.
Because apoCI is associated with the progression of vascular da- 
mage, it may be involved in the progression of diabetic nephropathy 
as well. This notion is supported by the finding that, as mentioned 
earlier, a gene polymorphism in APOC1 was found to be associated 
with an increased risk of developing diabetic nephropathy40. Interes- 
tingly, Bouillet et al. recently demonstrated that, compared to those 
in healthy control subjects, plasma levels of apoCI are increased in 
patients with diabetes – both type 1 diabetic patients and type 2 
diabetic patients103 – and correlate with triglyceride levels in type 2 
diabetes patients (this correlation has not been investigated for type 1 
diabetes patients)104. Furthermore, under physiological circumstances, 
apoCI inhibits cholesteryl ester transfer protein (CETP) activity. CETP 
promotes the exchange of neutral lipid species between plasma lipo-
proteins (i.e. cholesteryl esters and triglycerides). However, in patients 
with diabetes, the glycation of apoCI (as a result of hyperglycaemia) 
changes its electrostatic properties, thereby impairing its ability to 
inhibit CETP activity. This results in an increase in CETP activity in 
these patients compared to that in non-diabetic subjects103, which is 
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associated with the development of atherosclerosis105,106. 
Although this data supports the hypothesis that apoCI may be 
involved in the development of diabetic nephropathy, it has to be 
further elucidated whether an increase in plasma apoCI levels leads 
to the development of diabetic nephropathy, and, if so, whether this 
entails the effect of apoCI on inflammatory responses by monocytes 
and macrophages, or that on lipid metabolism, or both.  
Endoglin
As mentioned earlier, diabetic nephropathy is characterized by vascu-
lar changes, including endothelial cell activation, which aid in leuko-
cyte extravasation and inflammation. An important molecule involved 
in vascular health and functioning is endoglin. Endoglin is a co-recep-
tor for the transforming growth factor beta (TGF-β) receptor family, 
and modulates the signalling of TGF-β receptor type 2, activin re-
ceptor-like kinase (ALK)-1, and ALK-5107. Endoglin is mainly expressed 
on endothelial cells108, and it is crucial for vascular development 
and angiogenesis as demonstrated in endoglin deficient mice109. This 
is supported by the finding that endoglin is required for VEGF-A-
induced angiogenesis110. In various animal models of renal disease, 
the glomerular expression of endoglin is increased compared to that 
in healthy control animals. This increase in glomerular endoglin ex-
pression contributes to the severity of disease111-113 – potentially by 
promoting endothelial cell activation, vascular damage113, and macro-
phage infiltration114. Also, compared to those in non-diabetic subjects, 
soluble endoglin serum levels are increased in diabetes patients and 
correlate with endothelial dysfunction and cardiovascular damage115. 
However, whether a causal relationship exists between the altered en-
doglin expression levels in these patients and the observed glomerular 
endothelial cell activation and macrophage infiltration in their kidneys 
is uncertain.
VEGF-A leads to endothelial cell activation and subsequent leuko-
cyte adhesion via binding to the VEGFR2, upon which the VEGFR2 is 
phosphorylated and becomes associated with proto-oncogene tyro-




upon VEGF-A stimulation, and is critical for both the internalization 
and degradation of endoglin via endosomes, as well as for VEGF-A/
VEGFR2-induced endothelial cell functioning116,117. Therefore, endoglin 
may be a crucial co-receptor for VEGFR2 internalization and degra-
dation, as VEGFR2 co-localizes with endoglin in endosomes (early 
endosome antigen-1 (EEA-1)-, ras-related protein rab-5 (Rab5)-, and 
ras-related protein rab-7 (Rab7)-positive endosomes)117. Upon interna- 
lization of the VEGFR2, extracellular signal-regulated protein kinases 
1 and 2 (ERK1/2) are activated, which in turn translocate to the nu-
cleus, where they lead to activation of activating transcription factor 
2 (ATF-2). Activation of ATF-2 subsequently leads to the transcription 
and translation of endothelial cell activation markers (including VCAM-
1; Figure 3, black arrows)118. 
When the expression of endoglin is reduced, stimulation with 
VEGF-A leads to increased recycling of the VEGFR2 to the plasma 
membrane (i.e. less degradation of the VEGFR2), and to increased 
Akt serine/threonine kinase (Akt) phosphorylation, whereas ERK1/2 
activation remains unchanged119. However, a reduced endoglin ex-
pression may also lead to decreased internalization of the VEGFR2 
in endosomes. A decrease in VEGFR2 internalization may therefore 
result in an increased Akt activation, as it has been postulated that 
the VEGFR2 is able to activate Akt – but not ERK1/2 – while present 
on the plasma membrane120. Nevertheless, Akt activation is increased 
in endothelial cells with a reduced endoglin expression. Akt has been 
shown to inhibit ATF-2 phosphorylation121, and may therefore result 
in less endothelial cell activation (Figure 3, red arrows). Taken to-
gether, it is possible that endoglin affects endothelial cell activation 
and leukocyte adhesion by altering or inhibiting i) the internalization 
process of the VEGFR2, ii) intracellular signalling, and iii) subsequent 
transcription of endothelial cell activation markers.
Complement activation
The complement system is an effector mechanism of the innate im-
mune system. It has three main physiological functions: defending 
the host against infection, bridging the innate and adaptive immune 
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Figure 3: Schematic representation of the mechanism of endothelial cell acti-
vation by stimulation with VEGF-A. Binding of VEGF-A to the VEGFR2 leads to phos-
phorylation (P) and internalization of this receptor, which leads to increased VCAM-1 
expression via the ERK1/2/ATF-2 pathway (black arrows). Endoglin co-localizes with the 
VEGFR2 in endosomes, and may regulate VEGFR2 internalization and degradation. When 
endoglin expression is absent or reduced, the activation of Akt is increased, which may 
inhibit ATF-2 phosphorylation and consequently the activation of endothelial cells (red 
arrows). ?: uncertain.  
systems, and clearance of immune complexes in tissues and waste 
products of inflammatory injury122. The complement system consists of 
more than 35 proteins that form three pathways: the classical pathway, 
the lectin pathway, and the alternative pathway. Different processes 




complement factor (C)3 by C3 convertases, thereby initiating a final 
common pathway resulting in the formation of the membrane attack 
complex (Figure 4) – also known as C5b-9, which stimulates comple-
ment-mediated damage. In addition, protein fragments C3a and C5a, 
which are derived from C3 and C5, respectively, induce anaphylatoxic 
reactions leading to recruitment of inflammatory cells123.
Both clinical and experimental evidence support a role for the com-
plement system in the pathogenesis of diabetes complications124,125. 
For most diabetes complications the evidence for a role for com-
plement activation in the progression of damage is quite strong, in-
cluding diabetic retinopathy126, diabetic cardiovascular disease127, and 
diabetic neuropathy128. For diabetic nephropathy, however, data on 
this subject is scarce. Still, a growing body of evidence suggests that 
complement activation is also involved in the pathogenesis of diabetic 
nephropathy. In urine samples of patients with diabetic nephropathy, 
levels of C5b-9 are found to be increased129. Strong associations have 
been found between serum levels of mannose-binding lectin (MBL) 
and the presence of type 1 and type 2 diabetes. Serum levels of MBL 
correlate with renal function130-132, suggesting the involvement of the 
lectin pathway in the progression of diabetic nephropathy. In addition, 
in renal biopsies of patients with diabetic nephropathy, the expression 
of C3, C4, and C9 at the protein level, and of C1q, C1r, and C1s 
at the mRNA level is increased compared to those in non-diabetic 
subjects, suggesting a role for the classical complement pathway 
in patients with diabetic nephropathy133. Furthermore, hyperglycaemia 
results in glycation-induced inactivation of complement regulatory 
proteins, including cluster of differentiation 59 (CD59) – an inhibitor 
of the formation of C5b-9 under physiological circumstances – leading 
to increased formation of C5b-9134. Evidence for the involvement of 
complement activation in the progression of diabetic nephropathy also 
comes from diabetic animal models. When treated with a receptor 
antagonist against C3a, type 2 diabetic rats have less inflammation, 
demonstrate an improved renal function, have less albuminuria, and a 
reduced deposition of extracellular matrix proteins in glomeruli com-
pared to that in untreated diabetic rats135, supporting the hypothesis 




Although data on complement activation in renal tissues of pa-
tients with diabetic nephropathy potentially opens a new spectrum 
of treatment options for these patients, these studies were thus far 
performed on small patient numbers, making it difficult to generalize 
this data to the general population. 
Figure 4: Schematic overview of the complement system. The complement system 
consists of three pathways: the classical pathway, the lectin pathway, and the alterna-
tive pathway – each activated by different stimuli (immune complexes, mannose-binding 
lectin complexes, or C3b-coated pathogens, respectively). The classical and the lectin 
pathway both lead to the cleaving of C4. All three pathways converge at C3, which 




Aims of the work described in this thesis
Current treatment to prevent or delay the progression of diabetic 
nephropathy involves the control of both metabolic and hemodyna- 
mic changes. Specifically, patients receive medication to lower blood 
glucose levels, and to reduce serum lipids and blood pressure136. 
The prevalence of some diabetes complications has been reduced 
with these standard treatments over the last two decades – including 
death from hyperglycaemic crisis, stroke, and acute myocardial infarc-
tion. However, the prevalence of end-stage renal disease in diabetes 
patients has not yet been reduced35. Therefore, new preventive and 
therapeutic strategies are urgently needed. In order to achieve this, 
a better understanding of the mechanisms behind the progression 
towards diabetic nephropathy is paramount. The central aim of the 
studies described in this thesis was to investigate the involvement 
of the immune system and vascular changes in the development of 
diabetic nephropathy. 
In the work described in chapter 2, we investigated whether 
overexpressing apoCI – a molecule involved in lipid metabolism and 
inflammatory responses by macrophages, and associated with an 
increased risk of developing diabetic nephropathy – leads to the de-
velopment of glomerulosclerosis in mice transgenic for human APOC1 
(APOC1-tg mice), and if so, by which mechanism. Additionally, we 
investigated the prevalence of glomerular apoCI deposits in patients 
with diabetic nephropathy.
In the work described in chapter 3, we investigated whether 
treatment with sFLT-1, an inhibitor of VEGF-A, reduces albuminuria 
and renal histopathological changes in type 1 diabetic mice. We also 
studied whether treatment of type 1 diabetic mice with sFLT-1 has an 
effect on glomerular endothelial cell activation and on the influx of 
glomerular macrophages. 
In the work described in chapter 4, we investigated whether glo-
merular endoglin expression is associated with diabetic nephropathy 
in both mice and patients. Also, we studied the involvement of endo- 
glin in VEGF-A–stimulated endothelial cell activation, and in the adhe-
sion of monocytes to activated endothelial cells in vitro. Furthermore, 
we studied whether glomerular endoglin expression is correlated with 
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endothelial cell activation in patients with diabetic nephropathy. 
In the work described in chapter 5, the aim was to elucidate 
whether complement activation has taken place in kidneys of patients 
with diabetic nephropathy, and, if so, i) which complement pathway 
is activated in these patients, ii) whether complement deposits are 
correlated with the severity of diabetic nephropathy, and iii) whether 
there are differences in complement deposition between patients with 
type 1 diabetes and those with type 2 diabetes.
In the work described in chapter 2, we demonstrated that glome- 
rulosclerosis develops in APOC1-tg mice at 15 months of age. The 
relatively slow progression of the disease in this mouse model makes 
it less suitable to study therapeutic and preventive interventions. In 
the work described in chapter 6, we therefore aimed to accelerate 
the progression of glomerulosclerosis in APOC1-tg mice. We intro-
duced a second hit in eight-week-old APOC1-tg mice by transfecting 
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Diabetic nephropathy is the leading cause of end-stage renal disease. 
Diabetic patients have increased plasma concentrations of apolipo-
protein C-I (apoCI), and meta-analyses found that a polymorphism 
in APOC1 is associated with an increased risk of developing ne-
phropathy. To investigate whether overexpressing apoCI contributes 
to the development of kidney damage, we studied renal tissue and 
peritoneal macrophages from APOC1 transgenic (APOC1-tg) mice and 
wild-type littermates. In addition, we examined renal material from 
autopsied diabetic patients with and without diabetic nephropathy 
and from autopsied control subjects. We found that APOC1-tg mice, 
but not wild-type mice, develop albuminuria, renal dysfunction, and 
glomerulosclerosis with increased numbers of glomerular M1 macro-
phages. Moreover, compared to wild-type macrophages, stimulated 
macrophages isolated from APOC1-tg mice have increased cytokine 
expression, including TNF-alpha and TGF-beta, both of which are 
known to increase the production of extracellular matrix proteins in 
mesangial cells. These results suggest that APOC1 expression induces 
glomerulosclerosis, potentially by increasing the cytokine response 
in macrophages. Furthermore, we detected apoCI in the kidneys of 
diabetic patients, but not in control kidneys. Moreover, patients with 
diabetic nephropathy have significantly more apoCI present in glome- 
ruli compared to diabetic patients without nephropathy, suggesting 
that apoCI could be involved in the development of diabetic ne-
phropathy. ApoCI co-localized with macrophages. Therefore, apoCI is 
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Introduction
Diabetic nephropathy (DN) is the leading cause of end-stage renal 
disease in the Western world1. Several factors contribute to the 
development of DN, including hyperglycaemia2, hypertension3, hyper-
lipidaemia4, and genetic background5. Meta-analyses revealed that a 
polymorphism in the APOC1 gene, which encodes apolipoprotein C-I, 
is associated with an increased risk of developing DN6,7. Moreover, a 
recent study reported that patients with either type 1 or type 2 dia-
betes have higher plasma levels of apoCI compared to non-diabetic 
controls8.
In the circulation, apolipoproteins are found primarily on the surface 
of lipid complexes called lipoproteins (e.g., chylomicrons, very-low-den-
sity lipoproteins, and high-density lipoproteins). Apolipoproteins re- 
gulate the metabolism of lipoproteins, thereby determining the trans-
port and redistribution of lipids among various tissues. Lipoprotein 
catabolism is dependent on both the apolipoproteins present on 
their surface and the proteins—including enzymes and receptors—with 
which they interact. ApoCI slows the catabolism of triglyceride-rich 
lipoproteins primarily by inhibiting the enzyme lipoprotein lipase (LPL), 
thereby increasing plasma triglycerides9. In addition, apoCI has inflam-
matory properties, as it can stimulate the production of TNF-alpha by 
macrophages following an inflammatory stimulus10.
Studies performed in both human subjects and animal models re-
vealed that macrophages play an important role in the pathogenesis 
of DN11-17, and macrophage-derived TNF-alpha is believed to be a 
key mediator of this process17. Several studies regarding the role of 
macrophages in DN found increased number of macrophages both 
in glomeruli and in the interstitium. This influx of macrophages is 
correlated with glomerular and tubulointerstitial damage and with a 
decline in renal function11-16,18,19. Reciprocally, suppressing macrophage 
influx markedly reduces urinary albumin secretion, glomerular hyper-
trophy, and mesangial matrix expansion14,20,21.
We hypothesise that increased expression of apoCI plays an im-
portant role in the development of kidney damage, based on three 
key findings: i) the results of the meta-analysis, which showed an 
association between an APOC1 polymorphism and the development 
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of DN; ii) the finding that apoCI stimulates the inflammatory response 
in macrophages; and iii) that macrophages are involved in the devel-
opment of DN. To test this hypothesis, we examined whether human 
APOC1 transgenic mice develop kidney damage. Next, we investigated 
the role of macrophages in this process. Finally, to test whether apoCI 
is clinically relevant in the development of DN, we investigated the 
expression of apoCI in the kidneys of patients with and without DN 
as well as in kidneys from non-diabetic controls. 
Materials and methods
Animals
In this study, we used both male and female heterozygous transgenic 
mice expressing human apolipoprotein C-I (APOC1-tg) on a C57Bl/6J 
background. The construct was generated by the excision of an 18-kb 
EcoRI fragment from a cosmid carrying the APOE/APOC1/APOC1P1 
gene region. The fragment contained a 5-kb region upstream from 
APOC1 and an 8-kb region downstream from APOC1, including the 
hepatic control region element and part of APOC1P1 pseudogene22. 
Transgenic offspring were identified by polymerase chain reaction 
(PCR) analysis on genomic tail-derived DNA. Male and female wild-
type (WT) littermates were used as controls. Equal numbers of male 
and female mice were used. All mice used in this study were housed 
under standard laboratory conditions with free access to water and 
standard rodent chow (Hope Farms, Woerden, the Netherlands).
Experimental design 
All animal experiments were approved by the Institutional Ethics Com-
mittee for Animal Care and Experimentation. To measure the animals’ 
characteristics, WT and APOC1-tg mice (10 mice per group) were 
sacrificed at six months of age. The kidneys, heart, liver, brain, lungs, 
spleen, and pancreas were collected, and both absolute and relative 
weights were measured. From each organ, one piece was fixed in 
4% buffered formalin and embedded in paraffin, and one piece was 
snap-frozen for mRNA isolation. Blood was collected in heparin tubes 
and used to measure white blood cells (WBCs) and haemoglobin 
Chapter 2 
41
concentration. Blood plasma was used to measure triglycerides (TGs), 
total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), 
non-HDL-C, glutamate oxaloacetate transaminase (GOT), creatinine 
kinase (CK), and glucose levels. Serum was used to measure blood 
urea nitrogen (BUN) and serum creatinine. WBCs were counted using 
a Muse Cell Counter (Merck, Darmstadt, Germany). A BUN colori-
metric detection kit (Arbor Assays, Ann Arbor, MI, USA) was used 
in accordance with the manufacturer’s instructions. Serum creatinine 
was measured using an enzymatic method on a Roche Modular P800 
device (Roche, Woerden, the Netherlands) in accordance with the 
manufacturer’s instructions. Haemoglobin, GOT, and CK were mea-
sured using Reflotron Sprint (Roche) test strips in accordance with 
the manufacturer’s instructions. Serum creatinine was measured using 
an enzymatic/fluorometric creatinine assay kit (Abcam, Cambridge, 
UK). Plasma TGs and TC were assayed using commercially available 
enzymatic kits (Roche Diagnostics, Germany), and plasma glucose 
was measured using the glucose start reagent method (Instruchemie, 
Delfzijl, the Netherlands) in accordance with the manufacturer’s in-
structions. HDL-C was measured by precipitating apoB-containing par-
ticles with 20% polyethylene glycol in 200 mM glycine buffer (pH 10), 
and TC was measured in the supernatant. Non-HDL-C was calculated 
by subtracting HDL-C from TC. 
APOC1-tg mice (n=59) and age-matched WT littermates (n=19) 
were sacrificed at various ages ranging from 2 to 23 months. Sub-
sequently, the kidneys were removed and subjected to histological, 
immunohistochemical, and mRNA analyses. From each kidney, one 
piece of cortical tissue was snap-frozen in pre-cooled methylbutane; 
a second piece was fixed in 4% buffered formalin and embedded in 
paraffin for histological analysis and immunohistochemistry. Frozen re-
nal cortex samples (30 mg) from three WT and three APOC1-tg mice 
at 16 months of age were used to measure cholesterol, triglyceride, 
and phospholipid content as described previously for liver tissue23.
Albuminuria
Urine albumin levels were measured using rocket immunoelectro-
phoresis against rabbit anti-mouse albumin, with purified mouse se-
rum albumin (Sigma-Aldrich, Saint Louis, MO) as a standard. Urine 
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creatinine was measured using a creatinine assay, with picric acid, 
sodium hydroxide, and creatinine standards (Sigma-Aldrich). The rab-
bit anti-mouse albumin antibody was produced in our laboratory by 
immunising rabbits with an emulsion of mouse albumin and Freund’s 
adjuvant; specificity was confirmed using western blot analysis. Se-
rum creatinine and BUN were measured in accordance with the 
manufacturers’ instructions (Roche and Arbor Assays, respectively) in 
16-month-old mice as a measure of renal function.
Immunohistochemistry 
Frozen kidney sections (3-µm thickness) were cut on a Reichert cryo-
stat microtome. Goat anti-human apoCI (Academy Biomedical Compa-
ny, Houston, TX, USA), rabbit anti-human fibronectin (Sigma-Aldrich), 
rabbit anti-human collagen VI (Telios Pharmaceuticals, San Diego, CA, 
USA), goat anti-human collagen types I, III, and IV (all from Sera Lab-
oratories, West Sussex, UK), rat anti-VCAM-1 (Abcam), rat anti-MCP1 
(Abcam), rat anti-ICAM (Abcam), rat anti-FA-11 (Abcam), rabbit an-
ti-TNF-alpha (Abcam), rabbit anti-CD11b (Abcam), or rabbit anti-CD163 
(Santa Cruz Biotechnology, Dallas, TX, USA) primary antibodies were 
used for immunostaining, followed by the appropriate HRP-labelled 
secondary antibody with diaminobenzidine as the chromogen. Dou-
ble-label immunofluorescence was performed with rat anti-VCAM-1 
and goat anti-von Willebrand factor (Affinity Biologicals Inc., Ancaster, 
Canada), followed by the appropriate fluorescent secondary anti- 
bodies, after which the slides were mounted using Vectashield plus 
DAPI (Vector Laboratories, Burlingame, CA, USA). Double-label immu-
nostaining was performed with goat anti-human apoCI and mouse 
anti-CD68 (Dako, Glostrup, Denmark), followed by the appropriate 
secondary antibodies with diaminobenzidine and Vector Blue (Vector 
Laboratories) as the chromogens for detecting apoCI and CD68, re-
spectively. Frozen kidney sections (10 µm thickness) of 16-month-old 
WT and APOC1-tg mice were stained with oil red O. Paraffin-embed-
ded kidney sections (4 µm thickness) were stained with methenamine 
silver, periodic acid-Schiff (PAS), or Sirius red (supplementary material, 
Supplementary material and methods). Sections were immunostained 
with rabbit anti-WT1 (Abcam) or rat anti-F4/80 (Abcam) primary anti-
bodies, followed by the appropriate HRP-labelled secondary antibody 
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with diaminobenzidine as the chromogen. The anti-human antibodies 
used for staining mouse tissue are cross-reactive with mouse tissue 
(data not shown).
Staining quantification
The number of podocytes in each sample was determined by counting 
the number of WT1-positive nuclei in 25 glomeruli. Glomerular damage 
was scored morphologically on PAS-stained tissues in 25 glomeruli, 
using a scale of 0–4 as follows: 0, normal glomeruli; 1, <10% me-
sangial expansion; 2, 10-25% glomerulosclerosis; 3, 25-50% glomeru-
losclerosis; 4, >50% glomerulosclerosis24. Sections were scanned, and 
the images were digitised using a Philips Ultra-Fast Scanner 1.6 RA 
(Philips Digital Pathology, Best, The Netherlands). The levels of VCAM-
1, ICAM-1, and TNF-alpha expression per glomerulus were determined 
by measuring the surface stained by the respective antibody, relative 
to the total surface area of the glomerulus (ten glomeruli per section 
were measured) at 40X magnification (ImageJ). FA-11‒positive cells 
were counted in 10 glomeruli per sample. PAS-stained slides were 
used to measure the surface area of the glomerular tuft (i.e. glome- 
rular surface area, in µm2) in 25 glomeruli per sample using Philips 
Ultra-Fast Scanner 1.6 RA software. Interstitial fibrosis was determined 
by measuring the surface area stained by Sirius red in five cortical 
fields (using a 40X objective with a fluorescence microscope) relative 
to the total surface area of the cortical fields (ImageJ software). 
Glomeruli and vessels were excluded from the analysis.
Human APOC1 and mouse apoCI expression in APOC1-tg mice
RNA was extracted using RNA extraction buffer (TRIzol, Ambion) 
from kidney, liver, brain, heart, lung, spleen, and pancreas tissues of 
APOC1-tg and WT mice, and from the liver tissue of streptozotocin 
(STZ)-induced diabetic WT mice 4 months after STZ injection. APOC1 
and ApoC1 mRNA levels were measured using quantitative real-time 
PCR.
Macrophage isolation
WT and APOC1-tg mice (n=3 each) were given an intraperitoneal injec-
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tion of 1 ml thioglycolate (30 g/l) on day 1 in order to increase the 
macrophage yield. On day 5, after the mice were sacrificed, 6 ml of 
sterile PBS was used for vigorous peritoneal lavage. The resulting cell 
suspension was centrifuged at 500 rpm for 10 min and then washed 
twice with PBS. The cell pellets were resuspended in 2 ml RPMI 1640 
medium containing 10% FCS and 1% penicillin/streptomycin (referred 
to hereafter as ‘medium’). The macrophages were counted in a coun- 
ting chamber, and the cells were then incubated overnight in a six-
well plate (with 500.000 macrophages per well in 1.2 ml of medium). 
After the cells were washed with medium, they were incubated for 6 
h at 37°C in the following conditions: no stimulation; 10 ng/ml LPS25; 
or 10 ng/ml LPS and 10 ng/ml anti-CD14 antibody (Zimmer Biomet, 
Warsaw, IN, USA). After 6 h, the medium was collected and the cells 
were washed three times with PBS and then dissolved in 1 ml TRIzol.
Reverse transcription and CDNA amplification
Quantitative real-time PCR (qRT-PCR) reactions were prepared using 
SYBR Green I master mix (Bio-Rad, Hercules, CA, USA) as recommen- 
ded by the manufacturer and run on a Bio-Rad CFX real-time system. 
Ct (cycle threshold) values were normalised to the housekeeping gene 
Hprt1. The primer sequences used in this study are provided in the 
supplementary material, Supplementary materials and methods. 
Human kidney samples
Renal tissue specimens were obtained from autopsy samples collected 
from 17 control subjects without diabetes or renal disease, from 8 
patients with diabetes without nephropathy, and from 12 patients with 
nodular glomerulosclerosis (class III DN, based on the established his-
topathological classification for DN)26. Autopsy samples were retrieved 
from the pathology archives at Leiden University Medical Center. The 
non-diabetic control subjects, diabetic patients without nephropathy, 
and diabetic patients with nephropathy were 65±12, 76±12, and 72±9 
years of age, respectively (p=0.086). The duration of diabetes did not 
differ significantly between the two diabetic groups (p=0.13). 
Statistics
Because animals were randomly sacrificed between 2 and 23 months 
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of age, and because the relationship between glomerular damage and 
age produced a sigmoid-like curve for the APOC1-tg mice (compared 
to a linear relationship for the WT mice), we analysed our data by 
dividing mice into three age categories: ≤8 months, 8‒16 months, 
and >16 months. We studied the various outcomes using two-way 
ANOVAs with an interaction term between age and genotype in the 
model. Model fit was assessed by visual inspection of residuals of the 
ANOVA models. Patient data and in vitro experiments were analysed 
using the two-tailed Student’s t test. Differences were considered sig-
nificant at p<0.05. 
Results
Human APOC1 transgenic mice develop glomerulosclerosis
The animals’ baseline characteristics were measured at 6 months of 
age and are summarised in the supplementary material, Tables S1 
and S2. The absolute organ weights did not differ significantly be-
tween WT and APOC1-tg mice; however, the relative organ weights of 
the kidneys and heart were significantly higher in the APOC1-tg mice. 
The APOC1-tg mice had hyperlipidaemia, with increased serum levels 
of triglycerides, total cholesterol, and non-HDL-C (p<0.001). In the 
APOC1-tg mice, the human APOC1 transgene is primarily expressed in 
the liver and, to a lesser extent, peritoneal macrophages (Figure 1A). 
Accordingly, human apoCI protein was present primarily in the liver; 
in other organs, human apoCI protein was restricted to the blood 
vessels (Figure 1B-H). The liver mRNA levels of mouse ApoC1 were 
2.8-fold higher in STZ-induced diabetic mice than in WT mice (p<0.05; 
Figure 1I).  
   To examine whether APOC1-tg mice develop albuminuria, we next 
measured the urinary albumin:creatinine ratio at various ages (Figure 
2). Compared with WT mice, the albumin:creatinine ratio was signifi-
cantly higher in APOC1-tg mice from 14 months of age (p<0.05). In 
addition, at 16 months of age serum creatinine levels were 2.7-fold-
higher in the APOC1-tg mice than in WT mice (p<0.05; data not shown). 
Blood urea nitrogen (BUN) levels did not differ significantly between 
APOC1-tg mice and WT mice at 16 months of age (data not shown). 
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Figure 1: Transgenic mRNA and protein levels in APOC1-tg mice. A. Relative mRNA 
levels (ΔΔCq) of human APOC1 in the organs and peritoneal macrophages (P.M.) of 
6-month-old APOC1-tg mice. Human APOC1 mRNA level in the liver was set to 100%. 
B-H. Representative images of human apoCI-immunostained liver (B), lung (C), pancreas 
(D), spleen (E), heart (F), brain (G), and kidney (H) samples from a 6-month-old APOC1-
tg mouse. I. Relative mRNA levels (ΔΔCq) of mouse ApoC1 in the liver of 6-month-old 
WT and STZ-induced diabetic mice. WT liver mouse ApoC1 mRNA level was set to 
100%. Scale bars indicate 50 µm.
Next, we examined the morphology of the glomeruli in APOC1-tg 
and WT mice in three age categories. Interaction effects for age and 
genotype were found for the glomerular damage score, glomerular 
hypertrophy, and the number of podocytes (p<0.001). At 9 months of 
age, the APOC1-tg mice began to develop mesangial matrix expansion 
(Figure 3B); by 15 months, this had progressed to glomerulosclerosis 
and was accompanied by glomerular hypertrophy (Figure 3I, J). These 
glomerulosclerotic lesions have a nodular-like pattern (Figure 3D) and 
were positive for several extracellular matrix (ECM) proteins, inclu- 
ding collagen type I, collagen type IV, and fibronectin (supplementary 
material, Figure S1A-C). Lesions were also positive for collagen type 
VI; however, this protein was observed primarily at the periphery of 
the sclerotic lesions (supplementary material, Figure S1D). Decreased 
number of podocytes is a common feature in several kidney diseases, 
including DN27. Consistent with this finding, the number of podocytes 
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Figure 2: Time course of urinary albumin:creatinine ratio in WT and APOC1-tg 
mice. *p<0.05, Student’s t test. 
generally decreased with age in APOC1-tg mice (Figure 3E, F, K). WT 
mice displayed no sign of either mesangial matrix expansion (Figure 
3A, C, I) or podocyte loss at any time point studied (Figure 3K). 
Sirius red staining combined with fluorescence microscopy revealed 
that interstitial fibrosis increased significantly during ageing in both 
WT and APOC1-tg mice (p<0.01). Compared to WT mice, APOC1-tg 
mice developed significantly more interstitial fibrosis (p<0.05; Figure 
3G, H, L). In the APOC1-tg mice, interstitial fibrosis was correlated 
with the number of podocytes (r=‒0.630; p<0.001), glomerular da- 
mage (r=0.485; p<0.001), glomerular hypertrophy (r=0.358; p<0.001), 
and the number of glomerular macrophages (r=0.492; p<0.001). In 
contrast, the animals’ sex was not correlated with glomerular damage 
(p=0.939), the number of podocytes (p=0.486), glomerular hypertro-
phy (p=0.973), or interstitial fibrosis (p=0.542). We also found no 
significant difference between APOC1-tg and WT mice at 16 months 
of age with respect to renal cortex triglyceride (3.9±0.4 and 4.6±1.7 
nmol/mg tissue, respectively), total cholesterol (10.7±3.1 and 9.8±0.3 
nmol/mg tissue, respectively), or phospholipid (24.3±7.4 and 22.9±0.7 
nmol/mg tissue, respectively) levels. In addition, oil red O staining 
revealed no significant difference in renal lipid deposition between 
APOC1-tg and WT mice at 16 months of age (data not shown).
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Figure 3: APOC1-tg mice develop glomerulosclerosis and interstitial fibrosis. A 
and C. WT mice have normal glomerular morphology at 4 months (A) and 16 months 
(C) of age. B and D. APOC1-tg mice develop kidney damage with ageing, evident as 
mesangial matrix expansion beginning at 9 months of age (B); this expansion pro-
gressed to severe glomerulosclerosis by 15 months of age (D). E-F. The number of 
podocytes decreases with age in APOC1-tg mice, beginning at 13 months of age (E); 
by 20 months, extremely few podocytes remain (F). G-H. At 20 months of age, APOC1-
tg mice (H) develop significantly more interstitial fibrosis than age-matched WT mice 
(G). I. Glomerular damage score plotted against age. J. Glomerular surface area plotted 
against age. K. The number of podocytes per glomerulus plotted against age. L. Intersti-
tial fibrosis per field plotted against age. The sections shown in A-D were stained with 
methenamine silver. The sections shown in E-F were immunostained for WT1, a marker 
for podocytes, and the sections shown in G-H were stained with Sirius red. Scale bars 
indicate 50 µm (A-F) and 25 µm (G-H).
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Influx of inflammatory M1 macrophages in APOC1-tg mice 
Next we examined whether macrophages might be responsible for 
the development of glomerulosclerosis in APOC1-tg mice. Again, we 
separated mice into three age categories for analysis. Even in the 
youngest (≤8 months) APOC1-tg mice had more glomerular macro-
phages than their WT littermates (Figure 4A, B) (p<0.01). This differ-
ence in glomerular macrophages in favour of APOC1-tg mice over 
WT mice remained significant across the age categories (p<0.01) 
(Figure 4C, D, K). Male and female mice did not differ with respect 
to the number of glomerular macrophages (p=0.651). Positive staining 
for CD11b and FA-11 on adjacent slides28, combined with negative 
staining for CD163, indicates that the glomerular macrophages in 
APOC1-tg mice are M1 inflammatory macrophages. In addition, the 
glomeruli in APOC1-tg mice had greater levels of TNF-alpha than WT 
glomeruli (p<0.001) (Figure 4E, F, L), supporting the presence of M1 
macrophages. Both VCAM-1 (Figure 4G, H, M) and ICAM-1 (Figure 4I, 
J, N) were up-regulated in APOC1-tg mice as early as 4 months of 
age, suggesting that both adhesion molecules play a role in the in-
flux of glomerular macrophages. Double-staining for VCAM-1 and von 
Willebrand factor (vWF) revealed that VCAM-1 expression increased 
exclusively in endothelial cells (supplementary material, Figure S2). A 
histological examination of ICAM-1 revealed that its expression was 
also increased in endothelial cells.
ApoCI enhances the inflammatory response
We previously reported that apoCI increases the production of TNF- 
alpha in LPS-stimulated macrophages10 by enhancing the binding of 
LPS to Toll-like receptor 4 (TLR4) via CD1429. Based on these results 
and findings from the present study, we hypothesised that the glomeru-
losclerosis seen in APOC1-tg mice is caused by macrophages express-
ing human APOC1, which leads to an increased cytokine response in 
these macrophages upon activation, ultimately stimulating mesangial 
cells to up-regulate production of the ECM. To test this hypothesis, 
we isolated peritoneal macrophages from both WT and APOC1-tg 
mice, stimulated these cells with LPS, and measured the mRNA ex-
pression levels of inflammatory and fibrogenic cytokines. Compared 
with WT cells, the expression levels of Tnfa and Il1b (pro-inflammatory 
2
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Figure 4: APOC1-tg mice have increased numbers of glomerular macrophages 
and increased endothelial activation. A-D. At 4 months (A, B) and 16 months (C, D) 
of age, APOC1-tg mice (B, D) have more glomerular macrophages than WT mice (A, C). 
E-F. At 16 months of age, TNF-alpha protein levels are higher in APOC1-tg mice (F) than 
in WT mice (E). G-J. At 16 months of age, APOC1-tg mice have increased expression 
of VCAM-1 (H) and ICAM-1 (J) compared with WT mice (G and I, respectively). K. The 
number of macrophages per glomerulus plotted against age. L. TNF-alpha expression 
per glomerulus. M. VCAM-1 expression per glomerulus. N. ICAM-1 expression per glome- 
rulus. *p<0.05, **p<0.001, and ***p<0.001, one-way ANOVA. Scale bars indicate 50 µm.
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cytokines), and the expression levels of Tgfb1 and Pdgfb (both pro- 
fibrotic cytokines) were significantly increased in LPS-stimulated APOC1-
tg macrophages, as well as the expression level of Tlr4 (Figure 5). 
Incubating macrophages with LPS and anti-CD14 antibodies prevented 
the increased expression of cytokines in APOC1-tg macrophages (Fig-
ure 5), consistent with previous data that apoCI enhances the biolo- 
gical response to LPS via the CD14/TLR4 pathway29. 
Figure 5: APOC1-tg macrophages have an increased cytokine response. Macro-
phages were isolated from wild-type (WT) or APOC1-tg mice and stimulated with LPS 
(10 ng/ml) or LPS and anti-CD14 (10 ng/ml) for 6 h at 37°C. The mRNA levels of 
Tnf-alpha, Tgf-beta, Pdgf-beta, Il1-beta, and Tlr4 were measured. The expression levels 
were normalised to the respective LPS-stimulated WT control and are expressed as the 
mean ± sd. ***p<0.001, Student’s t test.
Patients with DN have increased expression of glomerular apoCI
As a first step towards testing the hypothesis that apoCI plays a 
role in human DN, we studied the presence of apoCI in glomeruli of 
non-diabetic subjects and diabetic patients with and without DN. The 
patient characteristics are summarised in the supplementary mate-
rial, Table S3. The glomeruli in non-diabetic controls were generally 
negative for apoCI (Figure 6A). In contrast, the glomeruli of kidneys 
obtained from diabetic patients were positive for apoCI (Figure 6B, 
C). The percentage of apoCI-positive glomeruli was greater in diabetic 
patients with nephropathy than in those without nephropathy (Figure 
6D). Double-label immunostaining revealed that apoCI co-localizes with 
macrophages. In addition, apoCI was present in resident renal cells 
(Figure 6E-G). 
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Figure 6: Patients with DN have increased expression of glomerular apoCI. A. 
Representative kidney section from a control subject showing no glomerular apoCI 
staining. B. Representative kidney section from a patient with diabetes without ne-
phropathy, positive for apoCI. C. Representative kidney section from a patient with 
diabetes and nephropathy. D. The percentage of apoCI-positive glomeruli in con-
trol subjects and diabetic patients with and without DN. E-G. Double-label immuno- 
staining for apoCI (E) and CD68 (F) shows co-localization of apoCI with CD68-po- 
sitive macrophages (arrows); Panel G shows a merged image. ApoCI is also pre- 
sent in resident renal cells. ***p<0.001, one-way ANOVA. Scale bars indicate 50 µm. 
Discussion
Here, we report that transgenic mice expressing the human APOC1 
gene develop glomerulosclerosis and renal dysfunction with increased 
albuminuria beginning at 14 months of age. The degree of kidney 
damage was correlated strongly with age, glomerular hypertrophy, 
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reduced podocyte numbers, and the number of glomerular macro-
phages. Moreover, apoCI increased the expression of inflammatory 
and fibrogenic cytokines in macrophages upon stimulation in vitro. 
Our finding that renal cortex lipid content – specifically, triglycerides, 
total cholesterol, and phospholipids – does not differ between APOC1-
tg mice and WT mice suggests that the development of renal damage 
in APOC1-tg mice is not due to changes in lipid metabolism, but is 
likely to be due to a different function of apoCI, possibly through 
the activation of macrophages. This notion is supported by the 
finding that the increased apoCI concentration in patients with type 
2 diabetes (T2D) is only partially explained by increased TG levels 
in these patients30. To further investigate the involvement of APOC1 
in the development of renal damage, we examined whether APOC1 
expression was increased in STZ-induced diabetic WT mice, an animal 
model for diabetic nephropathy. The mRNA levels of mouse ApoC1 in 
the livers of STZ-induced diabetic WT mice were 2.8-fold higher than 
those in control WT mice, supporting the role of apoCI in DN. These 
findings are clinically relevant, as they show that apoCI plays a role 
in the pathogenesis of glomerulosclerosis. Interestingly, we found that, 
compared with controls, patients with diabetes and DN showed a sig-
nificant increase in glomerular apoCI expression, supporting our hypo- 
thesis that apoCI plays a role in the pathogenesis of glomerulosclero-
sis in DN. Our double-label immunostaining experiments revealed that 
apoCI co-localized with macrophages, and apoCI was also present in 
resident renal cells. Given that the renal cells do not express human 
APOC1 mRNA, this indicates that the apoCI present in resident renal 
cells was taken up either from macrophages or from the circulation.
Bouillet et al. recently reported that patients with type 1 diabetes 
(T1D) develop less nephropathy compared with T2D patients, even 
though T1D and T2D patients have similar increases in plasma apoCI 
levels compared with control subjects8. It is important to note that 
Bouillet et al. used proteinuria levels as a measure of nephropathy; 
therefore, it is possible that nephropathy was underdiagnosed. This 
notion is supported by our recent finding that DN lesions can devel-
op before the onset of clinical findings; specifically, 20 out of 106 
patients with histologically confirmed DN did not present with DN- 
associated clinical manifestations31. 
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We propose that apoCI mediates the development of glomerulo-
sclerosis in APOC1-tg mice via at least two distinct mechanisms. First, 
APOC1 expression results in dyslipidaemia22,32, which is reported to 
increase the expression of VCAM-1 and ICAM-1 in glomeruli33,34. These 
proteins mediate monocyte/macrophage infiltration and thereby con-
tribute to the severity of DN. This is supported by the finding that 
diabetic ICAM-1-deficient mice have reduced glomerular infiltration 
of macrophages and are protected from developing renal injury20. 
Second, apoCI – either derived from the circulation10 or expressed by 
macrophages ‒ increases the inflammatory and fibrogenic response 
of stimulated macrophages, including increased expression of TNF- 
alpha and TGF-beta. These cytokines have been reported to increase 
the expression of ECM proteins in mesangial cells17,35-38. In addition 
to increasing matrix production, both TNF-alpha and TGF-beta down- 
regulate expression of the protein nephrin in podocytes, thereby al-
tering glomerular permeability and leading to albuminuria39. TGF-beta 
also induces apoptosis in podocytes40. 
Glomerular nodules, also known as Kimmelstiel-Wilson nodules, are 
characteristic of class III DN26 and may be a form of microangiopa-
thy41. APOC1-tg mice develop a renal phenotype with nodular glome- 
rulosclerosis, with increased collagen types I, IV, and VI, increased re-
nal dysfunction, increased glomerular hypertrophy, reduced podocyte 
numbers, and interstitial fibrosis – all of which are reminiscent of DN, 
even though these mice are not diabetic. These results support our 
previous finding that DN can develop without clinical manifestations31. 
With the exception of BTBR Ob/Ob mutant mice16, nodular glomeru-
losclerosis is generally not observed in mice. In addition to its role in 
the development of glomerulosclerosis, apoCI also plays a role in the 
development of atherosclerosis. The apoCI content of triglyceride-rich 
lipoproteins (TRLs) is an independent predictor of early atheroscle-
rosis42 and is correlated with plaque size in carotid atherosclerosis43. 
Likewise, we previously reported that endogenous apoCI expression in 
hyperlipidaemia mice increased the size of atherosclerotic lesions by 
60%, and this was related to an increased inflammatory response in 
macrophages44. Moreover, increased apoCI levels in TRL particles are 
also present in patients with DN45, and diabetes is known to increase 
the risk of cardiovascular disease, including atherosclerotic disease 
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and congestive heart failure46. The finding that apoCI is involved in 
both nodular glomerulosclerosis and atherosclerosis supports the no-
tion that glomerular nodules may be the result of vascular damage. 
Taken together, our results obtained from APOC1-tg mice and 
patients with DN provide new insights into the role that apoCI plays 
in the development of glomerulosclerosis and suggest apoCI as a 
therapeutic target for slowing the progression of DN in high-risk pa-
tients. These data also shed new light on the mechanism by which the 
inflammatory and fibrogenic response is increased in macrophages, 
potentially leading to the development of nodular glomerulosclero-
sis present in APOC1-tg mice. Future studies should help determine 
whether macrophages are indeed the key contributor to the observed 
renal phenotype and whether APOC1 affects the development of DN.
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Table S1: Absolute and relative organ weights in WT and APOC1-tg mice at 6 
months of age.













Kidney (left) 0.16±0.03 0.18±0.04 0.56±0.04 0.64±0.09**
Kidney (right) 0.17±0.03 0.18±0.03 0.57±0.04 0.66±0.09***
Heart 0.15±0.03 0.20±0.03 0.52±0.04 0.58±0.07*
Liver 1.36±0.25 1.27±0.25 4.62±0.19 4.55±0.58
Brain 0.33±0.02 0.34±0.04 1.16±0.21 1.24±0.20
Lungs 0.18±0.01 0.19±0.03 0.64±0.12 0.68±0.13
Spleen 0.09±0.01 0.10±0.02 0.32±0.07 0.38±0.10
Pancreas 0.28±0.07 0.26±0.05 0.96±0.18 0.95±0.17
Total Body Weight 29.4±5.0 27.9±4.3 NA NA
*p<0.05, **p<0.01, and ***p<0.001 versus WT; Student’s t test. NA, not applicable.
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Table S2: Laboratory values of WT and APOC1-tg mice at 6 months of age.
WT APOC1-tg
Triglycerides (mmol/L) 0.58±0.06 2.83±0.97***
Total cholesterol (mmol/L) 2.33±0.28 3.88±0.91***
HDL-C (mmol/L) 2.14±0.33 2.33±0.64
Non-HDL-C (mmol/L) 0.19±0.13 1.56±0.49***
GOT (U/L) 0.2±0.1x10-3 0.1±0.06x10-3
CK (U/L) 1.2±0.1x10-3 1.4±0.8x10-3
Haemoglobin (mmol/L) 11.03±0.71 10.91±0.72
White blood cells (x109) 2.607±0.59 2.391±0.30
BUN (mg/dl) 31.25±6.76 27.19±5.18
Serum creatinine (µmol/L) 11.0±2.7 13.0±2.8
Blood glucose (mmol/L) 11.83±1.60 11.42±2.54










Age (years) 65±12 76±12 72±9
DM duration (years) NA 12±10 23±13
HbA1c (%) NA 7.4±0.26 7.9±0.84
Serum creatinine (µmol/ml) NA 310±282 310±141
Blood pressure (systolic/diastolic) NA 137/73 134/79
Data are presented as the mean ± sd; blood pressure is presented as the mean value. 
DM, diabetes mellitus; DN, diabetic nephropathy; NA, not applicable.
Apolipoprotein C-I plays a role in the pathogenesis of glomerulosclerosis
Data are presented as the mean ± sd. HDL-C, high-density lipoprotein cholesterol; BUN, 
blood urea nitrogen; GOT, glutamate oxaloacetate transaminase; CK, creatinine kinase. 
*p<0.05, **p<0.01, and ***p<0.001 versus WT, Student’s t test.
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Figure S1: Sclerotic lesions contain deposits of collagen type I, collagen type 
IV, collagen type VI, and fibronectin. Glomerulosclerotic lesions in a 16-month-old 
APOC1-tg mice have an intense staining pattern for the extracellular matrix (ECM) 
proteins collagen type I (A), collagen type IV (B), and fibronectin (C). Collagen type VI 
is also present in the sclerotic lesions (D), but only in the peripheral areas (arrow).
Figure S2: VCAM-1 expression in endothelial cells. A-C. Double-label immunostaining 
for VCAM-1 (A) and von Willebrand factor (B) in the kidneys of a 16-month-old APOC1-




PAS, Silver, and Sirius Red staining
Paraffin-embedded sections (4 µm thickness) were oxidised in peri-
odic acid at 48°C for 30 minutes, then washed with demi-water. The 
sections were then incubated in 5% Schiff’s reagent for 20 minutes, 
incubated in tap water for 5 minutes, then rinsed briefly in demi-water. 
Finally, the sections were incubated in haematoxylin for 5 minutes, 
followed by incubation in tap water for 5 minutes. 
For silver staining, paraffin-embedded sections (1-µm thickness) 
were cut and incubated in 1% periodic acid for 10 minutes at 60°C, 
and then stained in a silver solution at 60°C until the glomerular 
basement membranes became black. The sections were then incuba- 
ted in 0.2% gold chloride until the sections became light grey. Finally, 
the sections were incubated for 2 minutes in 5% sodium thiosulfate, 
10 minutes in tap water, and 30 seconds in eosin. 
Paraffin-embedded sections were stained with Sirius Red by incu-
bating sections with 0.2% phosphomolybdic acid for 5 minutes, 0.1% 
Sirius Red for 90 minutes, and saturated picric acid for 1 minute.
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Primer sequences
Hprt1: 5’-GGCTATAAGTTCTTTGCTGACCTG-3’ and 5’-AACTTTTATGTC-
CCCCGTTGA-3’; human APOC1: 5’-AGCCGCATCAAACAGAGTGA-3’ and 
5’-TCCTGGGATGTCACCCTTCA-3’; mouse ApoC1: 5’- GTCCGGAACATTG-
GAGAGCA-3’ and 5’-CCTGAAAGGTCCTAACCGGG-3’; mouse Tnf-alpha: 
5’-GGTGCCTATGTCTCAGCCTC-3’ and 5’-GCTCCTCCACTTGGTGGTTT-3’; 
mouse Tgf-beta: 5’-AGCTGCGCTTGCAGAGATTA-3’ and 5’-AGCCCTGTAT-
TCCGTCTCCT-3’; mouse Pdgf-beta: 5’-TGTGAGACAGTAGTGACCCCT-3’ 
and 5’-AAACTTTCGGTGCTTGCCTTT-3’; mouse Il1-beta: 5’-GCTCTC-
CACCTCAATGGACA-3’ and 5’-GTGGGTGTGCCGTCTTTCAT-3’.

The VEGF-A inhibitor sFLT-1 improves renal function 
by reducing endothelial activation and inflammation 
in a mouse model of type 1 diabetes
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A. Bruijn and Hans J. Baelde




Aims/hypothesis Animal models of diabetic nephropathy show in-
creased levels of glomerular vascular endothelial growth factor 
(VEGF)-A, and several studies have shown that inhibiting VEGF-A in 
animal models of diabetes can prevent albuminuria and glomerular 
hypertrophy. However, in those studies, treatment was initiated before 
the onset of kidney damage. Therefore, the aim of this study was to 
investigate whether transfecting mice with the VEGF-A inhibitor sFlt-1 
(encoding soluble fms-like tyrosine kinase 1) can reverse pre-existing 
kidney damage in a mouse model of type 1 diabetes. In addition, we 
investigated whether transfection with sFlt-1 can reduce endothelial 
activation and inflammation in these mice. 
Methods Subgroups of untreated 8-week-old female C57BL/6J control 
(n=5) and diabetic mice (n=7) were euthanised 5 weeks after the start 
of the experiment in order to determine the degree of kidney damage 
prior to treatment with sFLT-1. Diabetes was induced by three i.p. in-
jections of streptozotocin (75 mg/kg) administered at 2 day intervals. 
Diabetic nephropathy was then investigated in diabetic mice trans-
fected with sFlt-1 (n=6); non-diabetic, non-transfected control mice 
(n=5); non-diabetic control mice transfected with sFlt-1 (n=10), and 
non-transfected diabetic mice (n=6). These mice were euthanised at 
the end of week 15. Transfection with sFlt-1 was performed in week 6. 
Results We found that transfection with sFlt-1 significantly reduced 
kidney damage by normalising albuminuria, glomerular hypertrophy 
and mesangial matrix content (i.e. glomerular collagen type IV protein 
levels) (p<0.001). We also found that transfection with sFlt-1 reduced 
endothelial activation (p<0.001), glomerular macrophage infiltration 
and glomerular TNF-α protein levels (p<0.001). Finally, sFLT-1 de-
creased VEGF-A-induced endothelial activation in vitro (p<0.001).
Conclusions/interpretation These results suggest that sFLT-1 might 
be beneficial in treating diabetic nephropathy by inhibiting VEGF-A, 
thereby reducing endothelial activation and glomerular inflammation, 
and ultimately reversing kidney damage.
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sFLT-1 improves renal function by reducing endothelial activation and inflammation
Introduction
Diabetic nephropathy is characterised by damage and dysfunction of 
the microvasculature1. A critical factor in maintaining the microvascu-
lature is vascular endothelial growth factor (VEGF)-A, which regulates 
many aspects of vascular physiology, including vascular permeability 
and the migration, proliferation and survival of endothelial cells (for 
review, see Bartlett et al.)2. Several studies in both human and animal 
models have indicated that proper glomerular function requires tight 
regulation of VEGF-A levels, as both upregulation and downregulation 
of VEGF-A can lead to kidney disease3.
Animal models of diabetic nephropathy develop increased levels of 
glomerular VEGF-A4,5, possibly due to the effect of high glucose on 
VEGF-A production in podocytes6. Therefore, inhibiting VEGF-A may be 
beneficial in treating renal complications. Consistent with this notion, 
antibodies directed against VEGF-A have been shown to prevent albu-
minuria7,8 and glomerular hypertrophy9 in animal models of diabetes. 
However, in these studies, the inhibition of VEGF-A was initiated prior 
to the onset of diabetic kidney disease (i.e. prior to the development 
of albuminuria, glomerular hypertrophy, and mesangial expansion/
matrix production); thus, whether this strategy is feasible for treating 
diabetic people with existing kidney damage is currently unknown.  
In addition to its role in maintaining vascular homeostasis, VEGF-A 
also facilitates the migration of monocytes and macrophages. Several 
studies found that macrophages play a role in diabetic nephropa-
thy10-12. VEGF-A‒induced migration of monocytes and macrophages 
is mediated by the binding of VEGF-A to VEGF receptor (VEGFR)-1 
(also known as fms-related tyrosine kinase (FLT)-1) expressed on 
these cells13-15. In addition, both VEGF-A16 and high glucose levels17 
can activate endothelial cells, leading to increased levels of vascular 
cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule 
(ICAM)-1, thereby promoting monocyte infiltration. 
Here, we investigated whether the VEGF-A inhibitor soluble FLT-1 
(sFLT-1; also known as soluble VEGFR-1) can reduce renal compli-
cations, including albuminuria and mesangial matrix expansion, in a 
mouse model of type 1 diabetes and pre-existing kidney damage. In 
addition, because diabetic nephropathy is accompanied by endothelial 
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activation1 and macrophage infiltration11,12,18, both of which are medi-
ated by VEGF-A, we also investigated the effect of inhibiting VEGF-A 
on these variables. Last, we investigated whether transfection with 
sFlt-1 reduces glomerular TNF-α protein levels (a measure of inflam-
mation) in diabetic mice.
Methods
sFlt-1 transfection 
pcDNA3.1 vectors (Invitrogen, Breda, the Netherlands) containing ei-
ther mouse sFlt-1-VSV or the luciferase gene, both of which are dri- 
ven by the cytomegalovirus promoter, were constructed as described 
previously19. The plasmids were amplified in Escherichia coli DH5α 
(Invitrogen), purified using the QIAfilter Plasmid Maxi-prep kit (Qiagen, 
Venlo, the Netherlands), and dissolved in EndoFree Tris–EDTA buffer 
(Qiagen). The mice were co-transfected with the sFlt-1-VSV and luci- 
ferase constructs in both calf muscles (20 µg each) using electropora-
tion, as described previously19. To monitor transfection efficiency, the 
mice were injected with i.p. luciferin at 2-week intervals. Five minutes 
after the luciferin injection, luciferase activity was visualized using a 
NightOWL bioluminescence camera (Xenogen Ivis Spectrum, Alameda, 
CA, USA), as described previously19.
Tube formation assay
To confirm functional expression of the sFlt-1 construct, we performed 
a tube formation assay as described previously20. In brief, human 
umbilical vein endothelial cells (HUVECs) (1.5x103 cells per well; Pro-
mocell, Heidelberg, Germany) were plated on Matrigel-coated 96-well 
plates (Corning, Amsterdam, the Netherlands). The HUVECs were incu-
bated for 6 h with culture medium obtained from human embryonic 
kidney 293 (HEK293) cells (ATCC, Manassas, VA, USA) transfected 
with an sFlt-1 construct (2 µg), or a luciferase construct (2 µg). The 
HEK293 cells were transfected using 6 µl X-tremeGENE (Roche, Ba-
sel, Switzerland); 2 days after transfection, the culture medium was 
collected and applied to the HUVECs in the presence or absence of 
VEGF-A (10 ng/ml; R&D Systems, Minneapolis, MN, USA). The number 
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of tube branch points was counted in five 400X fields. Images were 
taken using a Moticam camera (Motic, Xiamen, China). This experiment 
was performed three times.
Animals
This study used 8-week-old female C57BL/6J mice (specific pathogen 
free; Harlan Laboratories, Indianapolis, IN, USA), weighing 17.8 ± 1.1 
g (mean ± SD). All experiments were conducted in accordance with 
national guidelines for the care and use of experimental animals (DEC 
license 13163). Mice were housed in individually ventilated cages in 
groups of five mice, with food and water ad libitum. C57BL/6J mice 
were chosen because this study was a follow-up of a previous study 
that investigated podocyte-specific VEGF-A knock-down on a C57BL/6 
background21. Moreover, C57BL/6J mice respond well to the strep-
tozotocin (STZ) regimen in terms of blood glucose levels22. Diabetes 
was induced by three i.p. injections of STZ (75 mg/kg body weight; 
Sigma-Aldrich, St. Louis, MO, USA) administered at 2 day intervals. 
Blood glucose levels were measured (Accu-Chek, Roche) at the end 
of weeks 1, 5 and 15 after diabetes induction. Mice with a blood 
glucose level of 15 mmol/L or higher were considered diabetic. Mice 
were randomly divided into groups. Subgroups of untreated control 
mice (n=5) and diabetic mice (n=10) were killed 5 weeks after the 
start of the experiment in order to determine the degree of kidney 
damage prior to treatment with sFLT-1. In week 6, the mice were 
transfected with a plasmid containing sFlt-1. Diabetic nephropathy 
was then investigated in diabetic mice transfected with sFlt-1 (n=10), 
non-diabetic, non-transfected control mice (n=5), non-diabetic control 
mice transfected with sFlt-1 (n=10), and non-transfected diabetic mice 
(n=10). These mice were killed at the end of week 15. Three diabetic 
mice 5 weeks after the induction of diabetes, four diabetic mice trans-
fected with sFlt-1 and four diabetic mice 15 weeks after the induction 
of diabetes were excluded from the study as they did not met the 
inclusion criteria of a blood glucose level of 15 mmol/L or higher.
Measurement of the urine albumin excretion ratio 
To measure the urine albumin excretion ratio, spot urine was col-
lected in weeks 5 and 15. Urine albumin levels were measured using 
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rocket immunoelectrophoresis with rabbit anti-mouse albumin; purified 
mouse serum albumin (Sigma-Aldrich) was used as a standard. Urine 
creatinine was measured using a creatinine assay, with picric acid, 
sodium hydroxide and creatinine standards (Sigma-Aldrich); the albu-
min:creatinine ratio was then calculated. 
Immunohistochemistry
Paraffin-embedded kidney tissues (4 µm thickness) were cut using 
a Leica microtome (Wetzlar, Germany) and stained with periodic 
acid-Schiff’s reagent using a standard protocol. Rabbit anti-mouse 
platelet/endothelial cell adhesion molecule 1 (PECAM-1; 1:400; Santa 
Cruz Biotechnology, Dallas, TX, USA), rabbit anti-human Wilms tu-
mour (WT)1 (1:500; Santa Cruz Biotechnology) and rabbit anti-mouse 
collagen type IV (1:200; Abcam, Cambridge, UK) primary antibodies 
were used for immunostaining, followed by the anti-rabbit-Envision 
HRP-conjugated secondary antibody (undiluted; Dako, Glostrup, Den-
mark), with diaminobenzidine (DAB+; Dako) as the chromogen. The 
rabbit anti-human WT1 antibody cross-reacts with mouse WT1 (data 
not shown). As a negative control, non-specific isotype matched an-
tibodies were used.  
Frozen kidney tissues (4 µm thickness) were cut using a Leica 
cryostat. Rabbit anti-mouse fibronectin (1:2400; Sigma-Aldrich), rat 
anti-mouse CD68 (1:15; Abcam), rat anti-mouse VCAM-1 (1:1400; 
BD Pharmingen, San Diego, CA, USA), rat anti-mouse ICAM-1 (1:200; 
ATCC), rabbit anti-mouse TNF-α (1:100; Abcam), and rabbit anti-vesi- 
cular stomatitis virus (VSV; 1:2500; Sigma-Aldrich) primary antibodies 
were used for immunostaining, followed by the appropriate Envision 
(undiluted; Dako) or Impress (undiluted; Vector Laboratories, Bur- 
lingame, CA) HRP-conjugated secondary antibody, with DAB+ as the 
chromogen. As a negative control, non-specific isotype matched anti-
bodies were used. Antibodies were tested for specificity with western 
blot analysis (PECAM-1, WT1, fibronectin, CD68, ICAM-1, TNF-α, VSV), 
immunoprecipitation (VCAM-1) or immunogen affinity purified (collagen 




Sections were digitized using the Philips Ultra-Fast Scanner 1.6 RA 
(Amsterdam, the Netherlands). The surface area of the glomerular 
tuft (in µm2) was measured in periodic acid-Schiff’s reagent-stained 
slides with 25 glomeruli per section using Philips Ultra-Fast Scanner 
1.6 RA software (Philips). ImageJ software (https://imagej.nih.gov/ij/) 
was used to measure the levels of fibronectin, collagen type IV, PE-
CAM-1, VCAM-1, ICAM-1, and TNF-α. The positive area per glomerulus 
was determined by measuring the respective positively stained area, 
corrected for the total area of the glomerulus (ten and 25 glomeruli 
per frozen and paraffin-embedded section, respectively) at x400 mag-
nification. The number of podocytes in each sample was determined 
by counting the number of WT1-positive nuclei per glomerulus in 25 
glomeruli. The number of macrophages was determined by counting 
the number of CD68-positive cells in 10 glomeruli. The glomeruli used 
for these measurements were selected at random. Experimenters were 
blind to group assignment and outcome assessment.
Endothelial activation assay
HUVECs that were confluent for 2 days were incubated with VEGF-A 
(20 ng/ml; R&D Systems) for 2, 4, 6 and 8 h. To determine the 
effect of sFLT-1 on VEGF-A-induced endothelial activation, HUVECs 
were incubated for 4 h with sFLT-1 (0, 10, 100 or 1000 ng/ml; R&D 
Systems) in the presence of 20 ng/ml VEGF-A. These experiments 
were performed three times. Cell lines were negative for mycoplasma 
contamination.  
To quantify changes in gene expression, total RNA was extracted 
from HUVECs using TRIzol extraction buffer (ThermoFisher Scientif-
ic, Waltman, MA, USA) and converted to cDNA with AMV reverse 
transcriptase (Roche) using random hexamer primers. Quantitative 
real-time PCR was performed using IQ SYBR Green Supermix (Bio-Rad, 
Hercules, CA, USA) on a Bio-Rad CFX real-time system. Cycle thres- 
hold values were normalized to the housekeeping gene HPRT1. The 
following primers were used in this study: HPRT1: 5’-AGATGGTCAAG-
GTCGCAAGC-3’ and 5’-TCAAGGGCATATCCTACAACAAAC-3’; ICAM-1: 
5’-CAGAGGTTGAACCCCACAGT-3’ and 5’-CCTCTGGCTTCGTCAGAATC-3’; 
SELE: 5’-AGCCCAGAGCCTTCAGTGTA-3’ and 5’-AACTGGGATTTGCTGT-
sFLT-1 improves renal function by reducing endothelial activation and inflammation
3
70
GTCC-3’. Primers for amplifying VCAM-1 were obtained from Sino 
Biological (North Wales, PA, USA).
Statistical analyses
Data are expressed as means ± SD. Data were analyzed using the 
two-tailed Student’s t test or one-way ANOVA. We also used a one-
way ANOVA to analyse the effect of sFLT-1 treatment in diabetic mice 
(week 15), corrected for the effect of time. Differences were consi- 
dered significant at p<0.05.
Results
Transfection with sFlt-1 reduced endothelial tube formation 
in vitro
To confirm functional expression of the sFlt-1 construct, we per-
formed a tube formation assay. First, HUVECs were cultured in me-
dium obtained from luciferase-transfected HEK293 cells. The addition 
of VEGF-A (10 ng/ml) to the culture medium led to increased tube 
formation (Figure 1A, B), reflected by an increased number of branch 
points (Figure 1E). VEGF-A‒induced tube formation was significantly 
inhibited by medium obtained from sFlt-1‒transfected HEK293 cells 
(Figure 1D), confirming that expression of the sFlt-1 construct inhibits 
VEGF-A‒induced tube formation. As a control, culturing HUVECs with 
medium obtained from sFlt-1‒tranfected HEK293 cells had no effect 
on tube formation in the absence of VEGF-A (Figure 1C). 
Expression of sFLT-1 in mice by co-transfection with the sFlt-1-
VSV and luciferase constructs
Diabetes was induced in mice by i.p. injections of STZ (see Methods). 
In week 6, mice were transfected with the sFlt-1-VSV and luciferase 
constructs by bilateral injection in the calf muscle. Transfection was 
confirmed by injecting mice with luciferin (see electronic supplemen-
tary material [ESM] Figure 1). Staining for VSV was used to confirm 





Figure 1: sFLT-1 inhibited VEGF-A-induced tube formation in vitro. (a-d) HUVECs 
were cultured in the presence or absence of VEGF-A (10 ng/ml) and/or sFLT-1, and 
the number of branch points was measured. E. Summary of the total number of branch 
points measured in five fields under each condition. Boxes represent 1st and 3rd quar-
tiles; whiskers represent minimum and maximum number of branch points; horizontal 
line represents median number of branch points. ***p<0.001, one-way ANOVA. Scale 
bars, 100 µm.
Transfection with sFlt-1 reduced kidney damage in diabetic mice
We first determined the development of kidney damage in diabetic 
mice 5 weeks after diabetes was induced. Inducing diabetes led to
albuminuria, reflected by an albumin:creatinine ratio of 8.53 ± 2.59 
mg/mmol, which was significantly higher than in control mice (3.06 ± 
0.98 mg/mmol; p<0.001) (Figure 2A). In addition, compared with con-
trol mice, diabetic mice developed glomerular hypertrophy (p<0.001) 
(Figure 2B). Podocyte numbers did not differ between diabetic and 
control mice (Figure 2C). The protein levels of both collagen type IV 
and fibronectin—two markers of mesangial matrix expansion—were 
higher in the diabetic mice compared with control mice (p<0.001) 
(Figure 2D-F and Figure 2G-I, respectively). 
Having confirmed that kidney damage develops in these mice 
within 5 weeks, we next examined the effect of sFlt-1 transfection; 
transfection with sFlt-1 was performed in week 6 and the mice were 
analyzed 9 weeks after transfection (i.e. 15 weeks after diabetes was 
induced). Our analysis revealed that sFLT-1 significantly reduced all 
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markers of kidney damage in the diabetic mice, including albuminuria, 
glomerular hypertrophy, and mesangial matrix expansion (p<0.001) 
(Figure 2A, B, D, G). Compared with control-transfected diabetic mice, 
sFlt-1‒transfected diabetic mice had significantly fewer podocytes 
(p<0.01) (Figure 2C). Transfecting control (i.e. non-diabetic) mice with
Figure 2: sFLT-1 reversed kidney damage in diabetic mice. Mice were injected 
with STZ to induce diabetes. In week 6, diabetic (“D”) and control (“C”) mice were 
transfected with a construct expressing sFlt-1 (“S”). At 5 and 15 weeks, albuminuria (a; 
albumin:creatinine ratio [ACR]), glomerular hypertrophy (b), glomerular podocytes (c), 
collagen type IV positivity (d), and fibronectin positivity (g) were measured. e, f. Rep-
resentative images of collagen type IV immunostaining in an untreated diabetic mouse 
at week 15 (e) and a diabetic mouse transfected with sFlt-1 (f). h, i. Representative 
images of fibronectin immunostaining in an untreated diabetic mouse at week 15 (h) 
and a diabetic mouse transfected with sFlt-1 (i). ***p<0.001, Student’s t test between 
groups at week 5. *p<0.05, **p<0.01, and ***p<0.001, one-way ANOVA between groups 
at week 15. †p<0.05 and †††p<0.001 vs the corresponding diabetic mice at 5 weeks, one-
way ANOVA after correcting for the time effect. Bars represent means ± SD. Number 
of animals: non-diabetic, non-transfected control mice at 5 and 15 weeks (n=5 mice 
each); non-transfected diabetic mice at 5 and 15 weeks (n=7 and n=6, respectively); 
non-diabetic control mice transfected with sFlt-1 (n=10); and diabetic mice transfected 
with sFlt-1 (n=6). Scale bar: 50 µm.
Chapter 3 
73
sFlt-1 had no effect on any of the markers investigated (Figure 2). 
Finally, compared with diabetic mice at week 5, sFlt-1‒transfected 
diabetic mice at week 15 had significantly lower levels of albuminuria 
and collagen type IV (p<0.05 and p<0.001, respectively), indicating 
that transfection with sFlt-1 can reverse pre-existing kidney damage 
(Figure 2A, D). 
Transfection with sFlt-1 reduced endothelial activation and 
inflammation in diabetic mice 
Next, we measured endothelial activation in diabetic and control mice 
at the 5-week time point. Compared with control mice, the diabetic 
mice had increased glomerular endothelial activation, reflected by 
increased levels of VCAM-1, ICAM-1 and PECAM-1 (p<0.001) (Figure 
3A-C). The diabetic mice also had increased levels of glomerular 
TNF-α (p<0.001) (Figure 3D) and increased numbers of glomerular 
macrophages (p<0.001) compared with control mice (Figure 3E, F). 
At week 15, all three markers of glomerular endothelial cell activa-
tion remained increased in the diabetic mice compared with control 
(non-diabetic) mice (p<0.001) (Figure 3A-C). At week 15, the diabe- 
tic mice also had more infiltration of glomerular macrophages and 
increased levels of glomerular TNF-α compared with control mice 
(p<0.001). Strikingly, transfection with sFlt-1 significantly reduced all of 
these markers of glomerular endothelial activation and inflammation 
in the diabetic mice (p<0.01); in most cases, the marker was reduced 
to control levels (Figure 3A-E). Transfecting control (non-diabetic) mice 
with sFlt-1 had no effect on any of the markers investigated (Figure 
3A-E). Compared with diabetic mice at week 5, sFlt-1‒transfected di-
abetic mice at week 15 had significantly lower levels of ICAM-1 and 
PECAM-1 (p<0.01) (Figure 3B, C).
sFLT-1 reduced VEGF-A-induced endothelial activation in a 
dose-dependent manner
Our data suggest that sFlt-1 transfection in diabetic mice reduces 
kidney damage by reducing the glomerular infiltration of macro-
phages and by lowering the production of pro-inflammatory molecules 
such as TNF-α. Activation of endothelial cells is a key factor in this 
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Figure 3: sFLT-1 reduced glomerular endothelial activation, the number of glo-
merular macrophages and glomerular inflammation in diabetic mice. Mice were 
injected with STZ to induce diabetes. In week 6, diabetic (“D”) and control (“C”) mice 
were transfected with a construct expressing sFlt-1 (“S”). At 5 and 15 weeks, VCAM-1 
(a), ICAM-1 (b), PECAM-1 (c), TNF-α (d) and the number of glomerular macrophages (e) 
were measured. ***p<0.001, Student’s t test between groups at week 5. **p<0.01 and 
***p<0.001, one-way ANOVA between groups at week 15. ††p<0.01 vs the corresponding 
diabetic mice at 5 weeks, one-way ANOVA after correcting for the time effect. Bars 
represent means ± SD. Number of animals: non-diabetic, non-transfected control mice 
at 5 and 15 weeks (n=5 mice each); non-transfected diabetic mice at 5 and 15 weeks 
(n=7 and n=6, respectively); non-diabetic control mice transfected with sFlt-1 (n=10); 
and diabetic mice transfected with sFlt-1 (n=6). f. Representative image of macrophages 
present in a glomerulus of a diabetic mouse at week 15 after staining for CD68. Scale 
bar: 50 µm.
process, as it mediates the vascular adhesion of monocytes and their 
migration from the bloodstream into the tissue. Therefore, we inves-
tigated the in vitro effect of sFLT-1 on VEGF-A‒induced endothelial 
activation. First, we measured the time course of VEGF-A‒induced en-
dothelial activation. Incubating HUVECs with 20 ng/ml VEGF-A induced 
endothelial activation, reflected by significant increases in expression 
of the genes encoding E-selectin (SELE) and VCAM-1 (VCAM-1) com-
pared with unstimulated HUVECs; the mRNA levels of SELE and VCAM-
1 peaked 6 and 4 h, respectively, after stimulation (Figure 4A, B). In 
contrast, the expression of ICAM-1 was not significantly affected by 
VEGF-A stimulation (data not shown). 
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Next, we investigated the effect of applying various concentrations 
of sFLT-1 on endothelial activation in HUVECs 4 h after stimulation 
with VEGF-A (Figure 4C, D). We found that sFLT-1 significantly de-
creased the VEGF-A‒induced upregulation of VCAM-1 (p<0.001) in a 
dose-dependent manner. sFLT-1 did not significantly affect the VEGF-
A-induced upregulation of SELE. sFLT-1 had no effect on the mRNA 
levels of SELE or VCAM-1 in unstimulated cells.
Figure 4: In vitro treatment with sFLT-1 reduced VEGF-A‒induced endothelial 
activation in a dose-dependent manner. (a) SELE and (b) VCAM-1 mRNA levels were 
measured in HUVECs incubated with 20 ng/ml VEGF-A for 2, 4, 6 or 8 h; each mRNA 
level is plotted relative to the respective level in untreated HUVECs. (c) SELE and (d) 
VCAM-1 mRNA levels were measured in HUVECs incubated with 20 ng/ml VEGF-A for 4 
h in the presence of 10, 100 or 1000 ng/ml sFLT-1 (S10, S100 or S1000, respective-
ly). C, cells that were not treated with either VEGF-A or sFlt-1; V, cells stimulated with 
VEGF-A but were not treated with sFLT-1. Each mRNA level is plotted relative to the 
respective level in untreated cells. Bars represent average ± SD. *p<0.05 and ***p<0.001 
vs the respective untreated control group, one-way ANOVA. †††p<0.001 vs the respective 
VEGF-A‒stimulated group.




Here, we show that transfection with the VEGF-A inhibitor gene sFlt-1 
in mice with diabetic nephropathy reverses pre-existing kidney damage 
by normalising albumin:creatinine levels and mesangial matrix content. 
Furthermore, transfection with sFlt-1 in diabetic mice also reduced 
endothelial activation (measured as VCAM-1, ICAM-1, and PECAM-1 
protein levels), glomerular infiltration of macrophages, and glomerular 
TNF-α protein levels. Finally, treating HUVECs with sFLT-1 decreased 
VEGF-A-induced endothelial activation in a dose-dependent manner. 
Taken together, these data suggest that treatment with sFLT-1 may 
be beneficial in individuals with diabetic nephropathy.
Animal models of diabetic nephropathy develop increased levels of 
glomerular VEGF-A4,5, and inhibiting VEGF-A in diabetic animal models 
can prevent the development of albuminuria, glomerular hypertrophy 
and podocyte loss7-9,23. Consistent with these findings, podocyte-spe-
cific overexpression of sFlt-1 has been reported to reduce mesangial 
expansion and glomerular basement membrane thickening in diabetic 
mice24. However, this study did not investigate the effect of systemic 
sFLT-1 treatment, which will likely be required to treat individuals with 
diabetes. In contrast, other studies have found that anti-VEGF-A treat-
ment has no effect on early renal pathology25, and that podocyte-spe-
cific deletion of Vegfa in diabetic mice causes increased proteinuria 
and kidney damage21. Moreover, although another study reported that 
treating diabetic mice with sFLT-1 decreased albuminuria, it did not 
reduce glomerular matrix deposition and led to an increase in tubular 
damage26. These conflicting results could be due to a variety of fac-
tors, including the time at which treatment is initiated, and the dose 
and/or type of anti-VEGF-A treatment used (e.g. an anti-VEGF-A anti-
body, a VEGFR2 inhibitor or sFLT-1). For example, using a construct 
in which domain 2 of FLT-1 is linked to human IgG1Fc may lead to 
increased inflammation due to binding to Fc receptors on macro-
phages (for review, see Guilliams et al.27), leading to increased tubular 
damage26 independent of sFLT-1. In contrast, we used a full-length 
sFLT-1 construct without an Fc tag. In addition, VEGF-A inhibitors such 
as native sFLT-1 may have beneficial functions in addition to binding 
VEGF-A. For example, sFLT-1 has been reported to bind to lipid mi-
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crodomains in podocytes, thereby affecting the actin cytoskeleton and 
the function of the glomerular barrier28. Podocyte-specific deletion of 
Flt-1 expression causes reorganization of the cytoskeleton, leading to 
proteinuria and kidney damage; these effects are rescued by express-
ing a kinase-deficient mutant of Flt-1, suggesting that physiological 
levels of sFLT-1 are necessary for the proper structure and function 
of podocytes28. Therefore, with respect to kidney damage, treating in-
dividuals with sFLT-1 may provide improved outcomes compared with 
anti-VEGF-A antibodies and VEGFR2 inhibitors. 
Importantly, the studies discussed above investigated the preven-
tion—rather than the treatment—of diabetes-induced kidney damage, 
as therapy was initiated before the onset of kidney damage. There-
fore, it is difficult to estimate the effects of such treatments in dia-
betic individuals who have already developed kidney damage. Fioretto 
et al. reported that kidney lesions in diabetic individuals were reversed 
by normalizing glycaemia levels as a result of pancreatic transplan-
tation29. Therefore, we tested the effect of treating diabetic mice with 
the VEGF-A inhibitor sFLT-1 after the onset of kidney damage, inclu- 
ding albuminuria and mesangial matrix accumulation. We found that 
even though transfection with sFlt-1 did not normalize blood glucose 
levels in diabetic mice (ESM Figure 2), kidney damage was reversed, 
as both albuminuria and mesangial matrix accumulation were reduced. 
Several studies have reported that macrophages play a role in the 
development of diabetic nephropathy10-12. Moreover, VEGF-A plays a 
role in the migration of monocytes and macrophages13 by binding the 
FLT-1 receptor on these cells14,30. In addition, incubating endothelial 
cells with either glucose17 or VEGF-A16 results in endothelial activation, 
a key event in the adhesion and migration of monocytes from the 
circulation into the tissue. Consistent with this finding, both animals 
and people with diabetes have increased levels of endothelial activa-
tion31-33. Furthermore, we found that incubating HUVECs with VEGF-A 
increased endothelial activation, and that this effect was reversed by 
treating the cells with sFLT-1. We also found that transfection with 
sFlt-1 normalized both the number of glomerular macrophages and 
the level of TNF-α in diabetic mice. Taken together, these findings 
suggest that the VEGF-A inhibitor sFLT-1 reduces endothelial activa-
tion and subsequent macrophage infiltration. Treatment with sFLT-1 
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has reported benefits in treating other diseases, including arthritis34,35, 
vascular disease36,37, sepsis38, and psoriasis39; these clinical benefits 
are attributed primarily to reduced numbers of infiltrating macro-
phages and reduced inflammation. The current results indicate that 
sFLT-1 may be a valuable treatment for diabetic nephropathy, as well 
as other diseases in which inflammation plays an important role. Ma- 
crophages produce cytokines such as TNF-α and TGF-β, which in-
crease the production of matrix proteins by mesangial cells40. Thus, 
reducing the number of glomerular macrophages using sFLT-1 might 
also reduce mesangial matrix expansion in diabetic nephropathy.
As reviewed by Deeds et al.41, techniques using STZ (such as do- 
sage and administration) and consistency with respect to the resulting 
diabetes mellitus in small animal models have not been standardised. 
In our study, we used a moderate dosing regimen of three doses of 
75 mg/kg STZ, for two reasons: (1) this regimen is less nephrotoxic 
than a single high dose; and (2) this regimen induces more diabe-
tes-related histological damage compared with several low doses, 
which result in a relatively mild phenotype. In rodents, STZ can cause 
nephrotoxicity; however, Kraynak et al. have reported that STZ-induced 
cellular and molecular damage resolves within 3 weeks42. This sug-
gests that the albuminuria seen in our diabetic mice at 5 weeks was 
probably related to diabetes rather than STZ. This is supported by 
the histological characteristics typical of diabetic nephropathy seen 
in these diabetic mice (i.e. mesangial matrix expansion and glome- 
rular hypertrophy). Although some groups reported albuminuria and 
histological lesions at this time point43-45, other groups did not find 
albuminuria at this time point31,46; this discrepancy may be due to 
differences in the dose and/or route of administration of STZ. It is im-
portant to note that although present, the albuminuria in our STZ-in-
jected diabetic mice is not exceedingly high, and we suggest that the 
importance of albuminuria in C57BL/6 mice must be considered in 
combination with the presence (or absence) of histological findings.
Importantly, we found a small, but significant, decrease in podocyte 
numbers in sFlt-1‒transfected diabetic mice; decreased numbers of 
podocytes have also been reported in pre-eclampsia, which is char-
acterized by high circulating levels of sFLT-147. Despite this decrease 
in podocyte numbers, albuminuria was significantly reduced in sFlt-1‒
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transfected diabetic mice. It is possible that the decrease in podocyte 
numbers in these sFlt-1‒transfected mice was too small to functionally 
affect the filtration barrier. This notion is supported by previous re-
ports that a substantial decrease in podocyte numbers is required for 
increased albuminuria48,49. Nevertheless, we cannot exclude the possi-
bility that longer treatment and/or higher levels of sFLT-1 expression 
could affect the glomerular filtration barrier. Thus, we hypothesise 
that sFLT-1 will likely have a beneficial effect in people with diabetes 
until the production of VEGF-A by podocytes drops below a certain 
threshold, given that decreased VEGF-A levels also result in kidney 
damage21. In this respect, it is important to note that both VEGF-A and 
sFLT-1 levels should be adjusted with care, as both increased and 
decreased levels of VEGF-A can lead to renal pathology3,50.
In conclusion, we report that normalising VEGF-A levels with sFLT-
1 may represent a viable approach for treating patients with existing 
diabetic nephropathy by reducing endothelial activation, glomerular 
macrophage infiltration and glomerular inflammation, thereby reversing 
kidney damage. 
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ESM Figure 1: Transfection efficiency. The sFlt-1 and luciferase constructs were 
co-transfected bilaterally into both calf muscles. Following an i.p. injection of luciferin, 
luminescence was measured and is shown on an arbitrary pseudocolor scale; red color 
indicates high luminescence. 
ESM Figure 2: Blood glucose levels were measured in control (“C”) and diabetic mice 
(“D”) at 5 and 15 weeks. Where indicated, mice were transfected with sFlt-1 (“S”). 
The horizontal line at 15 mmol/L indicates the threshold used in this study to de-
fine diabetic mice. Transfection with sFlt-1 had no significant effect on blood glucose 
levels measured at week 15 in diabetic mice. Bars represent average ± SD. Number 
of animals: non-diabetic, non-transfected control mice at 5 and 15 weeks (n=5 mice 
each); non-transfected diabetic mice at 5 and 15 weeks (n=7 and n=6, respectively); 








Endoglin mediates VEGF-A-induced endothelial cell 
activation by regulating Akt signaling 
Pascal Bus, Tessa Gerrits, Sharon A.C. Heemskerk, Malu Zandbergen, Ron 





In diabetic nephropathy, differential expression of growth factors leads 
to vascular changes, including endothelial cell activation, monocyte 
infiltration, and inflammation. Endoglin plays an important role in 
endothelial function and is also associated with inflammation. In the 
kidney, vascular endoglin expression is increased in animal models 
of renal injury, where it contributes to disease severity – possibly 
by promoting endothelial cell activation and inflammation. Here, we 
investigated whether endoglin expression is associated with diabetic 
nephropathy. In addition, we examined whether reducing endothelial 
endoglin expression in vitro affects endothelial cell activation and 
monocyte adhesion, and if so, which intracellular pathways are in-
volved. Finally, we analyzed whether glomerular endoglin expression 
is correlated with endothelial cell activation in patients with diabe- 
tic nephropathy. Endoglin levels were significantly increased in mice 
with type 1 diabetes compared to control mice. Reducing endoglin 
expression in cultured endothelial cells significantly impaired the 
VEGF-A‒induced upregulation of activation markers and monocyte 
adhesion. This was mediated by increased phosphorylation of Akt, 
thereby inhibiting ATF-2 phosphorylation which regulates VCAM1 gene 
transcription in these cells. Lastly, endoglin co-localized with VCAM-1 
in the glomeruli of diabetic patients, glomerular VCAM-1 expression 
was significantly increased in these patients, and this increase in 
VCAM-1 expression was correlated with increased glomerular endoglin 
expression. Thus, targeting endoglin function may have therapeutic 




Diabetic nephropathy develops in 20-40% of diabetic patients and is 
the leading cause of end-stage renal disease worldwide1. Diabetic ne-
phropathy is characterized by microvascular injury resulting from hy-
perglycemia, high blood pressure, and dyslipidemia, and is associated 
with increased production of reactive oxygen species, an accumulation 
of advanced glycation end-products, and the activation of intracellular 
signaling molecules such as protein kinase C2. As a consequence of 
these processes, the expression of several growth factors changes 
– including vascular endothelial growth factor A (VEGF-A) – causing 
an angiogenic imbalance, ultimately leading to, but not limited to, 
endothelial dysfunction and activation3, monocyte infiltration4, and 
inflammation5. 
Endothelial cell activation is characterized by i) the increased 
surface expression of adhesion molecules such as vascular cell ad-
hesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, 
and E-selectin6, ii) increased endothelial permeability, and a iii) pro-
thrombotic and proinflammatory phenotype7. VEGF-A induces endo-
thelial activation by binding to vascular endothelial growth factor 
receptor 2 (VEGFR2/KDR), leading to activation and internalization of 
this receptor and subsequent phosphorylation and activation of ex-
tracellular signal–regulated kinases 1 and 2 (ERK1/2). Phosphorylated 
ERK1/2 translocates to the nucleus and promotes activating transcrip-
tion factor 2 (ATF-2) phosphorylation, which regulates VCAM1 gene 
transcription8. Increased expression of VCAM-1 on the endothelial cell 
surface in turn aids in leukocyte extravasation9, ultimately leading to 
inflammation. A link between VEGF-A-induced endothelial changes and 
endoglin have been suggested; however, it is currently unknown by 
which mechanism.
Endoglin is an important molecule involved in physiological and 
pathological vascular changes. Studies using endoglin-deficient mice 
showed that endoglin plays an essential role in angiogenesis and 
vascular remodeling10,11. Under physiological conditions, endoglin is 
expressed in endothelial cells at relatively low levels; however, en-
doglin expression increases during angiogenesis12 and in response to 
vascular damage13. Furthermore, the expression of endoglin in endo-
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thelial cells increases during inflammation and is associated with the 
infiltration of inflammatory cells such as macrophages14. 
Recently it has been demonstrated that endoglin co-localizes with 
VEGFR2 in early endosomes upon stimulation with VEGF-A and that 
endothelial cells with decreased endoglin expression display increased 
phosphorylation of Akt15. Activation of the Akt pathway has been 
shown to inhibit adhesion molecule expression after VEGF-A stimula-
tion3, possibly by reducing the phosphorylation of ATF-216. Therefore, 
decreasing the expression of endoglin might reduce VEGF-A-induced 
endothelial activation and subsequent leukocyte extravasation by in-
creasing the phosphorylation of Akt, thereby downregulating ATF-2-
induced transcription of VCAM1. 
Here, we investigated whether glomerular endoglin expression is as-
sociated with diabetic nephropathy using both mice and patient sam-
ples. Moreover, we examined whether reducing endothelial endoglin 
expression affects endothelial activation and/or monocyte adhesion 
upon stimulation with VEGF-A, and if so, which intracellular signaling 
pathways are involved. Finally, we studied whether glomerular endoglin 




The diabetic mouse model used in this study has been described pre-
viously17. All experiments were conducted in accordance with national 
guidelines for the care and use of experimental animals (DEC license 
13163). In brief, diabetes was induced in 8-week-old female C57BL/6J 
mice (obtained from Harlan Laboratories, Indianapolis, IN,) by three 
intraperitoneal injections of streptozotocin (75 mg/kg body weight; 
Sigma-Aldrich, Saint Louis, MO) administered at 2-day intervals. Mice 
that developed a blood glucose level ≥15 mmol/L were considered 
diabetic. Diabetic mice (n=10 per time point) and age-matched non- 
diabetic control mice (n=5 per time point) were sacrificed at 5 and 15 
weeks after the induction of diabetes, and renal tissues were collec- 





Immortalized human endothelial cells (ECRF)18 that were transduced 
with a lentiviral vector expressing either an shRNA against endoglin 
(ECRF+/-) or a non-targeting control shRNA (ECRF+/+) were generous-
ly provided by Dr. Luuk Hawinkels (Department of Gastroenterolo-
gy, Leiden University Medical Center, the Netherlands). Compared to 
ECRF+/+, endoglin mRNA and proteins levels in ECRF+/- were reduced 
by approximately 30% and 40%, respectively (Figure S1A,C). ECRF 
were cultured at 37°C in 5% CO2 in Medium 199 (Gibco Laboratories, 
Gaithersburg, MD) supplemented with 10% fetal bovine serum (Sig-
ma-Aldrich), 0.4% penicillin-streptomycin (Gibco Laboratories), 0.2% 
unfractionated heparin (LEO Pharma, Ballerup, Denmark), and 25 mg 
bovine pituitary extract (Gibco Laboratories). THP-1 cells (American 
Type Culture Collection, Manassas, VA) were cultured at 37°C in 5% 
CO2 in RPMI 1640 Medium (Gibco Laboratories) supplemented with 
10% fetal bovine serum (Sigma-Aldrich) and 1% penicillin-streptomy-
cin (Gibco Laboratories). Human umbilical vascular endothelial cells 
(HUVECs) were cultured in EGM-2 media (Lonza, Basel, Switzerland) 
at 37°C in 5% CO2.
Endothelial cell activation assay
ECRF+/+ and ECRF+/- that were confluent for two days were incubated 
with 20 ng/ml vascular endothelial growth factor-A165 (VEGF-A; R&D 
Systems, Minneapolis, MN) for 2, 4, 6, or 8 hours3. As control for 
VEGF-A, cells were incubated with 0.1% (w/v) bovine serum albumin 
(BSA). To quantify changes in gene expression, total RNA was ex-
tracted using TRIzol (Ambion, Foster City, CA) in accordance with the 
manufacturer’s instructions and transcribed into cDNA. Quantitative 
real-time PCR (qPCR) was performed using the IQTM SYBR Green Su-
permix (Bio-Rad, Hercules, CA) with a CFX real-time system (Bio-Rad). 
Ct (cycle threshold) values were normalized to the housekeeping gene 
HPRT1. The following primers were used in this study: endoglin (ENG) 
forward: 5’-CACTAGCCAGGTCTCGAAGG-3’ and reverse: 5’-CTGAGGAC-
CAGAAGCACCTC-3’; Eng forward: 5’-CTTCCAAGGACAGCCAAGAG-3’ 
and reverse: 5’- GTGGTTGCCATTCAAGTGTG-3’; Eng (short isoform) 
forward: 5’-TAGCACCTTGTCCCAGGAAG-3’ and reverse: 5’-GTGGAG
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GCTTGGGATACTCA-3’; Eng (long isoform) forward: 5’-TAGCACCTTGTC-
CCAGGAAG-3’ and reverse: 5’-GGCCACGTGTGTGAGAATAG-3; HPRT-1 
forward: 5’-AGATGGTCAAGGTCGCAAGC-3’ and reverse: 5’-TCAAGGG-
CATATCCTACAACAAAC-3’; ICAM1 forward: 5’-CAGAGGTTGAACCCCA-
CAGT-3’ and reverse: 5’-CCTCTGGCTTCGTCAGAATC-3’; E-selectin 
(SELE) forward: 5’-AGCCCAGAGCCTTCAGTGTA-3’ and reverse: 5’-AACT-
GGGATTTGCTGTGTCC-3’; VCAM1 (Sino Biological, Beijing, China); plas-
minogen activator inhibitor-1 (PAI-1) forward: 5’-ACTGGAAAGGCAACAT-
GACC-3’ and reverse: 5’-TGACAGCTGTGGATGAGGAG-3’; and connective 
tissue growth factor (CTGF) forward: 5’-CCTGGTCCAGACCACAGAGT-3’ 
and reverse: 5’-TTGAGATTTTGGGAGTACGG-3. These experiments were 
performed in triplicate. 
Immunoblotting
ECRF+/+ and ECRF+/- that were confluent for two days were se-
rum-starved for 5 hours. Cells were then incubated with 20 ng/ml 
VEGF-A (R&D Systems) for 5, 10, 15, 30, and 60 minutes. Cells were 
washed with ice-cold PBS and lysed in buffer containing 1% (w/v) 
SDS, Tris-buffered saline, 10mM EDTA, and protease and phosphatase 
inhibitor cocktails (Roche, Basel, Switzerland). Protein concentration 
was determined by using a detergent compatible protein assay (Bio-
Rad). A two-fold serial dilution of a HUVEC lysate (from 20 µg to 0.16 
µg) was used to generate a calibration curve in order to calculate 
relative endoglin protein levels in unstimulated and VEGF-A‒stimulated 
ECRF+/- and ECRF+/+. Protein lysates were subjected to SDS–PAGE and 
subsequent western blotting. Membranes were blocked for 1 hour in 
5% BSA/TBST (Tris-buffered saline with Tween 20) and then incubated 
over night with primary antibodies against phosphorylated Akt (Ser473), 
Akt, phosphorylated ERK1/2 (Thr202/Tyr204), ERK1/2, phosphorylated 
ATF-2 (Thr71) and ATF-2 (all from Cell Signaling Technology, Danvers, 
MA); GAPDH (Cell Signaling Technology) was used as loading control. 
Secondary antibodies were horseradish peroxidase-conjugated. Signals 
were visualized by chemiluminescent detection according to the man-
ufacturer’s protocol (SuperSignal West Pico, Thermo Fisher Scientific, 
MA, USA). Band intensity was quantified using Image Lab software 
(Bio-Rad). These experiments were performed in triplicate. Membranes 
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were also incubated in goat anti-human endoglin (R&D Systems) 
as the primary antibody, followed by an IRDye Infrared Fluorescent 
(LI-COR Biosciences, Lincoln, NE) secondary antibody. Signals were 
visualized using the LI-COR Odyssey Infrared Imaging System (LI-COR 
Biosciences). Band intensity was quantified using Odyssey V3.0 soft-
ware (LI-COR Biosciences). HUVEC protein concentrations and band 
intensities were used to calculate a calibration curve for measuring 
endoglin protein levels; this calibration curve was then used to quan-
tify endoglin protein levels in ECRF+/+ and ECRF+/-.
To inhibit Akt phosphorylation, ECRF+/+ and ECRF+/- that were con-
fluent for two days were incubated for 1 hour with wortmannin (3 nM, 
Selleckchem, Houston, TX), followed by 15 minutes stimulation with 20 
ng/ml VEGF-A (R&D Systems). The cells were then washed with ice-
cold PBS and lysed in buffer containing 1% (w/v) SDS, Tris-buffered 
saline, 10 mM EDTA, and protease and phosphatase inhibitor cocktails 
(Roche). Protein concentration was determined using a detergent-com-
patible protein assay (Bio-Rad). Protein lysates were subjected to SDS-
PAGE and subsequent western blot analysis. Membranes were blocked 
for 1 hour in 5% BSA/TBST, and then incubated overnight with pri-
mary antibodies against phosphorylated Akt (Ser473), Akt, phospho- 
rylated ATF-2 (Thr71), and ATF-2 (all from Cell Signaling Technology); 
GAPDH (Cell Signaling Technology) was used as a loading control. 
IRDye Infrared Fluorescent antibodies (LI-COR Biosciences) were used 
as the secondary antibody, and the signals were visualized using the 
LI-COR Odyssey Infrared Imaging System (LI-COR Biosciences). Band 
intensity was quantified using Odyssey V3.0 software (LI-COR Biosci-
ences). The ratio of phosphorylated to non-phosphorylated proteins 
was used to calculate whether the differences between ECRF+/+ and 
ECRF+/- were significant.
Monocyte adhesion assay
ECRF+/+ and ECRF+/- were plated in 96-well plates and grown to conflu-
ence. The cells were then stimulated with 20 ng/ml VEGF-A (or 0.1% 
BSA) for 2, 4, 6, or 24 hours, after which 150,000 Hoechst-labeled 
THP-1 cells were added to each well, and the cells were incubated for 
30 minutes at 37°C under static conditions. Subsequently, ECRF were 
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washed with phosphate-buffered saline (PBS) to remove the unbound 
THP-1 cells. The cells were then fixed in 100 µl 4% paraformaldehyde 
in PBS (Merck Millipore, Billerica, MA) for 10 minutes, followed by two 
washes with PBS. The number of attached THP-1 cells was measured 
with an ArrayScan XTI High Content Platform (Thermo Fisher Scientif-
ic) using a 5X objective; nine fields of view were measured, and these 
experiments were performed in triplicate.
Human kidney samples
Renal biopsy samples from eleven patients with histologically con-
firmed diabetic nephropathy were obtained from the pathology ar-
chives of the Leiden University Medical Center. Of these eleven 
patients, three (27%) had class II diabetic nephropathy, seven (64%) 
had class III diabetic nephropathy, and one (9%) had class IV diabetic 
nephropathy. As a control group, we used tumor-free renal resection 
material obtained from seven patients with impaired renal function 
who had a tumor elsewhere in the kidney; the tissue sections used for 
stainings were morphologically normal. Tissue samples in both groups 
were not matched for age and gender, but were included based on 
tissue morphology. Clinical data are provided in Table S1. All human 
samples were collected and handled in accordance with Dutch na-
tional ethics guidelines (Code of Conduct for Proper Secondary Use 
of Human Tissue).
Immunohistochemistry
 Sections (4-µm thick) of paraffin-embedded kidney tissues were cut 
using a Leica microtome. For staining endoglin, sections were sub-
jected to heat-induced antigen retrieval using Tris-EDTA (pH 9), and 
then stained with goat anti-human endoglin (1:800; R&D Systems); 
this antibody also cross-reacts with mouse endoglin. For staining 
VCAM-1, sections were subjected to heat-induced antigen retrieval 
with citrate buffer (pH 6), and then stained with mouse anti-hu-
man VCAM-1/CD106 (1:50; LSBio, Seattle, WA). The sections were 
then stained with either rabbit anti-goat HRP (1:150; Dako, Glostrup, 
Denmark) or rabbit anti-mouse Envision HRP (Dako) secondary anti-




Double-labeled immunofluorescence was performed on paraffin-em-
bedded tissue sections (4-µm thickness). Antigen retrieval was per-
formed as described in Table S2, and the sections were co-stained 
with goat anti-human endoglin (1:800; R&D Systems) together with 
mouse anti-human CD31 (1:200; Dako), mouse anti-human CD68 
(1:2000; Dako), or rabbit anti-mouse platelet endothelial cell adhesion 
molecule 1 (PECAM1; 1:400; Santa Cruz Biotechnology, Dallas, TX). 
Additional sections were also co-stained with goat anti-human endo- 
glin (1:200; R&D Systems) together with mouse anti-human VCAM-1/
CD106 (1:50; LSBio) or rabbit anti-human nephrin (1:1000; LSBio). The 
stained sections were then incubated with the appropriate secondary 
IgG Alexa antibody (see Table S2) and mounted with ProLong Gold 
antifade reagent containing DAPI (Life Technologies, Carlsbad, CA).
Digital image analysis
Immunohistochemically stained sections were imaged using a Philips 
Ultra-Fast Scanner 1.6 RA. ImageJ 1.8.0 was used to measure the 
glomerular levels of endoglin (mouse and human) and the glomerular 
levels of VCAM-1 (human). Mouse kidney sections were imaged at 
400X magnification, and the positive area per glomerulus was mea-
sured in 25 glomeruli per section and corrected for the total area 
of each glomerulus. Human kidney sections were imaged at 200X 
magnification, and the positive area per glomerulus was measured 
in 10 glomeruli per section (resection material) or in all, non-global 
sclerotized glomeruli (biopsy material), and corrected for the total 
area of each glomerulus. The examined glomeruli were selected at 
random, and the same glomeruli were used to measure VCAM-1 and 
endoglin in the human samples.
Statistical analyses
Data of the independent experimental repeats are expressed as the 
mean ± the standard deviation. Differences between groups were 
analyzed using the two-tailed unpaired Student’s t test or by using 
one-way ANOVA where appropriate. To analyze the relationship be-
tween VCAM-1 and endoglin levels, a linear regression was performed. 
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To this end, the glomerular endoglin and glomerular VCAM-1‒positive 
areas in patients with diabetic nephropathy were log-transformed in 
order to obtain a linear relationship. A linear mixed model was used 
to account for the correlation of repeated measurements within pa-
tients. Differences were considered significant at p<0.05. 
Results
Diabetic mice have increased glomerular endoglin expression
First, we measured the expression of endoglin in the glomeruli of 
mice 5 and 15 weeks after the induction of diabetes. At both 5 and 
15 weeks, diabetic mice had significantly higher levels of endoglin 
compared to age-matched non-diabetic mice (p<0.001; Figure 1A-C). 
Further analysis revealed that endoglin is expressed primarily in endo-
thelial cells (Figure 1D-F). Two isoforms of endoglin exist, the long and 
short isoform, which have been described to have opposite effects on 
angiogenesis19. Therefore, a shift in the expression of these isoforms 
might be involved in the development of endothelial cell activation and 
subsequent renal disease. We found no significant difference in either 
the short or long endoglin isoform (p=0.11 and p=0.35, respectively; 
Figure S2) between diabetic mice and age-matched non-diabetic con-
trols; we also found no significant difference in total endoglin mRNA 
levels (p=0.78; Figure S2). This suggests that the increased endo- 
glin protein levels in diabetic mice is likely caused by changes at the 
translational and/or posttranslational level, and not by an increase in 
endoglin transcription or mRNA stability.
Endoglin mediates the activation of endothelial cells
Because endoglin expression was upregulated in the glomerular en-
dothelial cells of diabetic mice, we hypothesized that endoglin might 
play a role in mediating the activation of these cells, as well as sub-
sequent inflammation. To test this hypothesis, we used two immorta- 
lized human endothelial cell lines that express either normal (ECRF+/+) 
or 30% reduced (ECRF+/-) levels of endoglin (Figure S1). These cells 
were stimulated with 20 ng/ml VEGF-A for 2-8 hours, after which the 
mRNA levels of VCAM1, SELE, and ICAM1 (which encode vascular cell
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Figure 1: Glomerular endoglin expression is upregulated in mice with expe- 
rimentally induced diabetic nephropathy. A-B. Representative images of endoglin 
immunostaining in the glomeruli of an age-matched, non-diabetic control mouse (A) 
and a diabetic mouse 5 weeks after streptozotocin-induced diabetes (B). C. Quantitative 
analysis of endoglin protein levels in the glomeruli of diabetic mice 5 and 15 weeks 
after streptozotocin (STZ)-induced diabetes (“D”), relative to the protein levels mea-
sured in age-matched non-diabetic mice (“C”). D-F. Representative images of endoglin 
(green; D) and PECAM1 (red; E) immunofluorescence in a kidney section obtained from 
a diabetic mouse. The nuclei were counterstained with DAPI (blue). ***p<0.001 vs. the 
respective non-diabetic group, Student’s t test. Scale bars: 50 µm.
adhesion molecule 1, E-selectin, and intercellular adhesion molecule 
1, respectively) were measured using qPCR. VEGF-A induced the ra- 
pid and robust activation of ECRF+/+, as illustrated by increased ex- 
pression of both VCAM1 and SELE (Figure 2). In contrast, VEGF-A 
had little effect on VCAM1 or SELE expression in ECRF+/-, indicating 
that these cells have impaired VEGF-A-induced activation. ICAM1 ex-
pression was not affected by VEGF-A stimulation in either ECRF+/+ or 
ECRF+/- (Figure 2). To investigate whether endoglin affects endothelial 
cell activation by modifying TGF-β signaling, we measured the mRNA 
levels of PAI-1 and CTGF, both of which are downstream target genes 
of TGF-β signaling20,21. Stimulating either ECRF+/+ or ECRF+/- with VEGF-A 
had no effect on the mRNA levels of PAI-1 or CTGF (Figure 2). This 
finding suggests that the effect of endoglin on VEGF-A‒induced endo-
thelial cell activation is independent of TGF-β signaling.
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Figure 2: Endoglin mediates VEGF-A‒induced endothelial cell activation indepen-
dent of TGF-β signaling. VCAM1, SELE, ICAM1, PAI-1, and CTGF mRNA levels were 
measured in ECRF+/+ (black bars) and ECRF+/- (gray bars). Where indicated, the cells 
were incubated for the indicated times with 20 ng/ml VEGF-A. All expression levels are 
expressed relative to the corresponding unstimulated (control) ECRF+/+ group. *p<0.05 
and **p<0.01 vs. the respective control, Student’s t test; †p<0.05, ††p<0.01, and †††p<0.001 
vs. the respective ECRF+/- group at the same time point, Student’s t test.
Reduced endoglin levels diminish endothelial cell acti- 
vation by increasing Akt phosphorylation
Because reduced endoglin expression resulted in reduced endothelial 
cell activation upon VEGF-A stimulation, we also investigated whe- 
ther VEGF-A stimulation affects endoglin protein levels. As shown in 
Figure S1B-C, VEGF-A stimulation reduced endoglin protein levels in 
ECRF+/+; in contrast, endoglin protein levels were unaffected by VEGF-A 
stimulation in ECRF+/-. Next, we investigated whether changes in en-
doglin expression altered VEGFR2 downstream signaling. Stimulation 
of ECRF+/+ with VEGF-A led to a rapid increase in ERK1/2 phospho- 
rylation (Figures 3 and S3). Basal Akt phosphorylation was strong in 
unstimulated ECRF+/+, which might be due to serum starvation22. Akt 
phosphorylation initially decreased after VEGF-A stimulation, but then 
increased over time and peaked at 15-30 min. In addition, VEGF-A 
induced ATF-2 phosphorylation thereby confirming other studies in 
endothelial cells8. In ECRF+/-, VEGF-A induced ERK1/2 phosphorylation 
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to a similar degree as in ECRF+/+ (Figures 3 and S3). Yet, phospho- 
rylation of Akt was stronger in ECRF+/- than in ECRF+/+, both after 
VEGF-A stimulation and under basal conditions. In contrast to ECRF+/+, 
phosphorylation of ATF-2 was significantly reduced in ECRF+/- upon 
stimulation with VEGF-A. Wortmannin inhibited Akt phosphorylation in 
both ECRF+/+ and ECRF+/- and increased the pATF-2/ATF-2 ratio upon 
VEGF-A stimulation (Figures 4 and S4). Taken together, these results 
suggest that endoglin affects VEGF-A-mediated activation of endothe- 
lial cells by reducing Akt phosphorylation and thereby promoting ATF-
2 induced transcription of VCAM1.
Endoglin mediates the adhesion of monocytes to activated en-
dothelial cells
Next, we investigated the consequences of impaired endothelial cell 
activation via reduced endoglin expression by measuring the adhesion 
of monocytes to endothelial cells. Both ECRF+/+ and ECRF+/- were 
stimulated with 20 ng/ml VEGF-A for 2, 4, 6, or 24 hours, after which 
THP-1 cells (a human leukemia monocytic cell line) were applied for 
30 minutes. We then counted the number of THP-1 cells that adhered 
to the ECRF+/+ and ECRF+/-. In ECRF+/+, VEGF-A significantly increased 
the adhesion of monocytes; in contrast, VEGF-A stimulation had no 
effect on the adhesion of monocytes to ECRF+/- (Figure 5). These 
results indicate that endoglin expression plays a role in the adhesion 
of monocytes to endothelial cells activated by VEGF-A. 
Endoglin is expressed in human glomerular endothelial cells 
Next, we examined the clinical relevance of endoglin expression in the 
glomeruli of human kidneys by immunostaining kidney sections ob-
tained from non-diabetic controls and from patients with diabetic ne-
phropathy. Sections were co-immunostained for endoglin and the en-
dothelial marker CD31 (Figure 6), showing that endoglin is expressed 
in glomerular endothelial cells. Interestingly, the co-localization of 
endoglin and CD31 was less robust in the patients with diabetic ne-
phropathy, which is likely due to reduced CD31 expression in these 
patients23. A close examination of the endoglin-positive cells in our 
immunohistochemical and immunofluorescence experiments suggests
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Figure 3: Akt phosphorylation is increased in endothelial cells with reduced 
endoglin expression. ECRF+/+ (+; black bars) and ECRF+/- (-; gray bars) were incubated 
with VEGF-A (20 ng/ml) for the indicated times. VEGF-A induced Akt phosphorylation 
was higher in ECRF+/- compared to ECRF+/+, whereas ATF-2 phosphorylation was lower 
in ECRF+/-. The VEGF-A-mediated effects were significantly different between the two 
cell lines after 10 minutes of stimulation; *p<0.05. VEGF-A also increased ERK1/2 
phosphorylation; however; this increase was similar between ECRF+/+ and ECRF+/-. The 
summary data are presented as the mean ± the standard deviation of three indepen-
dent experiments. 
that mesangial cells may also express endoglin, a finding supported 
by a previous study24. Furthermore, co-immunostaining for endoglin 
together with either nephrin or CD68 revealed that endoglin is not 
expressed in either podocytes or glomerular macrophages (Figure S5).
In contrast to our findings in diabetic mice, glomerular endoglin 
levels were similar between patients with diabetic nephropathy and 
non-diabetic controls (p=0.874) (Figure 7A). However, the level of 
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endoglin expression varied widely between glomeruli within some pa-
tients, as shown in Figures 7B and 7C. This suggests that activation 
of glomerular endothelial cells also varies within patients. 
Figure 4: Inhibiting Akt phosphorylation increases VEGF-A‒induced phosphory-
lation of ATF-2. ECRF+/+ and ECRF+/- were incubated with wortmannin (W; 3 nM) for 
1 hour, then stimulated with VEGF-A (V; 20 ng/ml) for 15 minutes. A. Representative 
western blot. B-C. Quantification of the western blot data shows that treating cells 
with wortmannin and VEGF-A reduces Akt phosphorylation (B) and increases ATF-2 
phosphorylation (C). The summary data are presented as the mean ± the standard 
deviation of four experiments and are plotted relative to unstimulated ECRF+/+. *p<0.05, 
**p<0.01, and ***p<0.001 versus the respective unstimulated control; ##p<0.01 versus 
VEGF-A stimulated ECRF+/+, one-way ANOVA. 
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Figure 5: Endoglin mediates the adhesion of monocytes to activated endothelial 
cells. ECRF+/+ (black bars) and ECRF+/- (gray bars) were incubated with VEGF-A (20 
ng/ml) for the indicated times, and the number of adherent Hoechst-stained THP-1 
cells was counted. *p<0.05 vs. the respective unstimulated control group; †p<0.05 and 
†††p<0.001 vs. the respective ECRF+/- group at the same time point, Student’s t test. 
VCAM-1 expression is increased in the glomerular capillaries of 
patients with diabetic nephropathy
Finally, we investigated whether endothelial cell activation is increased 
in patients with diabetic nephropathy, and we examined whether high 
glomerular endoglin expression is correlated with endothelial cell 
activation. We therefore co-immunostained kidney sections for endo- 
glin and the endothelial cell activation marker VCAM-1 (Figure 7G-I). 
We found that VCAM-1 co-localized with endoglin in the glomeru-
li of patients with diabetic nephropathy. In addition, immunohisto-
chemistry showed that the relative glomerular VCAM-1-positive area 
was significantly higher in patients with diabetic nephropathy com-
pared to non-diabetic controls (p<0.001; Figure 7D). Similar to our 
observation with respect to endoglin-stained sections, we observed 
high variability within patients with respect to glomerular VCAM-1 
levels (Figures 7E and 7F). Importantly, when we plotted the glome- 
rular VCAM-1‒positive area against the glomerular endoglin-positive 
area, we found that the difference in -2 log-likelihood (β=1.09) be-
tween the models was highly significant (p<0.001). This indicates 
that glomerular endoglin levels are significantly correlated with 
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Figure 6: Endoglin is expressed in glomerular endothelial cells in patients with 
diabetic nephropathy. Representative images of endoglin (red; A and D) and CD31 
(green; B and E) immunofluorescence in kidney sections obtained from a non-diabetic 
control (A-C) and a patient with diabetic nephropathy (D-F). Note the reduced CD31 
immunostaining in the patient with diabetic nephropathy (E). The arrowheads in D-F 
indicate examples of co-localization between endoglin and CD31. The nuclei were coun-
terstained with DAPI (blue). Scale bars: 10 µm.
glomerular VCAM-1 levels in patients with diabetic nephropathy (Fig-
ure 7J); meaning that glomeruli with increased levels of endoglin 
also have increased levels of VCAM-1. This finding supports our in 
vitro data and suggests that endoglin likely plays a role in media- 
ting endothelial cell activation in patients with diabetic nephropathy.
Discussion 
Here, we show that the expression of glomerular endoglin is increased 
in a mouse model of type 1 diabetes, and that endoglin plays an 
important role in VEGF-A-induced endothelial cell activation and in 
monocyte adhesion to VEGF-A-activated endothelial cells by regula- 
ting VEGFR2 signaling. Furthermore, we show that glomerular endoglin 
expression is positively correlated with glomerular VCAM-1 levels in 
patients with diabetic nephropathy, providing clinical evidence that 
endoglin mediates endothelial cell activation in diabetic nephropathy. 
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Figure 7: Glomerular endoglin protein levels are correlated with endothelial cell 
activation in patients with diabetic nephropathy. A-F. Endoglin (A-C) and VCAM-1 
(D-F) immunohistochemistry and quantification. Endoglin-positive glomerular area (A) 
and VCAM-1‒positive glomerular area (D) were measured in patients with diabetic 
nephropathy (DN, white bars) and non-diabetic controls (NDC, black bars). *p<0.05, Stu-
dent’s t test. The images show glomerular endoglin (B and C) and glomerular VCAM-1 
(E and F) immunohistochemistry in adjacent sections from a single patient with diabetic 
nephropathy; note the high variability in both endoglin and VCAM-1 staining. Note 
that the glomerulus with high endoglin staining (B) also has high VCAM-1 staining (E), 
and the glomerulus with low endoglin staining (C) also has low VCAM-1 staining (F). 
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Endothelial cell activation is characterized by the increased sur-
face expression of adhesion molecules such as VCAM-1, ICAM-1, and 
E-selectin6, increased endothelial permeability, and a prothrombotic 
and proinflammatory phenotype7. In the context of diabetes, a variety 
of factors can activate endothelial cells, including hyperglycemia25, 
advanced glycation end-products26, oxidative stress27, hyperlipidemia28, 
hyperinsulinemia29, proinflammatory cytokines30, and growth factors 
such as VEGF-A3. The increase in adhesion molecules on endothe- 
lial cells facilitates the binding and infiltration of monocytes9, which 
then produce cytokines that induce the typical glomerular changes 
associated with diabetic nephropathy, including mesangial matrix ex-
pansion31. 
Using animal models of diabetic nephropathy, we and other groups 
previously showed that the expression of both VCAM-1 and ICAM-1 
is increased in glomerular capillaries17,32,33, suggesting that endothelial 
cell activation may play a role in the pathogenesis of diabetic ne-
phropathy. Accordingly, deleting ICAM-1 expression in diabetic mice 
leads to decreased glomerular and interstitial macrophages, reduced 
albuminuria, and reduced renal fibrosis34,35. Here, we report that the
TGF-β co-receptor endoglin may play a role in endothelial activation 
in diabetic nephropathy. 
Several studies using animal models showed that endoglin is up-
regulated following renal injury and contributes to the severity of 
renal damage36-38, possibly by boosting endothelial cell activation and 
the subsequent infiltration of macrophages37. In our study, we found 
that glomerular endothelial endoglin levels were increased in an 
animal model of type 1 diabetes both 5 and 15 weeks after diabetes 
was induced. Using an in vitro system, we found that stimulation with 
VEGF-A caused endothelial cell activation, as evidenced by increased 
G-I. Example images of endoglin (red; G) and VCAM-1 (green; H) immunofluorescence 
in a kidney section obtained from a patient with diabetic nephropathy. The nuclei were 
counterstained with DAPI (blue). Scale bars: 50 µm. J. Linear mixed model regression 
analysis of the correlation between log-transformed endoglin-positive area (on the 
x-axis) and VCAM-1-positive area (on the y-axis) in the glomeruli of patients with di-
abetic nephropathy. Each symbol represents an individual glomerulus, and the solid 
line shows the linear regression. The difference in -2 log-likelihood (β=1.09) between 
the models is highly significant (p<0.001), indicating that glomerular endoglin levels are 
significantly correlated with glomerular VCAM-1 levels.
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levels of VCAM1 and SELE expression. However, in contrast with oth-
er studies3,39, we found no change in the expression of ICAM1. This 
apparent discrepancy may be due—at least in part—to the fact that 
we measured mRNA levels rather than protein levels. Interestingly, the 
activation of endothelial cells with downregulated endoglin expression 
(ECRF+/-) was reduced following stimulation with VEGF-A, with virtually 
no upregulation in VCAM1 or SELE expression. This finding may be 
due to endoglin’s effect on the kinetics and downstream signaling of 
the VEGFR215. Because expression of the TGF-β target genes PAI-1 
and CTGF was unaffected by VEGF-A stimulation in both ECRF+/+ and 
ECRF+/-, it is unlikely that TGF-β signaling plays a significant role in 
mediating endoglin’s effects in endothelial cells.
Analysis of VEGFR2 downstream signalling demonstrated that, in 
contrast to ECRF+/+, ECRF+/- had a stronger phosphorylation of Akt, as 
reported earlier15. Furthermore, ECRF+/- had a reduced phosphorylation 
of ATF-2 compared to ECRF+/+. ATF-2 is essential for VEGF-A induced 
endothelial cell activation8 and ATF-2 phosphorylation is decreased 
by the Akt-pathway16. Therefore, endothelial cell activation may be 
diminished in ECRF+/- by increased Akt phosphorylation which in turn 
downregulates the activation of ATF-2. This notion is supported by 
the finding that inhibiting Akt phosphorylation results in an increase 
in the pATF-2/ATF-2 ratio upon stimulation with VEGF-A. Figure 8 
schematically illustrates our hypothesis on VEGF-A-induced endothe-
lial cell activation in cells with different endoglin levels. Briefly, upon 
VEGF-A stimulation of endoglin proficient endothelial cells, endoglin 
co-localizes with VEGFR2 in early endosomes15 and is associated with 
ERK1/2 phosphorylation8. In contrast, when endoglin expression is 
reduced, phosphorylation of Akt is increased, thereby reducing ATF-2 
phosphorylation and subsequent VCAM1 expression15,16. The Akt-path-
way can be activated by plasma membrane bound VEGFR2 – whereas 
the ERK1/2-pathway cannot40 – suggesting that endoglin regulates the 
internalization and intracellular signaling processes of the VEGFR2. 
Pan et al. reported that upon stimulation with VEGF-A, both VEGFR2 
and endoglin are internalized in endosomes and may be subsequently 
degraded, resulting in decreased endoglin protein levels41. Our re-
sults support these findings, showing that endoglin protein levels are 
reduced in VEGF-A‒stimulated ECRF+/+ (Figure S1B-C). In contrast, in 
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Figure 8: Schematic model of endoglin-dependent endothelial cell activation 
upon VEGF-A stimulation. In endoglin proficient cells (ECRF+/+), VEGF-A drives en-
dothelial cell activation via phosphorylation of VEGFR2, which is then internalized in 
endosomes and in turn phosphorylates ERK1/2. Activated pERK1/2 then translocates 
to the nucleus, where it phosphorylates ATF-2, thereby upregulating VCAM1 expression, 
increasing VCAM-1 levels at the cell surface (signaling depicted by the black lines). In 
cells with reduced endoglin expression (ECRF+/-), VEGF-A stimulation causes increased 
Akt phosphorylation, which in turn inhibits ATF-2 activation, thereby resulting in reduced 
endothelial cell activation (signaling depicted by the red lines). The level of activation 
is indicated by the thickness of the line; a thicker line indicates stronger activation. 
Note: the residual endoglin levels in ECRF+/- cells allows ERK1/2 to still be activated. 
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cells with reduced endoglin expression, VEGFR2 recycling is increased 
upon stimulation with VEGF-A15. Because endoglin co-localizes with 
VEGFR2 in endosomes, this may also result in increased endoglin 
recycling. This would also explain why endoglin protein levels are un-
changed in ECRF+/- upon stimulation with VEGF-A (Figure S1C).
We also found that in addition to reduced VEGF-A-induced endo-
thelial cell activation, ECRF+/- also have reduced monocyte adhesion 
to VEGF-A activated endothelial cells. During leukocyte extravasation, 
E-selectin is involved primarily in the rolling of leukocytes on the ves-
sel’s endothelial cell lining, whereas ICAM-1 and VCAM-1 arrest leuko-
cytes at the endothelium9. This suggest that endoglin facilitates mono-
cyte adhesion by promoting endothelial cell activation. This hypothesis 
is supported by a recent study showing that the inflammation-induced 
transendothelial migration of leukocytes in the peritoneum and lungs 
is reduced in heterozygous endoglin-knockout mice (which have an 
approximately 50% reduction in endoglin levels) compared to wild-
type mice42. However, in their study, the authors found that endoglin 
binds to the integrin α5β1 on leukocytes via its RGD motif. Taken 
together, these results suggest that endoglin increases the adhesion 
and trans-endothelial migration of inflammatory cells by at least two 
distinct mechanisms: i) by a direct interaction with leukocytes, and ii) 
by activating endothelial cells.
Patients with diabetic nephropathy are reported to have increased 
plasma levels of soluble VCAM-1 and soluble ICAM-143,44, and these 
changes are correlated with albuminuria and vascular disease44-46. In 
addition, E-selectin, P-selectin, and ICAM-1 levels are increased in the 
glomerular capillaries of patients with diabetic nephropathy47, whereas 
VCAM-1 is not expressed48. In contrast, and consistent with previous 
studies using diabetic animal models17,33, we found increased levels of 
VCAM-1 protein in the glomerular capillaries of patients with diabetic 
nephropathy. This difference between previous studies and our results 
with respect to VCAM-1 expression in patients with diabetic nephro- 
pathy may be attributed to recent improvements in antibody specifi- 
city and/or signal amplification techniques. Moreover, in our patients 
with diabetic nephropathy, VCAM-1 was co-localized with endoglin in 
glomerular endothelial cells. Interestingly, although the levels of glo-
merular endoglin were similar between patients with diabetic nephro- 
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pathy and non-diabetic controls, within-sample endoglin expression 
varied widely among glomeruli. Finally, a mixed model regression ana- 
lysis revealed that glomeruli with high VCAM-1 expression also have 
high levels of endoglin. Taken together, these results suggest that i) 
endoglin may promote endothelial cell activation in patients, and ii) 
endothelial cell activation is not always uniform within the kidney of 
a given patient. 
In conclusion, our findings suggest that reducing endoglin function 
in patients at risk for diabetic nephropathy may be a viable strate-
gy for inhibiting endothelial cell activation and monocyte adhesion, 
thereby preventing and/or reducing inflammation and the subsequent 
development of nephropathy.
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Age, years1 50 (42-59) 62 (32-70) 0.042
Sex, male2 3 (43) 10 (91) 0.047
DM type 12 N.A. 2 (18) N.A.
DN Class2
Class I N.A. 0 (0) N.A.
Class II N.A. 3 (21) N.A.
Class III N.A. 7 (64) N.A.
Class IV N.A. 1 (9) N.A.
HbA1c, % units1 N.A. 6.6 (5.4-8.2) N.A.
Serum creatinine, 
µmol/l1
99 (88-247) 108.5 (154-230) 0.928
eGFR, ml/min per 
1.73m21
61 (25-66) 61 (25-90) 0.660
Proteinuria, g/24 
hours1
0.24 (0.04-0.45) 5.4 (0.06-11.00) 0.068
DM: diabetes mellitus; DN: diabetic nephropathy; HbA1c: glycated hemoglobin; eGFR: 
estimated glomerular filtration rate. N.A.: not applicable. 
1Data are presented as the median (range). 
2Data are presented as n (%).
Endoglin mediates VEGF-A-induced endothelial cell activation by regulating Akt signaling
4
112
















































































































































































































































































































































































































































































































































































































































































































Figure S1: Relative endoglin mRNA and protein levels in ECRF+/+ and ECRF+/-. A. 
Relative endoglin mRNA levels (ENG) in ECRF+/+ and ECRF+/-. B. Western blot analysis 
of endoglin protein levels in unstimulated ECRF+/+ and ECRF+/- and following stimulation 
with VEGF-A. The results of three independent experiments are shown. Endoglin levels in 
HUVECs were used to generate a calibration curve (bottom panel). C. Relative levels of 
endoglin protein in unstimulated ECRF+/+ (black bars) and ECRF+/- (gray bars) and after 
stimulation with VEGF-A for the indicated times. The summary data are presented as 
the mean mRNA or protein level (± standard deviation) from three experiments. Endoglin 
levels are displayed relative to unstimulated ECRF+/+. *p<0.05, ***p<0.001, and #p<0.05 
versus unstimulated ECRF+/+, Student’s t test. 
Figure S2: ENG mRNA levels are similar between diabetic mice and non-diabetic 
control mice. Total ENG mRNA levels, as well as the short and long isoforms, were 
measured in total kidney lysates obtained from diabetic mice (“D”) 15 weeks after the 
induction of diabetes (with STZ) and in age-matched non-diabetic control mice (“C”).
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Figure S3: Cells with reduced endoglin expression have increased Akt phospho- 
rylation and decreased ATF-2 phosphorylation. ECRF+/+ (+) and ECRF+/- (-) were incu-
bated with VEGF-A (20 ng/ml) for the indicated times. Compared to ECRF+/+, ECRF+/- had 
increased levels of phosphorylated Akt and decreased levels of phosphorylated ATF-2. 
In contrast, ERK1/2 phosphorylation was similar between ECRF+/+ and ECRF+/- following 
stimulation with VEGF-A.
Figure S4: Inhibiting Akt phosphorylation increases ATF-2 phosphorylation in 
VEGF-A‒stimulated cells. ECRF+/+ and ECRF+/- were incubated with wortmannin (W; 3 
nM) for 1 hour, and then stimulated with VEGF-A (V; 20 ng/ml) for 15 minutes. Cells 




Figure S5: Endoglin is not expressed in podocytes or glomerular macrophages. 
Example images of kidney sections obtained from a patient with diabetic nephropathy 
and co-stained with endoglin (A and D) together with nephrin (B) or CD68 (E). The nu-
clei were counterstained with DAPI (blue). Note the absence of co-localization between 
endoglin and nephrin immunoreactivity (C) and between endoglin and CD68 immuno- 
reactivity (F). Scale bars: 25 µm.
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Introduction Complement activation plays a role in various organs 
in patients with diabetes. However, in diabetic nephropathy (DN), the 
role of complement activation is poorly understood. We examined 
the prevalence and clinical significance of complement deposits in 
the renal tissue of cases with type 1 and type 2 diabetes with and 
without DN. 
Methods We measured the prevalence of glomerular C4d, C1q, man-
nose-binding lectin (MBL), and C5b-9 deposits in 101 autopsied dia-
betic cases with DN, 59 autopsied diabetic cases without DN, and 41 
autopsied cases without diabetes or kidney disease. The presence of 
complement deposits was scored by researchers who were blinded 
with respect to the clinical and histological data. 
Results C4d deposits were more prevalent in cases with DN than 
in cases without DN in both the glomeruli (46% vs. 26%) and the 
arterioles (28% vs 12%). C1q deposits were also increased in the 
glomerular hili (77% vs. 55%) and arterioles (33 vs. 14%) and were 
correlated with DN (p<0.01). MBL deposits were only rarely observed. 
C5b-9 deposits were more prevalent in the cases with diabetes melli-
tus (DM) than in the cases without DM (69% vs. 32%; p<0.001). Finally, 
glomerular C4d and C5b-9 deposits were correlated with the severity 
of DN (rho = 0.341 and 0.259, respectively; p<0.001). 
Discussion Complement activation is correlated with both the pre- 
sence and severity of DN, suggesting that the complement system is 
involved in the development of renal pathology in patients with dia-





Diabetic nephropathy (DN), the leading cause of end-stage renal di- 
sease worldwide, can occur in patients with either type 1 or type 2 
diabetes mellitus (DM)1-3. DN is characterized by a gradual increase in 
proteinuria and blood pressure, and a gradual decrease in glomeru-
lar filtration rate that may result in the need for renal replacement 
therapy. Prolonged hyperglycemia can lead to the development of DN 
via a number of pathways with complex interactions; however, the 
precise cellular and molecular mechanisms that underlie this process 
are poorly understood4-6.
The first evidence for a possible role of the complement system in 
the development of DN was provided by the finding that serum, urine, 
and renal samples obtained from patients with diabetes often con-
tained activated complement proteins, and that these proteins are as-
sociated with DN7-14. Serum levels of mannose-binding lectin (MBL) are 
correlated with the severity of DN, which suggest a role for the lectin 
complement pathway15. In addition, advanced glycation end-products 
can directly bind C1q and activate the complement system16, and DN 
has been associated with increased renal expression of complement 
factors C3, C4, and C9 (at the protein level), as well as increased ex-
pression of C1q, C1s, and C1r (at the mRNA level), which also suggest 
a role for the classical complement pathway8,17. Furthermore, hypergly-
cemia can cause glycation-induced dysfunction and/or inactivation of 
complement regulatory proteins, including CD59, which inhibits C5b-9 
under physiological conditions11,18; this glycation-induced complement 
dysregulation leads to increased C5b-9 levels in patients with DN11. 
In a rat model of type 2 diabetes, treating diabetic rats with a C3a 
receptor antagonist improved renal function and reduced both albu-
minuria and the deposition of extracellular matrix proteins19. 
Recently, 2 groups reviewed the role of complement activation in 
DM7,14. They concluded that the relative role of complement in the 
development of DM-related complications, including DN, are unknown. 
Moreover, it remains unclear whether these mechanisms are similar 
between type 1 DM and type 2 DM7. To address these questions, we 
examined whether complement activation occurred in renal autopsy 
samples obtained from a large cohort of cases with diabetes with 
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and without DN. Specifically, we measured the prevalence, localization, 
and staining patterns of renal C4d and C5b-9 deposits. Furthermore, 
because both the lectin and classical complement pathways can lead 
to C4d deposits, and because both pathways might be involved in 
the development of DN, we also determined which complement path-
way was associated with the deposition of C4d in cases with DN. We 
validated our findings in renal biopsy samples. Finally, we correlated 
complement deposition with histopathology, and examined differences 
in complement deposition between cases with type 1 and 2 DM. 
Methods
This study group includes a selection of a previously described 
cohort20. In brief, we retrospectively searched the database of our 
pathology department for native kidneys from adult cases with either 
type 1 or type 2 DM who were autopsied from 1984 through 2004. 
We initially included 184 autopsied kidneys that were prepared for 
light microscopy, electron microscopy, and immunohistochemistry. We 
subsequently excluded 25 cases due to poor tissue quality or missing 
tissue for immunostaining. Thus, we included a total of 159 samples 
from cases with diabetes for whom we confirmed the histopathological 
presence or absence of DN according to the classification for DN21. In 
addition, we included a control group consisting of autopsy samples 
obtained from 41 cases without diabetes without renal pathology. We 
validated our findings with autopsy tissue by examining 12 kidney 
biopsies from patients with DN and 10 biopsies obtained from healthy 
living transplantation donors.
Clinical data
The clinical information was obtained retrospectively via the medical 
records and autopsy reports available at Leiden University Medical 
Center, and the general practitioners of the patients. The following 
laboratory parameters were collected from a period starting 1 year 
before the patient died: serum creatinine, estimated glomerular filtra-
tion rate (eGFR) (calculated using the Modification of Diet in Renal 
Disease formula), microalbuminuria (defined as 30-300 mg/l), protein-
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uria (defined as >300 mg/l) measured via a 24-hour urine or dipstick 
test, systolic and diastolic blood pressures, serum hemoglobin, serum 
cholesterol, and serum glycosylated hemoglobin (HbA1c)20. The clinical 
data were analyzed to reflect a stable representation of the serum 
and/or urine levels, thereby excluding data that were clearly affec- 
ted by an unstable clinical condition (for example, patients who were 
clinically unstable in an intensive care unit before death). Cause of 
death was categorized into the following 5 general categories: can-
cer, cardiovascular, infection and/or sepsis, multiple pathologies, and 
other (e.g., high-impact trauma).   
Histopathology and transmission electron microscopy
Renal tissue was fixed in 10% buffered formalin and embedded in 
paraffin. Sections were cut and then stained with hematoxylin and 
eosin, periodic-acid Schiff, and silver using standard protocols. Glo-
merular lesions, interstitial lesions, and vascular lesions were scored 
according to the histopathological classification for DN21. Discrimina-
tion between class 0 (i.e., no DN) and class I DN was determined 
using transmission electron microscopy, as described previously20. 
Immunohistochemistry and immunofluorescence
To measure renal complement activation, immunohistochemistry was 
performed on adjacent kidney sections using primary antibodies 
against the following proteins: C4d (1:150; Biomedica Gruppe, Vien-
na, Austria), which is a cleavage product of C4 that binds covalently 
to the target tissue and can arise from both the classical and MBL 
pathways; C1q (1:1200; DakoCytomation, Glostrup, Denmark), which 
reflects activation of the classical complement pathway; MBL (1:300; 
Sigma-Aldrich Biotechnology, Saint Louis, MO), which reflects activa-
tion of the MBL pathway; and SC5b-9 (1:500; Quidel, San Diego, CA), 
which is formed by activation of any of the aforementioned pathways. 
To investigate the presence of natural antibodies, immunofluorescence 
was performed on sections using a fluorescein isothiocyanate-labeled 
anti-IgM antibody (1:20; DakoCytomation).
The immunostained tissue samples were scored semi-quantitatively 
as follows: staining of glomeruli was scored as absent (representing 
Complement activation in patients with diabetic nephropathy
5
122
either an absence of staining or trace levels of staining in <5% of 
glomeruli) or present (representing staining in ≥5% of glomeruli). If 
present, the distribution of glomerular staining was scored as focal 
(5%-50% of the glomeruli) or diffuse (>50% of the glomeruli), and the 
staining pattern was scored as segmental (<50% of the glomerular 
tuft) or global (>50% of the glomerular tuft). In addition, if present, 
glomerular staining was scored as present in the glomerular capillary 
walls, mesangial cells, or both. Immunohistochemical staining in the 
glomerular hilus, arterioles, and arterial branches, was scored as ab-
sent or present (i.e., the presence of staining in ≥1 glomerular hilus, 
arteriole, and/or arterial branch was scored as positive). Renal tissue 
specimens containing ≥100 glomeruli were scored by two investigators 
who were blinded with respect to the clinical data of the cases. 
Statistical analysis
The SPSS statistical software package (version 20.0; IBM, Armonk, 
NY) was used for all statistical analyses. Categorical variables were 
compared using the chi-squared test or the Fisher exact test, where 
appropriate. Continuous variables were compared using the Student’s 
t test or the Mann-Whitney U test, where appropriate. Spearman’s 
rank correlation coefficient was used to analyze the correlation be-
tween diabetes class and the presence of glomerular complement 
deposits. Differences with a p value <0.05 were considered statistically 
significant.
Results 
Clinical and histological characteristics 
We included 159 diabetic cases; histologically confirmed DN was 
present in 101 cases (64%) and absent in 58 cases (36%). We also 
included an age- and sex-matched control cohort of 41 renal samples 
from autopsied nondiabetic cases without renal pathology. The clinical 
characteristics of the cases are summarized in Table 1. The duration 
of diabetes was significantly higher in the cases with DN than in the 
cases without DN (p=0.017); however, we found no difference between 
these 2 groups with respect to age, sex, diabetes type, presence of 
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hypertension, serum creatinine, eGFR, or HbA1c levels. 
The histological features of the cases with diabetes are summa-
rized in Table 2. Among the 101 cases with DN, DN was distributed 
as follows: 20% with class I, 20% with class IIA, 10% with class IIB, 
45% with class III, and 5% with class IV. Compared with the cases 
without DN, the cases with DN had a significantly higher prevalence 
of glomerular hyalinosis, glomerular capsular drop, arteriosclerosis, 
and arteriolar hyalinosis (p<0.05). In addition, the cases with DN had 
more interstitial fibrosis and tubular atrophy (IFTA) compared with the 
cases without DN (p=0.028). 
C4d deposition is associated with DN
C4d deposits in the glomeruli, glomerular hili, and arterioles were 
significantly more prevalent in cases with diabetes than in the control 
cases without diabetes (p<0.05) (Table 3), in contrast to C4d deposits 
in arterial branches (p=0.171) (Figure 1). In the diabetic cohort, C4d 
deposits were present in the glomeruli, glomerular hili, and arterioles 
of 38%, 48%, and 22% of the cases, respectively. In the nondiabetic 
control cohort, C4d deposits were rarely observed in any vascular 
structure. 
In the cohort of cases with diabetes, cases with DN had a sig-
nificantly higher prevalence of C4d deposits in the glomeruli and 
arterioles than cases without DN (Figure 1) (p=0.019 and p=0.022, re-
spectively). The cases with DN had a higher prevalence of C4d in the 
glomerular capillary walls (45% vs. 26% of cases without DN; p=0.019) 
and in the mesangial cells (26% vs. 12%, respectively; p=0.041) than 
cases without DN. The distribution of glomerular C4d did not differ 
significantly between the 2 groups. However, the global staining pat-
tern of C4d was significantly more prevalent in cases with DN than 
patients without DN (15% vs 5%, p=0.044). 
Within our cohort of cases with DN, eGFR was significantly lower 
in the cases with glomerular C4d than in the cases without glomeru-
lar C4d (39.8 ± 28.6 ml/min per 1.73m2 vs. 60.3 ± 33.5 ml/min per 
1.73m2; respectively; p=0.004). In contrast, we found no other correla-
tion between C4d deposits and clinical data (Table 4). 
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Table 1: Clinical characteristics of the control cases and diabetic cases. 
DN, diabetic nephropathy; eGFR, estimated glomerular filtration rate; HbA1c, glycosyla- 
ted hemoglobin; IQR: interquartile range; T1DM, type 1 diabetes mellitus; T2DM, type 2 
diabetes mellitus. Data are presented as the mean ± standard deviation, unless stated 
otherwise.
a Between nondiabetic controls without renal disease, diabetic cases without DN and 
diabetic cases with DN. 
b Between diabetic cases without DN and diabetic cases with DN. 
Evidence for classical complement activation in diabetic patients
Next, to investigate which complement pathway(s) led to the depo-
sition of C4d in cases with DN, we stained renal tissue for MBL (to 
measure the lectin pathway) and C1q (to measure the classical path-
way). 
MBL was only observed in 6% of the kidneys from cases with 
diabetes and was not observed in the control cases without diabe-
tes. When present, the staining pattern of MBL in the glomeruli was 
predominantly focal and segmental; MBL was not observed in the 
glomerular hili, arterioles, or arterial branches. We found no significant 
differences between MBL deposition in the cases with diabetes and 
control cases without diabetes or between the cases with diabetes 
with DN and the cases with diabetes without DN (Figure 2A and Table 
3). 
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Age, years 63.8 ± 16.8 69.1 ± 12.6 69.0 ± 12.8 69.1 ± 12,7 0.100a 
Female, n (%) 16 (39) 24 (41) 47 (47) 71 (45) 0.754a 
T1DM, n (%) NA 5/48 (10) 12/89 (14) 17/137 (12) 0.603b 
Duration of diabetes, years NA 8.4 ± 7.3 15.3 ± 13.1 13.3 ± 10.0 0.003b 
    T1DM (median, IQR) NA 17.5 (2) 28.0 (33) 18.0 (28) 0.215b 
    T2DM (median, IQR) NA 5.0 (5) 10.0 (14) 8.0 (15) 0.004b 
Creatinine serum, mmol/L NA 155 ± 169 167 ± 112 163 ± 135 0.625b 
eGFR, ml/min/1.73m2 NA 59 ± 36 50 ± 33 54 ± 34 0.184b 
HbA1c, % unit NA 7.5 ± 1.8 8.5 ± 2.4 8.1 ± 2.3 0.117b 
Hypertension, n (%) NA 27/48 (56) 44/85 (52) 71/133 (53) 0.618b 
Systolic pressure, mmHg NA 134 ± 29 155 ± 29 135 ± 29 0.780b 
Diastolic pressure, mmHg NA 75 ± 14 75 ± 12 75 ± 13 0.961b 
Cause of death, n (%)     0.199a 
    Cancer 4 (10) 9 (16) 5 (5) 14 (9)  
    Cardiovascular 16 (39) 20 (34) 49 (48) 69 (43)  
    Infection/Sepsis 4 (10) 7 (12) 12 (12) 19 (12)  
    Multiple pathologies 13 (31) 14 (24) 17 (17) 31 (20)  




Table 2: Histological characteristics of the diabetic cases
DN, diabetic nephropathy; FSGS, focal segmental glomerulosclerosis; IFTA, interstitial 
fibrosis and tubular atrophy. 
a Between diabetic cases without DN and diabetic cases with DN. 
Data are presented as the number of cases (%).
Glomerular C1q was present in 36% of the cases with diabe-
tes, and the staining pattern was predominantly focal and global. 
The prevalence of glomerular C1q was not significantly different 
between the cases with diabetes and control cases without diabe-
tes (37% vs. 49%, respectively; p=0.150) (Figure 2B and Table 3). 
In contrast, the prevalence of C1q in the glomerular hili, arteri-
oles, and arterial branches was significantly higher in the cases with 
diabetes than in the control cases without diabetes (p≤0.001). Fur-
thermore, among the cases with diabetes, the cases with DN had 
a significantly higher prevalence of C1q in the glomerular hili and 
arterioles compared with the cases without DN (p<0.05), whereas the 
prevalence of C1q in the arterial branches did not differ significant-
ly between these 2 groups (p=0.106). Finally, the presence of C1q 
deposits was correlated with the presence of C4d deposits in the 
glomeruli (p=0.006), glomerular hili (p=0.027), and arterioles (p<0.001). 
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    0 (no DN) 58 (100) 0 (0) 58 (37) NA 
    I 0 (0) 20 (20) 20 (13) 
    IIA 0 (0) 21 (20) 21 (13) 
    IIB 0 (0) 10 (10) 10 (6) 
    III 0 (0) 45 (45) 45 (28) 
    IV 0 (0) 5 (5) 5 (3) 
Glomerular hyalinosis 19 (33) 85 (84) 104 (65) <0.001 
Glomerular capsular drop 2 (3) 15 (15) 17 (11) 0.025 
FSGS 2 (3) 12 (12) 14 (9) 0.071 
IFTA 
    
    absent 22 (38) 17 (17) 39 (25) 0.028 
    10-25% 25 (43) 56 (55) 81 (51) 
    25-50% 5 (9) 15 (15) 20 (13) 
    >50% 6 (10) 13 (13) 19 (12) 
Arteriosclerosis 46 (79) 92 (91) 138 (87) 0.035 
Arteriolar hyalinosis 46 (79) 92 (91) 138 (87) 0.035 


















Table 3:  Summary of complement deposition in nondiabetic controls, diabetic 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































DM, diabetic cases with-
out diabetic nephropa-
thy; DN, diabetic cases 
with diabetic nephropa-
thy; NDC, non-diabetic 
controls. All data are 
presented as the num-
ber of non-diabetic con-
trols or patients (%). 
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Figure 1: Prevalence of C4d deposits in cases and controls. The percentage 
of cases and controls with complement factor C4d is shown for the indicated renal 
structures. Asterisks represent the overall differences between the nondiabetic controls, 
the diabetic cases without diabetic nephropathy (DN), and the diabetic cases with DN; 
The p values shown between the 2 groups represent post hoc analyses. **p<0.01 and 
***p<0.001. 
C5b-9 deposits are associated with diabetes, but not with DN
In the cases with diabetes, glomerular C5b-9 staining was predomi-
nantly diffuse and global. Although the prevalence of C5b-9 deposits 
was significantly higher in the glomeruli, glomerular hili, and arterioles 
of the cases with diabetes compared with the control cases without 
diabetes (p<0.001) (Figure 2C and Table 3), the prevalence of C5b-9 
was still relatively high in the control cases without diabetes. Only the 
prevalence of C5b-9 deposits in the glomerular hili were significantly 
higher in the patients with DN than in patients without DN (p=0.047; 
Figure 2C). The presence of glomerular C5b-9 deposits was correlated 
with the presence of glomerular C4d deposits (p=0.002). 
The prevalence, location, distribution, and staining patterns of 
complement proteins in the glomeruli, glomerular hili, arterioles, and 
arterial branches of the cases with diabetes are listed in Table 3. 
Representative images of C1q, C4d, MBL, and C5b-9 staining in these 
structures are shown in Figure 3.
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C4d and C5b-9 deposits are cor-
related with histological lesions and 
DN class 
Among the cases with diabetes, the 
presence of glomerular C4d was cor-
related with glomerular hyalinosis 
(p=0.020), IFTA (p<0.001), arteriosclero-
sis (p=0.017), and arteriolar hyalinosis 
(p=0.017) (Supplemental Table S1A and 
S1B). Moreover, the presence of C4d in 
the glomerular hili was correlated with 
glomerular hyalinosis (p=0.002), and 
the presence of C4d in the arterioles 
was correlated with IFTA (p<0.001), 
arteriosclerosis (p=0.041), and arteri-
olar hyalinosis (p=0.041). Although glo-
merular C1q was not correlated with 
histological lesions, the presence of 
C1q in the arterioles was correlated 
with the presence of glomerular cap-
sular drop (p=0.034), arteriolar hyali-
nosis (p=0.048), and IFTA (p=0.027). 
The presence of MBL in the glomeruli, 
arterioles, and arterial branches was 
not correlated with any renal lesion. 
In addition, the presence of glome- 
rular C5b-9 was correlated with IFTA 
(p=0.008). Finally, with respect to DN 
class, the prevalence of glomerular C4d
 
Table 4: Correlation between clinical data 
and C4d deposition in autopsied cases with 
diabetic nephropathy
Art, arterioles; Art branch, arteriolar branches; DBP, 
diastolic blood pressure; Glom, glomerular; HbA1c, 
glycosylated hemoglobin; SBP, systolic blood pres-





























































































































































































































































































































































































































































































































































































and C5b-9 was correlated with more severe classes of DN 
(p≤0.001) (Figure 4), particularly with class III and class IV DN. 
Differences in complement deposition between type 1 DM and 
type 2 DM
Data on diabetes type was available for 137 patients (86% of cases 
with diabetes); 17 cases (12%) had type 1 DM and 120 cases (88%) 
had type 2 DM. Compared to cases with type 2 DM, cases with type 
1 DM had a significantly higher prevalence of C4d in glomeruli (64% 
vs 33%; p=0.012), C4d in arterioles (47% vs 18%; p=0.007), and 
C5b-9 in glomeruli (94% vs 64%; p=0.013). Within the subgroup of 
cases with DN, cases with type 1 DM also had a significantly higher 
prevalence of C4d in glomeruli (75% vs 35%; p<0.01), C4d in arteri-
oles (50% vs 22%; p=0.040), and C5b-9 in glomeruli (100% vs 68%; 
p<0.05). 
Evidence for the activation of the classical complement pathway 
in biopsies 
To support our findings with autopsy tissue, we found that the pre- 
valence of glomerular C4d was significantly higher in biopsies from 
cases with DN compared with a control group of biopsies obtained 
from healthy living transplantation donors (75% vs. 10%, respectively; 
p=0.002); similar results were obtained with respect to glomerular C5b-
9 deposits (75% vs. 0%, respectively; p=0.001; Figure 5). In contrast, 
the prevalence of glomerular C1q deposits did not differ significantly 
between these 2 groups (58% vs. 40%, respectively; p=0.392), and 
glomerular MBL deposits were not observed in either group. The pre- 
valence of glomerular IgM deposits was significantly higher in the ca- 
ses with DN compared with control cases (82% vs. 30%, respectively; 
p=0.017), and the prevalence of glomerular IgM deposits were signifi-
cantly correlated with the prevalence of glomerular C1q (p=0.003) and 
C4d (p=0.001) deposits. Finally, glomerular IgM deposits co-localized 
with glomerular C1q and C4d deposits (Figure 6), which suggested 
that the classical complement pathway was activated in cases with DN.
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Figure 2: Prevalence of mannose-binding lectin (MBL), C1q, and C5b-9 deposits 
in cases and controls. The percentage of cases and controls with complement factor 
MBL (a), C1q (b), and/or C5b-9 (c) is shown for the indicated renal structures. The 
p values shown between the 2 groups represent post hoc analyses. ***p<0.001, chi-
squared test between nondiabetic controls, diabetic cases without diabetic nephropathy 
(DN), and diabetic cases with DN.
Discussion 
DN is a microvascular complication that affects 20% to 40% of pa-
tients with diabetes, making it the leading cause of end-stage renal 




Figure 3: Representative images of complement staining in patients. Kidney 
sections were immunostained for the indicated proteins, and representative images 
containing the glomeruli, glomerular hili, arterioles, and arterial branches are shown. 
Mannose-binding lectin (MBL) staining was negative in the glomerular hilus, arterioles, 
and arterial branches. Scale bars: 50 µm
plement activation via the lectin and/or classical complement path-
way plays a role in the development of DN4-7,14. Here, we investi-
gated the deposition of complement proteins in a relatively large 
cohort of cases with diabetes with DN and without DN. We found 
that the complement activation marker C4d was correlated with DN, 
as well as with the severity of DN, microvascular and interstitial 
lesions, and lower eGFR in cases with DN, suggesting that com-
plement activation might play a role in the development of DN. 
Because C4d binds covalently to its target cells, C4d can be ob-
served long after the factors that activated the pathway have disso-
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Figure 4: Percentage of patients with glomerular C4d deposits and glomerular 
C5b-9 deposits plotted against diabetic nephropathy class. The presence of glo-
merular C4d (a) and C5b-9 (b) was correlated with diabetic nephropathy class. For C4d 
and C5b-9, the Spearman rank correlation coefficient (rho) was 0.344 and 0.228, re-
spectively (both p<0.01). Cases without diabetic nephropathy were classified as class 0.
ciated, making it a commonly used biomarker for complement acti-
vation22. The prevalence of C4d deposits in the glomeruli and arte-
rioles was significantly higher in cases with DN than cases without 
DN and in cases without diabetes without renal pathology, both in 
the autopsy cohort and in the biopsy cohort. Moreover, glomerular 
C4d and arteriolar C4d were more prevalent in the cases with vas-
cular and chronic renal lesions, and glomerular C4d was correlated 
with the severity of DN. These data suggested that complement ac-
tivation, together with the renal microvasculature, might be involved 
in the development of DN. This notion is supported by the general 
absence of C4d deposits among the control cases without diabe-
tes. To investigate which complement pathway could underlie the 
deposition of C4d, we studied the prevalence and localization of 
C1q (to measure the classical pathway) and MBL (to measure the 
lectin pathway) deposits. The presence of C1q, IgM, and C4d depo- 
sits were associated with each other, and co-localized in the same 
renal vascular structures, whereas MBL was detected rarely in our 
cohort. These findings suggest that the presence of C4d reflected 
activation of the classical complement pathway. However, because 
MBL is not covalently bound and because other proteins such as 
ficolins can initiate the lectin pathway, we could not exclude the 
possibility that activation of the lectin pathway led to C4d deposition. 
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Figure 5: Percentage of renal sections containing IgM, C1q, mannose-binding 
lectin (MBL), C4d, or C5b-9 deposits. Biopsy samples were obtained from living pa-
tients with diabetic nephropathy (n=12) and healthy living renal transplantation donors 
(n=10) and stained for IgM, C1q, MBL, C4d, and C5b-9. P values were calculated using 
the chi-square test. 
C4d deposits were significantly more prevalent in kidneys from 
cases with type 1 DM than in kidneys from cases with type 2 DM, 
both in the total cohort of cases with diabetes and in the subgroup 
of cases with DN. The presence of DN was not a confounder in this 
association because DN was not more prevalent in type 1 DM com-
pared with type 2 DM. Rowe et al. showed similar differences in pan-
creatic C4d deposition among cases with type 1 DM, type 2 DM, and 
control cases without diabetes23. The higher C4d prevalence between 
cases with type 1 DM and type 2 DM could possibly reflect a different 
pathogenesis. Nevertheless, we could not exclude the possibility that 
the difference observed in complement deposition might be attributed, 
at least in part, to the duration of diabetes rather than the type of 
diabetes.
Glomerular C4d was a common finding in our cases with class 
III DN. Paueksakon et al. suggested that Kimmelstiel-Wilson lesions, 
which are a hallmark lesion of DN and a diagnostic requirement for 
class III DN, might be a form of thrombotic microangiopathy. Spe-
cifically, they found that a subset of cases with DN had fragmented 
red blood cells exclusively in Kimmelstiel-Wilson lesions24. Recently, 
we reported that complement factor C4d was a common denomina-
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Figure 6: Glomerular IgM deposits co-localize with glomerular C1q and C4d. 
Adjacent sections of an autopsied kidney from a case with diabetic nephropathy were 
stained for C1q (a) or IgM (b). Adjacent sections of an autopsied kidney from a case 
with diabetic nephropathy were stained for C4d (c) or IgM (d); the arrowheads indicate 
co-localization between C4d and IgM. The scale bars in (a) and (c) represent 50 µm; 
the scale bars in (b) and (d) represent 25 µm.
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tor in several thrombotic microangiopathies25. Thus, our data further 
supported the hypothesis that Kimmelstiel-Wilson lesions might be a 
form of thrombotic microangiopathy that arises from complement ac-
tivation. The underlying cause of C4d deposits in the arterioles, arte- 
ries, and glomerular hilus (the junction between afferent and efferent 
arterioles) is currently unknown. Because both renal afferent arterioles 
and renal efferent arterioles play a role in regulating renal blood flow, 
these vessels can be exposed to extremely turbulent blood flow and 
high shear stress conditions26-29, which may increase vulnerability to 
vascular injury, complement deposition, and/or the development of 
renal pathology.
We found that C5b-9 deposits were more prevalent in our cases 
with diabetes than in control cases without diabetes; however, the 
clinical relevance of these deposits in our cohort is difficult to in-
terpret, because C5b-9 was relatively frequently prevalent in control 
cases without diabetes (albeit to a lesser extent than in the cases 
with diabetes). This finding might be related in part to our use of 
autopsy samples because we did not observe these deposits in renal 
biopsies obtained from living donors, which was consistent with find-
ings reported by Qin et al.11 Nevertheless, in our cohort of cases with 
diabetes with DN, the presence of glomerular C5b-9 was correlated 
with the severity of DN, which suggested that C5b-9 might play a 
role in the progression of renal damage. Our data suggested that the 
process that leads to C4d deposition also leads to C5b-9 deposition. 
However, C5b-9 could have also been activated due to a direct effect 
of hyperglycemia on regulatory proteins in the complement system. 
Hyperglycemia can lead to the glycation of CD59, which inhibits C5b-9 
under physiological conditions11,18. This glycation-induced inactivation 
of CD59 could lead to the formation of C5b-9.
In the setting of DN, several factors could have led to the depo-
sition of C4d. For example, autoantibodies can activate the comple-
ment system30. This notion is supported by the report of linear IgG 
staining along the glomerular basement membrane in 60% of type 2 
DM cases with DN31. In addition, high glucose levels in cases with DM 
can lead to increased levels of glycated proteins, including advanced 
glycation end-products and oxidized proteins32,33, which can activate 
the classical and/or lectin pathways either directly or by reacting with 
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autoantibodies16,34-36. The complement system can also be activated 
by the binding of natural (i.e., IgM) antibodies to either hypoxic or 
apoptotic cells in the setting of DN37,40,41. Natural antibodies play an 
important role in clearing damaged cells via intracellular antigens that 
are externalized during apoptosis and/or hypoxic conditions37-41. We 
found a significantly higher prevalence of glomerular IgM deposits in 
biopsies from cases with DN compared with healthy living transplanta-
tion donors. Moreover, glomerular IgM deposits co-localized with—and 
were significantly correlated with—both C1q and C4d, which supported 
the hypothesis that IgM antibodies activate the classical complement 
pathway in cases with DN.
It is currently unknown whether complement activation is a cause 
and/or consequence of microvascular damage in DN. Our data sug-
gested that complement activation was involved in the progression 
of renal damage in cases with diabetes mellitus because complement 
activation was correlated with more severe renal damage, including 
higher DN class and increased IFTA levels. These findings were con-
sistent with other studies with regard to complement activation in 
the development of DN and other diabetes-associated microvascular 
and/or macrovascular complications7,14. Furthermore, type 2 diabetic 
rats treated with a complement inhibitor had improved renal function 
and morphology compared with untreated rats19, which supported the 
notion that complement activation plays a role in the progression of 
diabetes-associated kidney disease. In the context of DM, hyperglyce-
mia can both directly and indirectly lead to complement deposition, 
which can then lead to the increased production of reactive oxygen 
species, activation of protein kinase C, and upregulation of nuclear 
factor-kB, thereby inducing the release of proinflammatory, prothrom-
botic cytokines, and growth factors7. Both complement-dependent 
and complement-independent mechanisms can then lead to inflam-
mation, proliferation, and thrombosis, which together characterize 
the diabetes-associated complications in target organs. In contrast, 
complement activation may also be a consequence of renal vascular 
damage, possibly following activation via natural antibodies. This hy-
pothesis is consistent with our findings regarding the presence of C4d 
and IgM antibodies in other renal microangiopathies25,42. Moreover, we 
previously reported that C4d deposits were associated with remo- 
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deling of the glomerular basement membrane43, which was consistent 
with cases with DN that presented with a remodeled glomerular base-
ment membrane. Nevertheless, despite our relatively large cohort and 
our ability to examine >100 glomeruli per case, the autopsy-based 
nature of this study precluded our ability to measure causality. There-
fore, future studies should be designed to determine whether com-
plement activation is a cause, consequence, or mediator of DN.
Our study has several limitations. First, the use of autopsy samples 
precluded our ability to investigate whether the prevalence of com-
plement deposition in the glomeruli, glomerular hili, and/or vessels 
was associated with patient survival and/or renal survival. Second, 
our study might have had a selection bias because not all cases with 
diabetes had an autopsy; generally speaking, most cases that are 
autopsied were in the hospital at the time of death. Third, because 
autopsy samples were used, we could not exclude the possibility that 
post-mortem changes and/or cause of death might have affected 
the tissue in terms of protein expression and/or tissue morphology. 
However, to address this possibility, we examined control samples 
obtained from autopsied cases without diabetes or renal pathology. 
Furthermore, because cause of death was not significantly correlated 
with the prevalence of complement deposits, and because our findings 
were supported by examining renal biopsy samples, we concluded 
that our data were not likely affected by autopsy-related artifacts. In 
contrast, the strength of our study was the relatively high number of 
cases combined with our ability to examine >100 glomeruli per case. 
In conclusion, complement activation is associated with DN, and 
both glomerular C4d and glomerular C5b-9 deposits are correlated 
with the class of DN. Furthermore, complement deposits in several 
renal vascular structures are correlated with more severe renal da- 
mage. Our data suggest that complement activation is involved with 
the development of renal damage in cases with diabetes, and that 
inhibition or modulation of complement activity could be a promising 
therapeutic strategy for patients with DN. 




All tissue samples were coded and then handled and analyzed anon-
ymously in accordance with the Declaration of Helsinki. Approval for 
the study was obtained from the medical ethics committee of Leiden 
University Medical Center.
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Supplemental Table 1: C1q, MBL, C4d, and C5b-9 deposits and histologic lesions 
in all diabetic cases.
Glom: glomeruli; glom hilus: glomerular hilus; Art: arterioles; Art Branch: arterial branch-
es; FSGS: focal segmental glomerulosclerosis; IFTA: interstitial fibrosis and tubular 
atrophy. All data are presented as the number of patients (%).































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplemental Table 1: C1q, MBL, C4d, and C5b-9 deposits and histologic lesions 
in all diabetic cases.
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Soluble fms-like tyrosine kinase-1 reduces inflamma-
tion in APOC1 transgenic mice





A polymorphism in the APOC1 gene, which encodes apolipoprotein 
C-I (apoCI), has been associated with the development of diabetic ne-
phropathy. In addition, patients with diabetes have increased plasma 
levels of apoCI compared to non-diabetic control subjects. APOC1 
transgenic (APOC1-tg) mice develop nodular glomerulosclerosis by 
the age of 15 months; however, the slow disease progression in this 
model makes it poorly suited for studying therapeutic and preventive 
interventions. In an attempt to accelerate the progression of glomeru-
losclerosis in APOC1-tg mice, we introduced a second genetic ‘hit’ by 
transfecting these mice with the sFlt-1 gene, which encodes soluble 
fms-like tyrosine kinase-1 (sFLT-1), an inhibitor of vascular endothe-
lial growth factor A (VEGF-A). We then investigated whether inducing 
a systemic increase in sFLT-1 levels for 15 weeks in 8-week-old 
APOC1-tg mice accelerates the development of glomerulosclerosis. 
Our results demonstrate that a systemic increase in sFLT-1 levels for 
15 weeks does not induce the development of glomerulosclerosis in 
APOC1-tg mice. Instead, APOC1-tg mice transfected with sFlt-1 had 
significantly fewer glomerular macrophages compared to non-trans-
fected APOC1-tg mice (p<0.01). Surprisingly, the atopic dermatitis that 
normally develops in APOC1-tg mice was resolved following transfec-
tion with sFlt-1, presumably by reducing the infiltration of inflamma-
tory cells into the skin. Moreover, we found no significant change in 
glomerular endothelial cell activation or glomerular VEGF-A mRNA le- 
vels in sFlt-1‒transfected APOC1-tg mice compared to non-transfected 
APOC1-tg mice. Taken together, these data suggest that sFLT-1 has 





Diabetic nephropathy remains the leading cause of end-stage renal 
disease worldwide1. Although the risks of acute myocardial infarction, 
stroke, and amputation among diabetic patients have decreased con-
siderably over the past two decades, the risk of developing end-stage 
renal disease has remained high in these patients2. Thus, new preven-
tive and therapeutic strategies, as well as a clearer understanding of 
the mechanisms that underlie the development and repair process in 
diabetic nephropathy, are urgently needed.
The risk factors associated with the development of diabetic ne-
phropathy include hyperglycaemia, hyperlipidaemia, hypertension, and 
genetic factors. With respect to genetics, a polymorphism in the 
APOC1 gene, which encodes apolipoprotein C-I (apoCI), has been 
associated with an increased risk of developing diabetic nephropa-
thy3. Furthermore, compared to non-diabetic control subjects, patients 
with diabetes have increased plasma levels of apoCI4. Recently, we 
reported that patients with diabetic nephropathy have higher levels 
of glomerular apoCI protein compared to both diabetic patients with-
out nephropathy and non-diabetic controls5. We also reported that 
transgenic mice carrying the APOC1 transgene (APOC1-tg mice), but 
not wild-type mice, develop albuminuria and nodular glomeruloscle-
rosis, features that are highly reminiscent of diabetic nephropathy. 
In addition, apoCI increases the inflammatory response of activated 
macrophages in vitro; specifically, these cells have increased ex- 
pression of tumour necrosis factor alpha (TNF-alpha)5,6. Moreover, TNF- 
alpha production by glomerular macrophages has been suggested to 
promote the development of diabetic nephropathy7. Together, these 
data support the hypothesis that apoCI increases the inflammatory re-
sponse of glomerular macrophages in APOC1-tg mice, resulting in the 
development of nodular glomerulosclerosis. Unfortunately, however, 
APOC1-tg mice do not develop glomerulosclerosis until 15 months of 
age5; thus, the relatively slow disease progression in this model makes 
it unsuitable for studying therapeutic and preventive interventions.
Vascular endothelial growth factor A (VEGF-A) is another important 
mediator of kidney disease, and studies have shown that VEGF-A 
plays an important role in the maintenance and survival of endothe-
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lial cells8. A decrease in glomerular VEGF-A levels below physiological 
levels results in the development of renal disease. Specifically, mice 
that lack VEGF-A expression in the glomeruli are not viable and have 
a wide range of endothelial cell defects; moreover, mice that are 
heterozygous for VEGF-A selectively in podocytes (i.e. mice with podo-
cyte-specific VEGF-A haploinsufficiency) develop proteinuria, endothe-
liosis, and progressive loss of endothelial cells9. Similarly, treating 
rats with soluble fms-like tyrosine kinase-1 (sFLT-1) – an inhibitor of 
VEGF-A – causes endothelial cell damage and loss, hypertension, and 
proteinuria10. Together, these findings indicate that too little VEGF-A 
and too much sFLT-1 can both lead to glomerular endothelial dys-
function. 
In an attempt to accelerate the progression of glomerulosclerosis 
in APOC1-tg mice, we introduced a second genetic ‘hit’ by transfecting 
8-week-old mice with sFlt-1. We then examined whether systemically 
increasing sFLT-1 levels leads to an accelerated development of glo-
merulosclerosis by monitoring the mice for 15 weeks post-transfection. 
Methods
sFlt-1 transfection
Two pcDNA3.1 vectors (Invitrogen, Breda, the Netherlands) containing 
either sFlt-1-VSV or the luciferase gene were generated as described 
previously11,12. The resulting plasmids were amplified in DH5α E. coli 
(Invitrogen), purified using the QIAfilter Plasmid Maxi-prep kit (Qiagen, 
Venlo, the Netherlands), and dissolved in Endo-Free Tris–EDTA buffer 
(Qiagen). Mice were transfected by electroporation of the sFlt-1-VSV 
and luciferase constructs into both gastrocnemius muscles (20 µg 
each) as described previously11. To monitor transfection efficiency, 
the mice were injected intraperitoneally with luciferin at 2-week in-
tervals. Five minutes after each luciferin injection, luciferase activity 
was visualised at the transfection sites using a Night-OWL biolumi-





For this study, we used 8-week-old female C57BL/6J mice (Harlan 
Laboratories, Indianapolis, IN) and APOC1-tg mice. All experiments 
were conducted in accordance with national guidelines for the care 
and use of experimental animals (DEC licence 13163). Mice were 
housed in individually ventilated cages in groups of up to five mice/
cage, with food and water provided ad libitum. For the experiments, 
the mice were randomly assigned to groups. At 8 weeks of age, the 
mice were transfected with sFlt-1. The development of glomeruloscle-
rosis was then monitored in sFlt-1‒transfected and non-transfected 
APOC1-tg mice (n=6 mice/group), as well as in sFlt-1‒transfected and 
non-transfected C57BL/6J (wild-type) mice (n=6 mice/group). Fifteen 
weeks after transfection, the mice were sacrificed; this time point was 
chosen because we previously found that treatment with sFLT-1 for 15 
weeks results in significant changes in kidney function and morpholo-
gy12. One mouse in the non-transfected APOC1-tg group was removed 
from the study due to the development of severe atopic dermatitis 
complicated by open wounds.
Measurement of the urine albumin:creatinine ratio 
To measure the urine albumin:creatinine ratio, spot urine was collec- 
ted at 5 and 15 weeks after the start of the experiment. Urine albu-
min levels were measured using rocket immunoelectrophoresis with 
a rabbit anti-mouse albumin; purified mouse serum albumin (Sigma- 
Aldrich, Saint Louis, MO) was used as a standard. Urine creatinine 
was measured using a creatinine assay, with picric acid, sodium hy-
droxide, and creatinine standards (Sigma-Aldrich); the albumin:creati-
nine ratio was then calculated.
Immunohistochemistry
Paraffin-embedded kidney tissues were cut at 4-µm thickness using a 
Leica microtome and stained with periodic acid-Schiff (PAS) using a 
standard protocol. A rabbit anti-human Wilms tumour 1 (WT1; 1:500; 
Santa Cruz Biotechnology, Dallas, TX) primary antibody was used for 
immunostaining, followed by an anti-rabbit-Envision HRP-conjugated 
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secondary antibody (Dako, Glostrup, Denmark), with diaminobenzidine 
(DAB+; Dako) as the chromogen. This rabbit anti-human WT1 antibody 
cross-reacts with mouse WT1 (data not shown). A non-specific iso-
type-matched antibody was used as a negative control. 
Paraffin-embedded skin tissues were cut at 4-µm thickness using a 
Leica microtome and stained with hematoxylin and eosin (H&E) using 
a standard protocol. The rat anti-mouse F4/80 (1:100; kindly provided 
by the Department of Human Genetics, LUMC) primary antibody was 
used for immunostaining, followed by the anti-rat-Impress (Vector Lab-
oratories, Burlingame, CA) HRP-conjugated secondary antibody, with 
DAB+ as the chromogen.
Frozen kidney tissues were cut at 4-µm thickness using a Reichert 
cryostat and immunostained using the following primary antibodies: rat 
anti-mouse CD68 (1:15; Abcam, Cambridge, MA), rat anti-mouse vas-
cular cell adhesion molecule-1 (VCAM-1; 1:1400; BD Pharmingen, San 
Diego, CA), rat anti-mouse intercellular adhesion molecule-1 (ICAM-1; 
1:200; ATCC, Manassas, VA), and rabbit anti-vesicular stomatitis virus 
(VSV; 1:2500; Sigma-Aldrich), followed by the appropriate Envision 
(Dako) or Impress (Vector Laboratories) HRP-conjugated secondary 
antibody, with DAB+ as the chromogen. For each immunostaining 
experiment, the respective non-specific isotype-matched antibody was 
used as a negative control.
Frozen skin tissues were cut at 4-µm thickness using a Reichert 
cryostat and immunostained with rat anti-mouse CD3 (1:20; Abcam), 
followed by the appropriate Impress (Vector Laboratories) HRP-conju-
gated secondary antibody, with DAB+ as the chromogen.
Digital image analysis
Images of tissue sections were digitised using a Philips Ultra-Fast 
Scanner 1.6 RA. The surface area of the glomerular tuft was measured 
in PAS-stained slides containing 25 glomeruli per section using Philips 
Ultra-Fast Scanner 1.6 RA software. ImageJ (NIH, Bethesda, MD) was 
used to quantify the levels of VCAM-1 and ICAM-1. The positive area 
per glomerulus was determined by measuring the positively stained 
area (corrected for the total area of the glomerulus) at 400X mag-
nification with 10 glomeruli per section. The number of podocytes in 
each sample was determined by counting the number of WT1-positive 
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nuclei per glomerulus, measured in 25 glomeruli. The number of ma- 
crophages was determined by counting the number of CD68-positive 
cells in 10 glomeruli per section. The glomeruli that were used for 
these measurements were selected at random. The average thickness 
of the epidermal layer was determined by averaging 10 measurements 
per field in 5 fields at 20X magnification using  Philips Ultra-Fast 
Scanner 1.6 RA software.
RNA isolation and quantitative real-time PCR
Frozen kidney tissues were chopped and then dissolved in 1 ml TRIzol 
(Ambion, Foster City, CA) to obtain total RNA. Quantitative real-time 
PCR (qRT-PCR) was then performed using SYBR Green I master mix (Bio-
Rad, Hercules, CA) in accordance with the manufacturer’s instructions; 
the reactions were run on a Bio-Rad CFX real-time system. Ct (cycle 
threshold) values were normalised to the housekeeping gene Hprt1. 
The following primers were used: Hprt1: 5’-GGCTATAAGTTCTTTGCT-
GACCTG-3’ and 5’-AACTTTTATGTCCCCCGTTGA-3’; Vegf-a: 5’-CTGGAC-
CCTGGCTTTACTGC-3’ and 5’-GCTTCGCTGGTAGACATCCA-3’.
Statistics
Data were analysed using a one-way ANOVA. Differences were con-
sidered significant at p<0.05.
Results
Transfection efficiency
First, we tested the efficacy and efficiency of our transfection protocol. 
Transfected and non-transfected mice were injected intraperitoneally 
with luciferin, and luciferase activity was visualised using a Night-OWL 
bioluminescence camera. As shown in Figure 1, non-transfected mice 
had no luminescence in the gastrocnemius muscles following injection 
with luciferin (Figure 1, mice 1 and 2); in contrast, transfected mice 
had robust luminescence at the site of transfection (Figure 1, mice 
3-5). Staining for VSV (to measure the VSV-tagged sFLT-1 protein) 
confirmed the presence of exogenous sFLT-1 in the renal vasculature 
(data not shown).
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Figure 1: Transfection efficiency. The sFlt-1 and luciferase constructs were co-trans-
fected bilaterally by injection into the gastrocnemius muscles. Luciferase activity was vi-
sualised using a Night-OWL bioluminescence camera and is depicted using an arbitrary 
pseudocolour scale with red and blue corresponding to high and low luminescence, 
respectively. 1 and 2: two representative non-transfected APOC1-tg mice following an 
i.p. injection of luciferin; 3-5: three representative sFlt-1‒transfected APOC1-tg mice 
following an i.p. injection of luciferin.
Albuminuria and glomerulosclerosis
APOC1-tg mice and age-matched wild-type mice have a similar al-
bumin:creatinine ratio (Figure 2A). Moreover, APOC1-tg mice that 
were transfected with sFlt-1 had a similar albumin:creatinine ratio as 
non-transfected APOC1-tg mice. Furthermore, the glomerular surface 
area was similar between APOC1-tg mice and wild-type mice (Figure 
2B), and transfection with sFlt-1 did not significantly affect glomerular 
surface area. Non-transfected APOC1-tg mice had significantly fewer 
podocytes compared to wild-type mice, and transfecting APOC1-tg 
mice with sFlt-1 had no further effect on the number of podocytes 
(Figure 2C). No other changes in glomerular histology were observed 
(data not shown). These data indicate that transfecting APOC1-tg mice 
with sFlt-1 does not accelerate the development of glomerulosclerosis.
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Figure 2: Overexpressing sFlt-1 in APOC1-tg mice for 15 weeks does not cause 
albuminuria or glomerulosclerosis. At 8 weeks of age, wild-type (WT) and APOC1-
tg mice were transfected with sFlt-1; 15 weeks later, the albumin:creatinine ratio (A), 
glomerular surface area (B), and number of podocytes per glomerulus (C) were mea-
sured. In this and subsequent figures, summary data are presented as the mean ± 
the standard deviation. *p<0.05 and ***p<0.001 versus the respective wild-type group, 
one-way ANOVA. 
Endothelial cell activation
Glomerular VCAM-1 protein levels were similar between APOC1-tg mice 
and wild-type mice (Figure 3A). In contrast, glomerular ICAM-1 protein 
levels were significantly higher in the APOC1-tg mice compared to 
wild-type mice (Figure 3B); however, transfection with sFlt-1 had no 
effect on either glomerular VCAM-1 or glomerular ICAM-1 protein 
levels compared to the respective non-transfected groups. Lastly, 
glomerular Vegf-a mRNA levels were similar between all four groups 
(Figure 3C).
sFlt-1‒transfected APOC1-tg mice have fewer glomerular macro-
phages compared to non-transfected APOC1-tg mice
Consistent with our previous findings5, we found that APOC1-tg mice 
have significantly more glomerular macrophages compared to wild-
type mice (Figure 4). Interestingly, however, we found that APOC1-tg 
mice transfected with sFlt-1 have significantly fewer glomerular macro-
phages compared to non-transfected APOC1-tg mice; 15 weeks after 
transfection, the number of glomerular macrophages was reduced to 
wild-type levels (Figure 4).
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Figure 3: APOC1-tg mice have increased glomerular endothelial cell activation. 
APOC1-tg and wild-type mice were treated as in Figure 2, and glomerular VCAM-1 
(A), ICAM-1 (B), and Vegf-a mRNA (C) were measured 15 weeks after transfection. 
***p<0.001 versus wild-type mice and †††p<0.001 versus sFlt-1‒transfected wild-type 
mice, one-way ANOVA.
Figure 4: Expressing sFlt-1 in APOC1-tg mice reduces the glomerular infiltration 
of macrophages to wild-type levels. APOC1-tg and wild-type mice were treated as 
in Figure 2, and the number of glomerular macrophages was counted 15 weeks after 
transfection. ***p<0.001 versus non-transfected wild-type mice and ††p<0.01 versus 
both sFlt-1-transfected wild-type mice and sFlt-1-transfected APOC1-tg mice, one-way 
ANOVA.
Atopic dermatitis is resolved in APOC1-tg mice following trans-
fection with sFlt-1
Consistent with a previous report13, APOC1-tg mice developed atopic 
dermatitis, with increased thickness of the epidermal layer compared 
to wild-type mice (Figure 5). Interestingly, these lesions were not pre- 
sent in the APOC1-tg mice that were transfected with sFlt-1 (Figure 
5C, F). The quantification of the thickness of the epidermal layer is 
provided in Figure 5G. In addition, we found that inflammatory cells 
were present in the skin of APOC1-tg mice (Figure 5H), including 
macrophages (Figure 5I) and few T cells (Figure 5J). In contrast, 
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inflammatory cells were not present in the skin of sFlt-1‒transfected 
APOC1-tg mice (Figure 5F).
Figure 5: Transfecting APOC1-tg mice with sFlt-1 prevents atopic dermatitis. 
Representative images of the skin of a wild-type mouse (A, D), an APOC1-tg mouse (B, 
E, H-J), and an sFlt-1‒transfected APOC1-tg mouse (C, F). (G) Summary of epidermal 
thickness measured in the indicated groups. The sections shown in D-F and H were 
stained with H&E. Example images of F4/80 (I) and CD3 (J) immunohistochemical stain-
ing in skin sections from an APOC1-tg mouse. The scale bars represent 100 µm (D-F) 
and 50 µm (H-J). **p<0.01 versus all three other groups, one-way ANOVA.
Discussion
APOC1-tg mice develop nodular glomerulosclerosis by the age of 15 
months5, making them poorly suited for use in therapeutic or pre-
ventive intervention studies. Therefore, we attempted to accelerate 
the development of glomerulosclerosis by transfecting these mice 
with sFlt-1 at 8 weeks of age; we then looked for signs of glome- 
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rulosclerosis 15 weeks after transfection. To our surprise, APOC1-tg 
mice transfected with sFlt-1 did not develop glomerulosclerosis within 
the investigated time frame; instead, these mice had fewer glomerular 
macrophages compared to non-transfected APOC1-tg mice, and they 
showed no signs of atopic dermatitis. 
VEGF-A plays a key role in the health and function of endothelial 
cells, controlling their migration, proliferation, and survival8. Decreased 
levels of glomerular VEGF-A result in damage to the glomerular en-
dothelium; specifically, homozygous glomerular VEGF-A knockout mice 
are not viable, present with a wide range of glomerular endothelial 
defects, and fail to develop a glomerular filtration barrier9. Moreover, 
diabetic mice that are heterozygous for VEGF-A selectively in podo-
cytes have increased proteinuria, mesangial matrix expansion, and 
increased glomerular cell death compared to wild-type diabetic mice14. 
Furthermore, deleting VEGF-A in the kidneys in an inducible VEGF-A 
knockout mouse induces vascular damage by promoting thrombotic 
microangiopathy15. Similarly, increasing the serum levels of sFLT-1, 
a decoy receptor for VEGF-A, causes hypertension, glomerular en-
dotheliosis, and proteinuria in rats10. In patients with kidney cancer, 
breast cancer, or colorectal cancer, treatment with an anti-VEGF-A 
antibody in order to inhibit tumour angiogenesis leads to proteinuria 
in a dose-dependent manner16. Finally, treating wild-type mice with 
either anti-VEGF-A antibodies or sFLT-1 causes a loss of glomerular 
endothelial cells, glomerular hypertrophy, and proteinuria17. Taken 
together, these findings indicate that decreasing glomerular VEGF-A 
levels with sFLT-1 results in glomerular endothelial damage and sub-
sequent glomerular disease. Therefore, we hypothesised that trans-
fecting mice with sFlt-1 would lead to a systemic increase in sFLT-1, 
thereby affecting the health and function of glomerular endothelial 
cells, consequently accelerating the progression of glomerulosclerosis 
in APOC1-tg mice. However, we found that transfecting 8-week-old 
APOC1-tg mice with sFlt-1 did not lead to the development of glome- 
rulosclerosis, even after 15 weeks. Furthermore, similar to a previous 
report13, APOC1-tg mice develop atopic dermatitis, a skin disease 
characterised by scaling, lichenification, excoriations, and pruritus, 
with thickening of the epidermis and influx of inflammatory cells. The 
majority of these inflammatory cells were macrophages, although a 
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few T cells were also present (Figure 5I-J). Interestingly, however, 
atopic dermatitis was resolved in sFlt-1-transfected APOC1-tg mice, 
resulting in normal epidermal thickness and a lack of inflammatory 
cells in the skin (Figure 5). We previously reported that type 1 diabetic 
mice transfected with sFlt-1 have fewer glomerular macrophages, nor-
mal glomerular morphology, and improved renal function compared 
to non-transfected type 1 diabetic mice12.
One possible explanation for the lack of accelerated glomerulo-
sclerosis in sFlt-1‒transfected APOC1-tg mice may be that the syste- 
mic levels of sFLT-1 were insufficient to induce glomerular endothelial 
damage within the investigated time frame; in other words, glomerular 
VEGF-A levels may have remained within physiological levels, thereby 
maintaining the health and function of glomerular endothelial cells. 
On the other hand, the higher levels of sFLT-1 may have affected 
other VEGF-A targets aside from its effect on endothelial cells, for 
example by affecting VEGF-A‒induced migration of monocytes and/or 
macrophages18,19, which is mediated by the binding of VEGF-A to the 
FLT-1 receptor on these cells19. This possible reduction in cell migra-
tion may be the result of VEGF-A sequestering by sFLT-1. In addition, 
VEGF-A can induce the activation of endothelial cells12,20; however, the 
observed increase in glomerular endothelial cell activation (measured 
as an increase in glomerular ICAM-1 levels) in APOC1-tg mice was not 
reduced by transfecting APOC1-tg mice with sFlt-1. Finally, glomerular 
Vegf-a mRNA levels were similar between APOC1-tg mice and wild-
type mice. Taken together, these results suggest that VEGF-A does 
not appear to play a role in the increase in glomerular macrophages 
in APOC1-tg mice. 
Interestingly, Jin et al. recently reported that sFLT-1 has other 
functions in addition to sequestering VEGF-A21. Specifically, sFLT-1 
plays an essential role in podocyte cell morphology and glomerular 
barrier function ‒ independent of VEGF-A ‒ by binding directly to the 
glycosphingolipid monosialodihexosylganglioside (GM3) in lipid rafts 
on the surface of podocytes. Monocytes also express GM3, and this 
expression is increased upon differentiation of monocytes into macro-
phages and during inflammatory responses22,23. Therefore, sFLT-1 may 
bind to monocytes/macrophages in a similar fashion as sFLT-1 binds 
to podocytes (i.e. via GM3), subsequently altering cellular function. 
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This notion is supported by the finding that sFLT-1 downregulates the 
FLT-1 receptor in leukocytes by decreasing the activity of the FLT-
1 promoter, thereby preventing subsequent migration of these cells 
upon stimulation with VEGF-A24; thus, the reduction in monocyte/
macrophage migration with sFLT-1 may be independent of VEGF-A 
sequestering. Preliminary in vitro data by our group suggest that sFLT-
1 does indeed affect monocyte/macrophage function. For example, 
monocytes that differentiate into macrophages in the presence of 
sFLT-1 develop a different morphology than monocytes that differen- 
tiate in the absence of sFLT-1; specifically, the former are more cir-
cular in shape and have fewer ‒ or no ‒ filopodia. In addition, the cy-
tokine expression pattern in macrophages that are activated with lipo-
polysaccharide (LPS) differs depending on whether the macrophages 
were differentiated in the presence or absence of sFLT-1; specifically, 
LPS-activated macrophages that were differentiated in the presence 
of sFLT-1 have reduced expression of several inflammation-related 
proteins, including interleukin-6 and TNF-alpha (our unpublished data). 
Taken together, these data suggest that transfecting APOC1-tg mice 
with sFlt-1 reduces the migration of monocytes by downregulating 
FLT-1 promoter activity in these cells, potentially affecting the cells’ 
differentiation into macrophages, thereby reducing both atopic derma-
titis and the number of glomerular macrophages. 
Similar results have been reported by groups that investigated the 
use of sFLT-1 to treat a variety of other conditions, including vascu-
lar disease25,26, arthritis27,28, sepsis29, and psoriasis30; specifically, these 
studies showed that sFLT-1 was beneficial in terms of reducing both 
systemic and local inflammation, as well as reducing the number of 
macrophages at the site of pathology. 
In summary, we report that transfecting APOC1-tg mice with sFlt-1 
to increase systemic sFLT-1 levels does not accelerate the devel-
opment of glomerulosclerosis in the investigated time frame; rather, 
this treatment significantly reduces the number of glomerular macro-
phages and completely resolves the atopic dermatitis that normally 
develops in APOC1-tg mice. Future studies are needed in order to 
determine whether these effects of sFLT-1 treatment are dependent 
upon VEGF-A or whether sFLT-1 has other immunosuppressing pro- 
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SUMMARY
Diabetic nephropathy is one of the major causes of end-stage renal 
disease and is typically characterised by vascular damage. Although 
traditional therapies such as glycaemic control have been found to 
be beneficial, at least to some degree1, the percentage of patients 
with diabetes who progress to end-stage renal disease has remained 
unchanged over the past two decades. Therefore, there is an urgent 
need for new preventive and therapeutic options for diabetic patients, 
particularly patients with diabetic nephropathy. Developing new treat-
ment strategies requires a better understanding of the mechanisms 
that lead to the development of diabetic nephropathy. In the work 
described in this thesis, we investigated various mechanisms by which 
the immune system plays a role in the development of diabetic ne-
phropathy.
A meta-analysis performed by our group revealed that a polymor-
phism in the apolipoprotein C1 gene (APOC1), which encodes apolipo-
protein C-I (apoCI), is associated with an increased risk of developing 
diabetic nephropathy2. Recently, Bouillet et al. reported that diabetic 
patients have higher plasma levels of apoCI compared to non-diabe- 
tic subjects3. In addition, apoCI increases the inflammatory response 
in activated macrophages in vitro4, and this increased response can 
exacerbate the development of diabetic nephropathy5. In the work 
described in Chapter 2 of this thesis, we investigated whether over-
expressing APOC1 leads to the development of kidney damage using 
transgenic mice that overexpress the human APOC1 gene (APOC1-tg 
mice); wild-type littermates served as the control group; in addition, 
we investigated the role of macrophages in this process. To comple-
ment these findings, we also examined the presence of glomerular 
apoCI deposits in renal autopsy material obtained from diabetic 
patients with and without diabetic nephropathy, as well as material 
from non-diabetic controls. We found that APOC1-tg mice ‒ but not 
wild-type mice ‒ develop albuminuria, kidney dysfunction, and nodu-
lar glomerulosclerosis; APOC1-tg mice also have increased numbers 
of glomerular inflammatory M1 macrophages. Compared to wild-type 
macrophages, APOC1-tg macrophages also have an increased in-
flammatory response upon activation in vitro. Furthermore, we found 
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that patients with diabetic nephropathy have a higher prevalence of 
glomerular apoCI deposits compared to both diabetic patients without 
nephropathy and non-diabetic controls. These apoCI deposits were 
co-localised with glomerular macrophages. Taken together, these re-
sults suggest that apoCI may exacerbate the development of diabetic 
nephropathy by increasing the inflammatory response in activated 
glomerular macrophages. Therefore, apoCI may represent a promising 
new therapeutic target for patients who are at risk for developing 
diabetic nephropathy. 
Vascular endothelial growth factor A (VEGF-A) plays a role in the 
migration of both monocytes and macrophages and facilitates the 
extravasation of leukocytes by activating endothelial cells6. In animal 
models, glomerular VEGF-A levels are higher in animals with diabetes 
compared to non-diabetic controls7, and glomerular VEGF-A levels are 
correlated with increased severity of diabetic nephropathy8. In the 
work described in Chapter 3 of this thesis, we investigated whether 
treatment with soluble fms-like tyrosine kinase-1 (sFLT-1), an inhibitor 
of VEGF-A, can reduce diabetes-induced renal pathology in type 1 
diabetic mice. The severity of diabetic nephropathy was measured in 
diabetic mice that were transfected with the sFlt-1 gene 15 weeks 
after the induction of diabetes; these findings were compared to an 
age-matched, non-transfected group of diabetic mice. We found that 
overexpressing sFlt-1 in diabetic mice significantly improves kidney 
function, resolves diabetes-related kidney damage, and reduces endo-
thelial cell activation and inflammation; specifically, treatment reduced 
the number of glomerular macrophages and reduced the glomerular 
levels of tumour necrosis factor alpha (TNF-alpha) protein. In vitro, 
sFLT-1 decreases VEGF-A‒induced endothelial cell activation. Taken 
together, these data suggest that inhibiting VEGF-A with sFLT-1 can 
reduce the severity of diabetic nephropathy, thereby reducing glome- 
rular inflammation and supporting cellular repair mechanisms. 
Activation of endothelial cells is a key factor in inflammation. Up-
regulation of surface activation markers on endothelial cells leads to 
an increase in leukocyte extravasation9. Both VEGF-A and endoglin 
are critical mediators of endothelial cell function and health, and 
both are associated with endothelial cell activation10,11. Although re-
search has suggested that VEGF-A and endoglin interact12, the precise 
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mechanism by which these two proteins interact is currently unclear. 
In the work described in Chapter 4 of this thesis, we investigated: i) 
whether glomerular endoglin expression is associated with diabetic ne-
phropathy; ii) whether reducing endothelial endoglin expression affects 
endothelial cell activation and/or monocyte adhesion, and ‒ if so ‒ 
by which mechanism; and iii) whether glomerular endoglin expression 
is correlated with endothelial cell activation in patients with diabetic 
nephropathy. Compared to non-diabetic control mice, we found that 
diabetic mice have increased glomerular levels of endoglin protein, 
localised primarily in glomerular capillary walls. In vitro, compared to 
endothelial cells expressing normal levels of endoglin, endothelial cells 
that express approximately 30% lower levels of endoglin have reduced 
activation upon stimulation with VEGF-A, as well as reduced monocyte 
adhesion. Reducing endoglin expression also increases the activation 
of the Akt serine/threonine kinase (Akt) upon VEGF-A stimulation, 
thereby reducing ATF-2 (activating transcription factor 2)‒mediated ex-
pression of endothelial cell activation markers. Furthermore, we found 
that the expression of glomerular vascular cell adhesion molecule-1 
(VCAM-1) is significantly higher in patients with diabetic nephropa-
thy compared to non-diabetic controls. Interestingly, the glomerular 
level of endoglin protein was correlated with the glomerular level of 
VCAM-1 protein in these patients. These data suggest that targeting 
endoglin ‒ thereby reducing endothelial cell activation and subsequent 
inflammation ‒ may have therapeutic value in patients who are at risk 
for developing diabetic nephropathy.
In patients with diabetes, activation of the complement system 
plays a role in the development of complications in a variety of 
organs13. However, the role of the complement system in diabetic 
nephropathy is poorly understood. In the work described in Chapter 
5 of this thesis, we studied the prevalence of specific complement 
components in renal vascular compartments in a large autopsy co-
hort consisting of diabetic patients both with and without diabetic 
nephropathy. We found that complement activation is associated with 
several factors, including more severe classes of diabetic nephropa-
thy, reduced kidney function, and the presence of histological lesions; 
these results were supported by examining a small cohort of renal 
biopsies obtained from patients with diabetic nephropathy. Specifically, 
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we found a high prevalence of glomerular IgM and complement factor 
C1q deposits, as well as an absence of glomerular mannose-binding 
lectin (MBL) deposits. These findings suggest that the classical path-
way of the complement system plays a role in the development of 
diabetic nephropathy.
APOC1-tg mice, which express human APOC1, develop nodular glo-
merulosclerosis by 15 months of age. This relatively slow disease pro-
gression makes this model less suitable for studying therapeutic and 
preventive interventions. To overcome this limitation, as described in 
Chapter 6 of this thesis, we attempted to accelerate the progression 
of glomerulosclerosis in APOC1-tg mice by transfecting these mice 
with sFlt-1 at 8 weeks of age; we then asked whether systemically 
increasing sFLT-1 expression for 15 weeks accelerates the develop-
ment of glomerulosclerosis. We found that transfecting APOC1-tg mice 
with sFlt-1 does not accelerate the development of glomerulosclerosis 
within the time period studied. In contrast, we found that sFlt-1‒trans-
fected APOC1-tg mice have fewer glomerular macrophages compared 
to non-transfected APOC1-tg mice. These data suggest that sFLT-1 
treatment has an anti-inflammatory effect.  
GENERAL DISCUSSION
Diabetes mellitus develops when pancreatic β-cells are functionally 
impaired or lost, which leads to reduced or absent levels of insulin 
production, or when cells become less sensitive to insulin. Conse-
quently, changes in insulin secretion, changes in insulin sensitivity, 
or both, lead to perturbations in glucose homeostasis, which ‒ via 
various processes ‒ leads to the development of clinical complica-
tions, including nephropathy. 
Clinically, hyperglycaemia can be controlled using a variety of 
therapies, including: i) the administration of exogenous insulin; ii) the 
use of drugs to either increase insulin secretion or decrease the re-
lease of glucose from the liver; iii) the use of drugs to increase the 
utilisation of glucose by skeletal muscle and fat; and iv) delaying the 
absorption of dietary glucose14. Studies have found that early, inten-
sive glucose control therapy in patients diagnosed with type 1 or type 
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2 diabetes can reduce the development of microvascular complica-
tions, lower the risk of impaired glomerular filtration rate, and slow the 
progression towards end-stage renal disease15-17. However, a recent 
meta-analysis by Ruospo et al. revealed that both type 1 and type 2 
diabetic patients who follow an intensive glucose control regimen have 
the same risk of kidney failure, death, and cardiovascular events as 
patients who follow a less stringent blood glucose control regimen18; 
this finding may be attributed to the negative side effects associated 
with intensive glucose control (e.g. hypoglycaemia). Moreover, only 
marginal benefits were obtained with respect to the onset and pro-
gression of microalbuminuria and myocardial infarction. In addition, 
although the progression of diabetic nephropathy can be delayed by 
standard treatment regimens such as glucose control therapy, the 
percentage of patients who develop end-stage renal disease has not 
decreased over the past two decades1. Taken together, these findings 
suggest that other factors ‒ acting either alone or in combination 
with hyperglycaemia ‒ play an important role in the development of 
diabetic nephropathy. Therefore, new preventive and therapeutic stra- 
tegies are urgently needed. To reach this goal, a better understan- 
ding of the mechanisms underlying the development and reversal of 
diabetic nephropathy is needed.
One mechanism by which hyperglycaemia may lead to diabetic 
nephropathy is by increasing inflammation at both the local and sys-
temic levels. In the work described in this thesis, we investigated a 
variety of mechanisms by which the immune system may play a role 
in the development of diabetic nephropathy. 
Apolipoprotein C1
ApoCI regulates lipid metabolism by slowing the catabolism of tri-
glyceride-rich lipoproteins, primarily by inhibiting the enzyme lipo-
protein lipase (LPL), thereby increasing plasma triglyceride levels19. 
ApoCI also plays a role in inflammation by increasing the binding of 
lipopolysaccharide (LPS) to macrophages via CD14/MD2/TLR4 (cluster 
of differentiation 14/myeloid differentiation protein-2/toll-like receptor 
4), thereby increasing the expression of TNF-alpha by these cells4,20. 
This is relevant in the setting of diabetes, as diabetic patients have 
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increased plasma levels of LPS due to altered gut microbiota; speci- 
fically, these patients have increased numbers of Gram-negative bac-
teria and increased gut permeability, a condition known as metabolic 
endotoxaemia21. Furthermore, these patients can also have increased 
numbers of renal glomerular and interstitial macrophages22. The pro-
duction of TNF-alpha by glomerular macrophages has been proposed 
to serve as the key mediator of diabetic nephropathy5.
The finding that a polymorphism in the APOC1 gene is associated 
with an increased risk of developing diabetic nephropathy, as well as 
the finding that plasma apoCI levels are elevated in patients with type 
1 or type 2 diabetes compared to non-diabetic controls, supports 
the notion that apoCI plays a role in the development of diabetic 
nephropathy. Taken together, these data suggest that apoCI facilitates 
the development of diabetic nephropathy by promoting hyperlipidae-
mia, by increasing the inflammatory response in activated glomerular 
macrophages, or both.
As discussed in Chapter 2 of this thesis, APOC1 overexpression 
is causally associated with the development of glomerulosclerosis. 
APOC1-tg mice (which overexpress the human APOC1 gene) develop 
nodular glomerulosclerosis, which is reminiscent of patients with class 
III diabetic nephropathy. Our data suggest that hyperlipidaemia may 
not be the driving force behind the development of glomerulosclerosis 
in these mice, as we found no difference between APOC1-tg mice 
and wild-type mice with respect to renal cortex triglycerides, total 
cholesterol, or phospholipid levels. In contrast, we found higher num-
bers of glomerular macrophages in APOC1-tg mice compared to wild-
type mice, and peritoneal macrophages isolated from APOC1-tg mice 
develop an increased inflammatory response upon LPS stimulation 
in vitro compared to wild-type macrophages. This finding may have 
clinical relevance, as we also found that the prevalence of glomerular 
apoCI deposits is higher among patients with diabetic nephropathy 
compared to both diabetic patients without nephropathy and non-dia-
betic control subjects. Moreover, in patients with diabetic nephropathy 
these apoCI deposits co-localise with glomerular macrophages. Taken 
together, this suggests that glomerular macrophages in patients with 
diabetic nephropathy may also have an increased inflammatory re-
sponse; this response is likely augmented by apoCI, and ‒ consistent 
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with our findings with APOC1-tg mice ‒ may facilitate the development 
of diabetic nephropathy. Therefore, reducing the expression of APOC1 
may be a viable therapeutic approach for delaying or even preventing 
the development of diabetic nephropathy by reducing the production 
of inflammatory cytokines in glomerular macrophages.
The use of statins has been shown to benefit diabetic patients by 
lowering low-density lipoprotein (LDL) cholesterol levels23. Interestingly, 
a genome-wide association study found that changes in LDL choleste- 
rol levels following statin therapy are associated with a polymorphism 
in the APOC1 gene24. Statins may be clinically beneficial to diabetic 
patients by reducing APOC1 expression, particularly in macrophages 
(Figure 1). This notion has been confirmed in in vitro experiments in 
which treating macrophages with statins reduces the expression and 
secretion of apoCI by these cells25. Thus, the statin-induced decrease 
in plasma lipids (due to the effect of apoCI on lipid metabolism, as 
discussed above) may be an indirect ‒ albeit positive ‒ side effect, 
and statins may provide clinical benefits by reducing both local and 
systemic inflammation. 
With the exception of an increased risk of developing new-onset 
diabetes mellitus, no side effects have been reported in statin-trea- 
ted patients with chronic kidney disease26 or cardiovascular disease27. 
This suggests that statins are relatively safe for use in patients. 
Therefore, statins should be considered for all patients with diabetes, 
as this treatment may prevent or delay the development of diabetic 
nephropathy in these patients by reducing apoCI-mediated inflamma-
tion; this approach may be most beneficial to diabetic patients who 
have the specific polymorphism in the APOC1 gene associated with 
an increased risk of developing diabetic nephropathy.
Despite these promising findings, further study is needed in order 
to determine the precise role of apoCI in the pathogenesis of dia-
betic nephropathy, the precise mechanism(s) by which overexpressing 
APOC1 facilitates the development of glomerulosclerosis, and the 
potential clinical value of therapeutic and preventive interventions for 
diabetic patients with and without diabetic nephropathy. The induction 
of diabetes in this model is a first step towards investigating the 
putative role of apoCI in the development of diabetic nephropathy. 
However, this model is not ideally suited for addressing these ques-
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tions, as it takes up to 15 months for APOC1-tg mice to develop 
nodular glomerulosclerosis. Furthermore, using a modified model in 
which APOC1-tg mice develop glomerulosclerosis more rapidly, ma- 
crophage-depletion techniques and/or bone marrow transplantation 
between APOC1-tg and wild-type mice may provide important insight 
with respect to the relative contribution of apoCI in lipid metabolism 
and/or inflammation as the driving force in the development of glo-
merulosclerosis in this model.
Figure 1: Hypothetical scheme by which statins may confer clinically beneficial 
effects. Statins reduce expression of the APOC1 gene, reducing apoCI in lipoproteins, 
thereby reducing the inhibitory effect of apoCI on lipid uptake and lowering serum 
lipoprotein levels. Reduced APOC1 expression also reduces the release of apoCI by 
monocytes/macrophages. Reduced circulating apoCI levels ‒ by reduced apoCI on lipo-
proteins, by reduced secretion of apoCI by monocytes/macrophages, or both ‒ leads 
to diminished activation of monocytes/macrophages, thereby reducing both local and 
systemic inflammation. 
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Vascular endothelial growth factor A
VEGF-A is a critical factor in the maintenance and survival of endo-
thelial cells and is also involved in the migration of monocytes and 
macrophages6. Glomerular VEGF-A levels are tightly regulated in order 
to ensure that they remain at physiological levels; if these levels are 
either too high or too low, kidney disease can occur, primarily due 
to changes in the renal endothelium28.
Glomerular VEGF-A levels are higher in animal models of dia-
betic nephropathy compared to healthy control animals. Moreover, 
increased glomerular VEGF-A levels are associated with more severe 
kidney damage in a mouse model of type 1 diabetes8. Treating 
animal models of diabetes with anti-VEGF-A prevents the development 
of albuminuria and glomerular hypertrophy29-31; however, the results 
are inconsistent32, possibly due to differences in the type and/or 
dose of anti-VEGF-A therapy used. Nevertheless, whether anti-VEGF-A 
treatment can reverse existing diabetes-related kidney damage in di-
abetic animals has not been studied, and whether this treatment can 
reduce the number of glomerular macrophages remains unknown. In 
the work described in Chapter 3 of this thesis, we show that treating 
diabetic mice with the VEGF-A inhibitor sFLT-1 restores kidney func-
tion and morphology, likely by reducing the glomerular infiltration of 
macrophages. 
In cancer patients, treatment with anti-VEGF-A antibodies (e.g. be- 
vacizumab) has been shown to be effective as an anti-cancer 
therapy33; however, these antibodies can increase the risk of pro-
teinuria and hypertension in these patients. Therefore, use of these 
antibodies would not be suitable for patients with diabetic nephro- 
pathy, as it may actually worsen their diabetic nephropathy, rather 
than providing a treatment. In contrast, treating diabetic mice with 
sFLT-1 restored albuminuria to normal levels, suggesting superior 
performance compared to anti-VEGF-A antibodies. It is important to 
note, however, that the patient’s levels of sFLT-1 should be monitored 
closely, as a long-term increase in systemic sFLT-1 levels can lead to 
proteinuria, kidney lesions, or both, primarily by affecting the function 
of endothelial cells34.
In the work described in Chapter 6, we tested the hypothesis that 
transfecting 8-week-old APOC1-tg mice with sFlt-1 can accelerate the 
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development of glomerulosclerosis, thereby providing a potentially 
more suitable model for studying therapeutic and preventive inter-
ventions; thus, we effectively induced a long-term systemic increase 
in sFLT-1 levels in these mice. However, rather than accelerating the 
development of glomerulosclerosis in APOC1-tg mice, overexpressing 
sFLT-1 for 15 weeks had no effect on kidney morphology or function 
compared to age-matched, non-transfected APOC1-tg mice; specifi-
cally, transfected mice did not develop glomerulosclerosis within the 
investigated time frame. In contrast, APOC1-tg mice that were trans-
fected with sFlt-1 had significantly fewer glomerular macrophages 
compared to age-matched, non-transfected APOC1-tg mice. Further-
more, atopic dermatitis – a skin disease characterised by scaling, 
lichenification, excoriation, and pruritus ‒ develops in APOC1-tg mice 
by six weeks of age due to an infiltration of inflammatory cells, in-
cluding macrophages35, and this was completely resolved in APOC1-tg 
mice following sFlt-1 transfection. 
The aforementioned findings, which are described in Chapters 3 
and 6 of this thesis, suggest that treatment with sFLT-1 can reduce 
inflammation in the kidney by antagonising VEGF-A‒induced activation 
of glomerular endothelial cells and migration of monocytes and ma- 
crophages. However, APOC1-tg mice that overexpress sFLT-1 still have 
increased activation of glomerular endothelial cells, and renal Vegf-a 
expression in these mice was similar to age-matched wild-type mice. 
This finding suggests that the reduced kidney inflammation following 
sFLT-1 treatment may be independent of inhibited VEGF-A. It is there-
fore interesting to speculate that sFLT-1 has functions other than se-
questering VEGF-A, suggesting that an sFLT-1‒based therapy may be 
more effective than therapies based on anti-VEGF-A antibodies, which 
only inhibit VEGF-A signalling. 
The first evidence in support of this hypothesis was published re-
cently by Jin et al.36, who reported that sFLT-1 binds directly – and 
independently of VEGF-A ‒ to lipid rafts in podocytes via glycosphin-
golipid monosialodihexosylganglioside, thereby modulating the mor-
phology and function of these cells. sFLT-1 can bind to other cell 
types as well, including endothelial cells, thus supporting the notion 
that sFLT-1 has a direct effect on these cells. Interestingly, monocytes 
also express glycosphingolipid monosialodihexosylganglioside, and its 
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expression in monocytes is increased upon differentiation to macro-
phages37 and upon exposure to inflammatory stimuli38, suggesting that 
sFLT-1 may be able to bind to these cells via a similar process as 
it binds to podocytes (i.e. via glycosphingolipid monosialodihexosyl-
ganglioside). Furthermore, preincubating leukocytes with sFLT-1 pre-
vents their subsequent VEGF-A‒stimulated migration by downregulating 
the FLT-1 promoter39, thereby preventing leukocyte migration via a 
mechanism independent of sequestering VEGF-A. sFLT-1 has been 
used to treat various immune-mediated diseases, including vascular 
disease40,41, arthritis42,43, sepsis44, and psoriasis45, by reducing both 
local and systemic inflammation, by reducing the number of tissue 
macrophages, or both. Therefore, we hypothesise that sFLT-1 – in ad-
dition to functioning as a ‘decoy’ receptor for VEGF-A – modulates the 
inflammatory response in monocytes and macrophages. Preliminary 
data from our group support this hypothesis. For example, we found 
that differentiating monocytes into macrophages in the presence of 
sFLT-1 alters the morphology of the resulting macrophages compared 
to the morphology of monocytes differentiated in the absence of 
sFLT-1. In addition, when stimulated with LPS, macrophages that were 
differentiated in the presence of sFLT-1 have a different inflamma-
tory response compared to macrophages that were differentiated in 
the absence of sFLT-1. Specifically, they have reduced expression of 
TNF-alpha and IL-6. These data support our hypothesis that sFLT-1 
can modulate the immune response by regulating monocyte differen-
tiation and macrophage-mediated inflammation. 
Vascular endothelial growth factor A, endoglin, and endothelial 
cell activation 
Activation of glomerular endothelial cells is a key step in the devel- 
opment of kidney inflammation9. Therefore, maintaining the health 
and function of glomerular endothelial cells is an important compo-
nent in preventing kidney disease. VEGF-A is an important mediator 
of a variety of processes in endothelial cells, including their activa-
tion, proliferation, and migration, as well as angiogenesis6. Endoglin 
has been proposed to play a role in signalling via VEGF receptor 2 
(VEGFR2), thereby modulating the response of endothelial cells upon sti- 
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mulation with VEGF-A. This notion is supported by the finding that endo- 
glin and VEGFR2 are co-localised in endosomes, and by the finding 
that endoglin prevents arteriovenous malformation by changing blood 
flow‒induced cell migration12. Finally, VEGF-A‒induced angiogenesis is 
impaired in endoglin-deficient endothelial cells11. 
In the work described in Chapter 4 of this thesis, we show that 
endoglin plays a role in the activation of endothelial cells and con-
sequently affects adhesion between endothelial cells and leukocytes. 
Under physiological conditions, VEGF-A activates endothelial cells 
by inducing phosphorylation of VEGFR2 and the downstream kinase 
ERK1/2 (extracellular signal-regulated kinases 1 and 2), which phos-
phorylates ATF-2 in the nucleus, activating this transcription factor. 
Activated ATF-2 then drives the expression of endothelial cell acti-
vation markers46. Our data show that endothelial cells with reduced 
endoglin expression have increased levels of phosphorylated Akt and 
decreased levels of activated ATF-2 upon stimulation with VEGF-A 
(Figure 2), resulting in impaired activation of these cells compared to 
endothelial cells that express normal levels of endoglin. 
Upon binding VEGF-A, VEGFR2 associates with the proto-oncogene 
tyrosine-protein kinase Src (Figure 2A)47. In the presence of VEGF-A, 
Src also induces the internalisation and degradation of endoglin via 
lysosomes. The association between Src, VEGFR2, and endoglin is a 
critical step in angiogenesis as well as other VEGF-A‒induced endothe-
lial cell functions, including proliferation, migration, and capillary tube 
formation48. Furthermore, endoglin co-localises with VEGFR2 in specific 
endosomes12, promoting the activation of ERK1/2 and the subsequent 
activation of endothelial cells49. Taken together, these findings sug-
gest that endoglin is associated with VEGFR2 at the cell surface upon 
stimulation with VEGF-A (possibly via Src) and that endoglin is critical 
for the internalisation and signalling activity of VEGFR2. 
On the other hand, reduced levels of endoglin protein may prevent 
the internalisation of VEGFR2 (Figure 2B). This notion is supported by 
the increased levels of activated Akt in endothelial cells with reduced 
endoglin expression. At the cell surface, Akt ‒ but not ERK1/2 ‒ can 
be activated via membrane-bound VEGFR249. In addition, recycling of 
internalised VEGFR2 to the plasma membrane increases when endoglin 
expression is reduced (i.e. VEGFR2 degradation is reduced)12, possibly 
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via reduced endoglin-mediated lysosomal degradation of VEGFR248. 
The resulting increased level of activated Akt inhibits the phospho- 
rylation of ATF-2, thereby reducing endothelial cell activation. This 
suggests that endoglin mediates the activation ‒ and other cellular 
functions ‒ of endothelial cells following VEGF-A stimulation by driving 
the internalisation and downstream signalling of VEGFR2. 
Interestingly, the anti-endoglin antibody TRC105 reduces endoglin 
levels at the cell surface via a Src-mediated process and increases 
the internalisation and degradation of endoglin (Figure 2C), thereby 
preventing VEGF-A‒induced angiogenesis48, possibly due to decreased 
internalisation of VEGFR2 and reduced signalling via ERK1/2. 
Although TRC105 is a promising treatment option for patients with a 
variety of cancer types50, a common adverse event is telangiectasias51, 
which causes capillary malfunction. Interestingly, telangiectasias can also 
develop in patients with a mutation in either activin receptor-like kinase 1 
(ALK1) or ALK5 – thus affecting endoglin-mediated signalling via TGF-beta 
(transforming growth factor beta) – as well as in heterozygous endo- 
glin-deficient mice52. This suggests that ‒ like VEGF-A ‒ the levels of 
endoglin must be maintained at physiological levels. Interestingly, 
Gordon et al. recently reported that some cancer patients whose 
cancer progressed when treated with bevacizumab (an anti-VEGF-A 
antibody) alone experienced a reduction in tumour volume when 
treated with both bevacizumab and TRC10553. Although patients re-
ceiving this combination therapy developed hypertension and pro-
teinuria, these and other side effects were less severe than when 
patients received monotherapy with either bevacizumab or TRC105 
alone, even though both drugs in the combination therapy were given 
at their respective recommended monotherapy doses. This finding 
suggests that the combination therapy provided superior regulation 
of the endoglin and VEGFR2 signalling pathways. Our own data show 
that treatment with sFLT-1 is clinically beneficial in terms of re-
solving kidney lesions and by restoring kidney function in diabetic 
mice. Furthermore, we found that endoglin is associated with glome- 
rular endothelial cell dysfunction in patients with diabetic nephropathy 
and plays a role in endothelial cell activation and monocyte adhesion 
in vitro. Therefore, a combination of anti-endoglin and anti-VEGF-A 
(i.e. sFLT-1) may have therapeutic benefits in patients with diabetic 
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nephropathy and warrants future study. 
Figure 2: Schematic representation of VEGF-A‒induced endothelial cell activation. 
A. VEGF-A binds to VEGFR2, which in turn becomes phosphorylated (P) and associates 
with both Src and endoglin. Phosphorylated VEGFR2 is then internalised via endosomes 
and subsequently activates ERK1/2. Phosphorylated ERK1/2 then translocates to the 
nucleus, where it activates the transcription factor ATF-2, thereby activating the endo-
thelial cell. B. In the absence of endoglin, activated VEGFR2 remains at the cell surface 
and activates Akt, which then inhibits the phosphorylation of ATF-2, thereby reducing 
endothelial cell activation. C. Binding of the anti-endoglin antibody TRC105 to endoglin 
results in the Src-mediated internalisation and degradation of endoglin, thereby pre-
venting VEGFR2 internalisation and the subsequent activation of the endothelial cell. 




The complement system is another important mediator of endothelial 
cell dysfunction and vascular disease. The complement system plays 
a role in both innate and adaptive immunity and consists of three 
pathways that are activated by specific stimuli. Several components 
in the complement system play a role in endothelial dysfunction 
and vascular disease in patients with diabetes54-56; these components 
include soluble C3a and C5a (protein fragments that result from 
the cleavage of C3 and C5, respectively), as well as C5b-9. Given 
that endothelial cells express receptors for C3a and C5a, as well as 
complement regulators on the cell surface57,58, these cells are likely 
a direct target of the complement system. Although the complement 
system itself can give rise to complement-mediated damage59, com-
plement activation can also lead to the recruitment of other immune 
cells such as macrophages via C3a and C5a. These macrophages may 
then promote the development of kidney damage via the production 
of macrophage-derived inflammatory cytokines, including TNF-alpha5.
Evidence suggests that the complement system plays a role in 
the development of diabetes and diabetes-related complications. For 
example, Hillian et al. reported that activation of the classical com-
plement system plays a role in the development of insulin resistance, 
as C1q-deficient mice are protected from hepatic insulin resistance 
and complement activation induced by consuming a high-fat diet60. 
In addition, intracellular signalling via CD59 (cluster of differentiation 
59) – also an inhibitor of C5b-9 formation – in pancreatic islet cells is 
required for the efficient release of insulin, as siRNA-mediated knock-
down of CD59 prevents this release59. CD59 expression in pancreatic 
islet cells is decreased in diabetic animals61 compared to non-diabetic 
controls, suggesting that this downregulation of CD59 in pancreatic 
islet cells in diabetes contributes to altered glucose metabolism by 
decreasing insulin production. 
In the work described in Chapter 5 of this thesis, we show that 
complement activation is correlated with the severity of diabetic 
nephropathy; specifically, the prevalence of complement activation 
is higher in patients with more severe diabetic nephropathy and is 
associated with decreased eGFR (estimated glomerular filtration rate). 
In addition, we show that the prevalence of complement deposits is 
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higher in patients with type 1 diabetes than in patients with type 2 
diabetes; this may be due to the longer average disease duration in 
patients with type 1 diabetes, as these patients are exposed to hy-
perglycaemia longer than type 2 diabetic patients, and this could lead 
‒ either directly or indirectly ‒ to activation of the complement system. 
Our data suggest that the classical complement pathway is activated 
in patients with diabetic nephropathy, as glomerular C1q deposits are 
highly prevalent among these patients; in contrast, glomerular de-
posits of MBL were observed only rarely in these patients. Additional 
evidence that the classical complement pathway is activated in these 
patients comes from the finding that the prevalence of glomerular IgM 
deposits is significantly higher in patients with diabetic nephropathy 
than in non-diabetic subjects, and these glomerular IgM deposits both 
co-localise and are correlated with glomerular C1q and C4d deposits.
These data suggest that complement activation via naturally oc-
curring antibodies (i.e. IgM) may be the result of renal vascular da- 
mage in patients with diabetic nephropathy. IgM antibodies play an 
important role in clearing damaged cells via intracellular antigens that 
become externalised during apoptosis, or under hypoxic conditions, 
or both. Binding of IgM antibodies to hypoxic or apoptotic cells may 
therefore serve to activate the complement system in patients with 
diabetic nephropathy62-66. This notion is supported by the finding that 
the presence of C4d and IgM is highly prevalent among patients with 
other renal microangiopathies67,68.  
Nevertheless, whether complement activation is the cause or the 
consequence of diabetic nephropathy remains unclear and should be 
addressed in a prospective cohort study. Regardless, complement ac-
tivation clearly contributes to the progression of diabetic nephropathy, 
as rats with type 2 diabetes treated with complement inhibitors have 
reduced albuminuria, fewer histological changes, and improved kidney 
function compared to untreated, type 2 diabetic rats69. The increasing 
body of evidence showing the activation and/or involvement of the 
complement system in diabetic nephropathy suggests that inhibiting 
the complement system may represent a viable therapy for preventing, 
slowing, or even reversing diabetic nephropathy. Given that comple-
ment inhibitors such as eculizumab are already approved and have 
been shown to be clinically beneficial in several diseases, and given 
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that many new inhibitors are now being tested in clinical trials13,70, 
clinical trials designed specifically to test the effect of inhibiting the 
complement system in patients with diabetic nephropathy may be 
performed in the near future.
FUTURE PERSPECTIVES
Diabetes mellitus has traditionally been considered a metabolic di- 
sease characterised by obesity, high blood glucose levels, high blood 
pressure, high serum triglyceride levels, and low levels of high-density 
lipoproteins. However, evidence that the immune system plays a role 
in this disease and in diabetes-related complications suggests that 
the picture is more complicated than previously believed. Although 
current therapies designed to treat patients with diabetic nephropathy 
‒ including glycaemic control, blood pressure control, and reducing 
serum lipids ‒ are clinically beneficial to some degree, they remain 
insufficient for reducing the risk of these patients progressing to end-
stage renal disease1, giving rise to the notion that other factors must 
also be involved in the pathogenesis of diabetic nephropathy. The 
results of the work described in this thesis suggest that the focus of 
treatment strategies for patients with diabetic nephropathy may need 
to shift towards interfering with the immune system in order to reduce 
kidney inflammation. 
Although the research described in this thesis provides several 
promising new targets (e.g. apoCI, the complement system, endoglin, 
and sFLT-1) for treating diabetic nephropathy with respect to inhi- 
biting the immune system and reducing kidney inflammation, seve- 
ral questions remain. Our results demonstrate that sFLT-1 treatment 
reduces kidney inflammation and restores kidney morphology and 
function. However, future research should investigate whether the 
beneficial properties of sFLT-1 are mediated by sequestering VEGF-A 
(i.e. an indirect effect on immune cells) or by binding to leukocytes 
(i.e. a direct effect on immune cells). If sFLT-1 has a direct immune- 
modulating effect (as we hypothesise), then sFLT-1 treatment may 
also be beneficial for patients with other diseases in which inflamma-
tion plays a key role. Importantly, the optimal dose of sFLT-1 should 
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be determined, as a long-term increase in systemic sFLT-1 levels can 
result in kidney damage. 
Interestingly, treating cancer patients with both anti-endoglin and 
anti-VEGF-A is more beneficial than either treatment alone, although 
the underlying mechanism is currently unclear. Although our results 
provide important mechanistic insights, future studies should be de-
signed in order to determine the precise mechanism by which VEGF-A, 
endoglin, and VEGFR2 interact. Nevertheless, the addition of anti- 
endoglin antibodies to sFLT-1 treatment may counteract the potential 
side effects of sFLT-1 monotherapy. In addition, prolonged immuno-
suppressive therapy can result in complications that may limit the 
effectiveness of sFLT-1 treatment, including endothelial dysfunction 
and infection. Furthermore, given that complement activation contri- 
butes to the development of diabetic nephropathy, prospective studies 
designed to investigate complement deposits in diabetic nephropathy 
may reveal whether complement activation is the cause or the conse-
quence of diabetic nephropathy. This would be an important finding, 
as it would offer insight into the treatment window during which com-
plement inhibitors should be given to diabetic patients (i.e. before or 
after these patients develop diabetic nephropathy). In the short term, 
we recommend that patients with diabetic nephropathy ‒ as well as 
patients who are at risk for developing diabetic nephropathy ‒ receive 
statins, as this treatment is relatively save and is beneficial in terms 
of preventing and/or treating cardiovascular disease in general. Fur-
thermore, statins may also be beneficial for treating diabetic patients 
by reducing apoCI-mediated kidney inflammation. 
Our central conclusion based on the work described in this thesis 
is that the immune system plays a clear role in the development 
and progression of diabetic nephropathy. Therefore, future studies re-
garding the treatment and prevention of diabetic nephropathy should 
focus on targeting the immune system and kidney inflammation. 
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Diabetes mellitus, ook wel suikerziekte genoemd, ontwikkelt zich wan-
neer specifieke cellen van de alvleesklier – de β-cellen – minder 
of geen insuline meer maken, of als bepaalde cellen ongevoelig 
worden voor insuline. Door een verlaagde insulineproductie, een ver-
laagde reactiviteit op insuline, of een combinatie hiervan, raakt de 
glucosehuishouding verstoord. Door deze verstoorde glucosehuishou- 
ding ontwikkelen patiënten met diabetes mellitus verschillende soorten 
complicaties, waaronder diabetische nierschade – ook wel diabetische 
nefropathie genoemd. In Nederland neemt het aantal patiënten met 
diabetes mellitus snel toe: van 2,8 procent van de bevolking in 2001 
naar 4,5 procent in 2013. Diabetes mellitus beïnvloedt de levens van 
ongeveer 750.000 Nederlanders. Ongeveer twintig tot veertig procent 
van de mensen met diabetes mellitus ontwikkelen diabetische nefro- 
pathie. 
Diabetische nefropathie wordt gekenmerkt door vasculaire schade 
en is de grootste oorzaak voor eindstadium nierfalen. Dit houdt in 
dat de nieren niet goed genoeg meer functioneren, waardoor patiën- 
ten dialyse-afhankelijk worden of zelfs een niertransplantatie moeten 
ondergaan. Vanzelfsprekend heeft dit een grote invloed op de levens- 
kwaliteit van deze mensen.
Traditionele behandelmethoden van diabetisch mellitus, zoals het 
verlagen van de bloedsuikerspiegel, helpen de ontwikkeling van be- 
paalde complicaties te voorkomen of te remmen. Desondanks is het 
percentage patiënten met diabetes mellitus dat eindstadium nier-
falen ontwikkelt de afgelopen decennia nauwelijks gedaald. Dit geeft 
aan dat er naast – of in combinatie met – een verstoorde glucose- 
huishouding ook andere factoren moeten zijn die bijdragen aan de 
ontwikkeling van diabetische nefropathie. 
Diabetes mellitus is historisch gezien altijd beschouwd als een 
metabolische ziekte. Steeds meer publicaties beschrijven echter de 
betrokkenheid van het immuunsysteem in deze ziekte en de ontwikke-
ling van bijbehorende complicaties. Het centrale doel van de studies 
beschreven in dit proefschrift was om de bijdrage van het immuun- 
systeem en vasculaire veranderingen te onderzoeken in de ontwikke-
ling van diabetische nefropathie. 
Genetische studies hebben aangetoond dat een afwijking in het 
apolipoproteïne C1 gen (APOC1) leidt tot een verhoogd risico voor 
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patiënten met diabetes mellitus om diabetische nefropathie te ontwik-
kelen. Recent is ook gevonden dat patiënten met diabetes melli-
tus verhoogde concentraties van apolipoproteïne C-I (apoCI) in het 
bloed hebben ten opzichte van gezonde mensen. ApoCI speelt een 
belangrijke rol in het lipiden metabolisme, maar is ook betrokken 
bij ontstekingsreacties. ApoCI versterkt namelijk de ontstekingsreactie 
van geactiveerde macrofagen. Het is eerder aangetoond dat de ont-
stekingsreactie van macrofagen bijdraagt aan de ontwikkeling van dia-
betische nefropathie. In hoofdstuk 2 van dit proefschrift laten we zien 
dat muizen die transgeen zijn voor het humane APOC1 gen (APOC1-tg 
muizen) albuminurie, een verminderde nierfunctie en glomeruloscle-
rose ontwikkelen. Daarnaast hebben deze APOC1-tg muizen een ver-
hoogd aantal macrofagen in glomeruli ten opzichte van het aantal in 
wildtype muizen. Met celkweekexperimenten hebben we gevonden dat 
activatie van macrofagen afkomstig uit APOC1-tg muizen leidt tot een 
sterkere ontstekingsrespons dan activatie van macrofagen afkomstig 
uit wildtype muizen. Ten slotte hebben we in deze studie laten zien 
dat er meer apoCI deposities aanwezig zijn in glomeruli van patiënten 
met diabetische nefropathie dan in diabetespatiënten zonder nier-
schade en in gezonde mensen. Samengevat suggereren deze data 
dat toename van apoCI de ontwikkeling van diabetische nefropathie 
bevordert. Dit komt mogelijk door het versterken van de ontstekings-
reactie van macrofagen aanwezig in glomeruli van deze patiënten.
Vasculair endotheel groei factor A (VEGF-A) is belangrijk voor ver-
schillende functies van endotheelcellen, de cellaag aan de binnenzijde 
van bloedvaten. Het is cruciaal dat VEGF-A levels binnen bepaalde 
fysiologische waarden blijven, omdat zowel een verhoging als een ver-
laging van VEGF-A niveaus leidt tot de ontwikkeling van nierschade. In 
diabetische dieren zijn VEGF-A niveaus hoger dan in niet-diabetische 
dieren. Ook is laten zien dat een verhoging van VEGF-A niveaus 
specifieke cellen van de glomerulus de ontwikkeling van diabetische 
nefropathie verergert. 
VEGF-A is op twee manieren betrokken bij de ontwikkeling van glo-
merulaire ontsteking. Ten eerste zorgt VEGF-A ervoor dat monocyten 
(ontstekingscellen) naar de glomerulus migreren. Ten tweede draagt 
VEGF-A bij aan de extravasatie van monocyten door het activeren 




steking is activatie van het glomerulaire endotheel. Dit houdt in dat 
bepaalde adhesiemoleculen worden opgereguleerd op het endotheel. 
Monocyten kunnen vervolgens aan deze adhesiemoleculen binden, die 
op deze manier bijdragen aan de extravasatie van monocyten. VEGF-A 
zorgt voor de opregulatie van deze markers op het endotheel. Zodra 
monocyten extravaseren, differentiëren deze cellen naar macrofagen. 
Zoals eerder genoemd dragen macrofagen bij aan de ontwikkeling van 
diabetische nefropathie.  
In hoofdstuk 3 van dit proefschrift beschrijven we dat het rem-
men van VEGF-A in diabetische muizen ertoe leidt dat deze mui-
zen minder albuminurie en minder glomerulaire schade ontwikkelen 
dan diabetische muizen die niet behandeld zijn met VEGF-A-remmers. 
Daarnaast zorgt remming van VEGF-A in diabetische muizen voor 
minder glomerulaire ontsteking ten opzichte van onbehandelde dia-
betische muizen. Deze data suggereren dat het remmen van VEGF-A 
in patiënten mogelijk de ernst van de diabetische nefropathie zou 
kunnen verminderen.
Endoglin is een type 1 membraan glycoproteïne aanwezig op het 
oppervlak van endotheelcellen. Endoglin is belangrijk voor het on-
derhoud van endotheelcellen en is daarnaast geassocieerd met en-
dotheelactivatie. Er zijn aanwijzingen dat er een interactie is tussen 
VEGF-A-signalering en endoglin. Dit mechanisme is echter nog on-
duidelijk. In hoofdstuk 4 van dit proefschrift laten we zien dat er 
meer endoglin in endotheelcellen in glomeruli van diabetische muizen 
aanwezig is dan in niet-diabetische muizen. Vervolgens hebben we 
met celkweekexperimenten de betrokkenheid van endoglin in VEGF-A 
geïnduceerde endotheelactivatie onderzocht. We stelden vast dat een 
verlaging van de aanwezigheid van endoglin leidt tot verminderde 
endotheelactivatie na stimulatie met VEGF-A ten opzichte van de en-
dotheelactivatie in endotheelcellen met een normale aanwezigheid van 
endoglin. Dit had ook tot gevolg dat minder monocyten bonden aan 
deze endotheelcellen met een verminderde endoglin aanwezigheid. De 
verlaging van endoglin had tot gevolg dat de intracellulaire signalering 
van VEGF-A, die normaal gesproken leidt tot endotheelactivatie, was 
veranderd. In nierweefsel van patiënten vonden we dat de hoeveel-
heid endoglin in de glomerulus correleert met endotheelactivatie. Dit 
wil zeggen: hoe meer endoglin, hoe meer endotheelactivatie, en vice 
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versa. Deze data suggereren dat het verlagen van endoglin levels in 
diabetespatiënten – en daarmee glomerulaire ontsteking – mogelijk 
een nieuwe behandelmethode zou kunnen zijn om de ontwikkeling van 
diabetische nefropathie te voorkomen, dan wel te remmen.
Het complementsysteem is onderdeel van het aangeboren im-
muunsysteem. Een belangrijke taak van het complementsysteem is 
beschermen tegen infectie. Het systeem bestaat uit drie verschillende 
routes, elk geactiveerd door specifieke stimuli. Er is zowel klinisch als 
experimenteel bewijs dat het complementsysteem betrokken is bij het 
ontstaan van diabetische complicaties zoals diabetische oogschade. 
Er is echter minder bekend over de betrokkenheid van het comple-
mentsysteem bij de ontwikkeling van diabetische nefropathie.
In hoofdstuk 5 van dit proefschrift laten we zien dat comple- 
mentactivatiemarkers worden opgereguleerd in patiënten met dia-
betische nefropathie ten opzichte van diabetes patiënten zonder 
diabetische nefropathie en ten opzichte van niet-diabetische controles. 
Daarnaast vonden we een sterke positieve correlatie tussen de aan-
wezigheid van het complementsysteem in vasculaire structuren van 
de nier, onder andere in glomeruli, en de ernst van de diabetische 
nefropathie. Ook vonden we een sterke negatieve correlatie tussen 
de aanwezigheid van het complementsysteem en de nierfunctie van 
patiënten met diabetische nefropathie. Deze bevindingen suggere-
ren dat het complementsysteem betrokken is bij de ontwikkeling 
van diabetische nefropathie. De remming van de activatie van het 
complementsysteem zou daarom mogelijk diabetespatiënten kunnen 
beschermen tegen het ontwikkelen van diabetische nefropathie, of de 
ontwikkeling van diabetische nefropathie kunnen vertragen.      
Zoals in hoofdstuk 2 van dit proefschrift beschreven, ontwikkelen 
APOC1-tg muizen nodulaire glomerulosclerose. Deze laesies zijn echter 
in deze muizen pas aanwezig vanaf de leeftijd van 15 maanden. De 
relatief trage ontwikkeling van deze ziekte maakt dit model daarom 
minder geschikt om therapeutische en preventieve interventiestudies 
mee uit te voeren. In hoofdstuk 6 van dit proefschrift hebben wij 
geprobeerd om de progressie van de ziekte in dit model te versnellen 
door VEGF-A te remmen. Een langdurige verlaging van VEGF-A leidt 
namelijk tot de ontwikkeling van nierschade, voornamelijk door de 




was dat de combinatie van APOC1-overexpressie en VEGF-A remming 
zou leiden tot een versnelde progressie van de ziekte in dit mo- 
del. Onze bevindingen lieten echter zien dat dit niet het geval was. 
APOC1-tg muizen met verlaagde VEGF-A levels hadden juist minder 
ontstekingscellen in glomeruli dan onbehandelde APOC1-tg muizen. 
Dit suggereert dat het remmen van VEGF-A een anti-inflammatoire 
werking zou kunnen hebben. 
De centrale conclusie van het werk in dit proefschrift is dat 
het immuunsysteem een belangrijke rol speelt in de ontwikkeling en 
progressie van diabetische nefropathie. Daarom zou de focus van 
toekomstige studies, betreffende de behandeling en preventie van 
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